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English summary  
Osteoporosis is the most common bone disease in humans, and osteoporotic fracture is a major health 
problem. In the absence of fracture, however, osteoporosis is asymptomatic and often remains 
undiagnosed. There is no universally accepted policy for population screening in Europe to identify patients 
with osteoporosis or those at high risk of fracture. Most countries adopt a case-finding strategy where 
individuals with clinical risk factors are identified for further assessment. This strategy does not seem to 
work as intended, however, as osteoporosis remains underdiagnosed and undertreated in Denmark, and 
probably also elsewhere. New strategies are thus needed to reduce the large number of osteoporotic 
fractures expected in the future due to the aging of the world’s population. Targeting individuals with 
increased risk of osteoporotic fracture is an important challenge, and risk assessment tools may contribute 
to health care decision-making by identifying individuals at highest risk of osteoporotic fracture. 
The primary aim of this thesis was to investigate the potential use of risk assessment tools in the clinical 
management of osteoporosis to identify women in highest risk of fracture. Specific objectives were 
addressed in four separate papers. In paper I, we evaluated whether the WHO fracture risk assessment tool 
(FRAX®) without BMD was applicable to Danish women. In paper II, we examined the prevalence of risk 
factors for fractures and the use of DXA scans in Danish women in relation to age, risk factors, distance to 
DXA-clinics and socio-economic factors. In paper III, we compared the power of FRAX® and simpler 
screenings tool to predict fractures. In the systematic review described in paper IV, we compared the 
power of valid and reliable risk assessment tools to identify women at highest risk of fractures.  
For the purpose of this thesis, we developed and validated a questionnaire on risk factors for osteoporosis 
based that was based on and included the FRAX® risk factors. The thesis uses data collected using this 
questionnaire as well as data from Danish national registers and the published literature on osteoporosis 
fractures and osteoporosis risk assessment tools. The four studies conducted were prospective, cross-
sectional and population-based, and used different statistical analyses as appropriate for their aims and 
designs: chi2-test, various regression analyses, survival analyses, ROC and Harrell´s C. The systematic review 
followed the guidelines established by the PRISMA Group for reporting systematic reviews and meta-
analyses and applied the QUADAS checklist to assess the methodological quality of included papers. 
The self-administered questionnaire was mailed to 5,000 women aged 40-90 years and living in the Region 
of Southern Denmark, randomly selected from the Danish civil Registration system. A total of 4,194 (84%) 
responded and 3,860 (77%) completed the questionnaire. Fracture risk was calculated using different 
screening tools, e.g. FRAX®. 
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FRAX® without BMD appeared well calibrated for Danish women as regards hip fracture risk, as the 
predicted 10-year hip fracture risk calculated by FRAX® (without BMD) and the observed fracture risk from 
age-specific hip fracture rates from the National Patient Register and survival tables from Statistics 
Denmark were nearly identical; 7.9% and 7.6%, respectively (paper I).  
When evaluating the prevalence of risk factors (paper II), we found that 37.4% of the women had no risk 
factors and 62.6% had one or more risk factors. However, 10.3% of women without risk factors had a 
history of DXA, while only 36.3% of women with three or more risk factors had a history of DXA. The study 
thus showed a relatively high use of DXA in low-risk women and a relatively low coverage in women with 
multiple risk factors, suggesting that the case-finding strategy does not work as intended. The study further 
showed that distance to the DXA clinic, patient age and a number of other socio-economic factors were 
associated with the use of DXA.   
During the three years of follow-up (through the Danish National Register), we found that 4% of the women 
experienced a new osteoporotic fracture (paper III). Comparing the discriminatory power to predict future 
fractures, no difference was found between FRAX® and simpler tools such as OST1, ORAI2, OSIRIS3, SCORE4  
or age alone with regards to the area under the curve (AUC) values, which were between 0.703 and 0.722 
(p=0.86).  
In paper IV, we identified 48 risk assessment tools for prediction of osteoporotic fractures, but only 20 of 
them were externally validated. Eight tools were developed to identify individuals at risk of low BMD and 
12 tools were developed to identify individuals with increased risk of fractures. Only six of these tools had 
been tested more than once in a population-based setting with acceptable methodological quality. None of 
the tools performed consistently better than the others, and simple tools (i.e. OST, ORAI and Garvan) often 
did as well or better than more complex tools (i.e. SCORE, FRAX® and Qfracture). No studies had 
determined the effectiveness of tools in selecting patients for therapy and thus improving fracture 
outcomes.  
In conclusion, the results presented in this thesis suggest that risk assessment tools could be potentially 
useful in the clinical management of osteoporosis by identifying women at highest risk of fracture, as a 
replacement for the case-finding strategies used in Denmark and elsewhere. FRAX® is the only tool 
incorporated in national guidelines, but in this thesis FRAX® did not perform better than simpler tools in 
predicting fractures. Simpler tools with fewer risk factors, which would be easier to use in clinical practice 
                                                          
1 Osteoporosis Self-assessment Tool, 2 Osteoporosis Risk Assessment Instrument, 3 OSteoporosis Index Risk, 4 Simple Calculated Risk Estimation 
Score 
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by the general practitioner or the patient herself, may be just as effective as FRAX® in the clinical 
management of osteoporosis. These simpler tools have not yet been validated in prospective randomized 
studies, however. Future research could thus focus on the validation of simpler tools (e.g. Garvan) in high 
quality, randomized studies with population-based samples or patient cohorts with different case mixes.  
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Dansk resumé (Danish summary) 
Knogleskørhed (osteoporose) er den mest almindelig knoglesygdom hos mennesker, og osteoporotiske 
knoglebrud er et omfattende sundhedsproblem. Ved udeblivelsen af brud er osteoporose symptomfri og 
forbliver derfor ofte u-diagnosticeret. I øjeblikket er der ikke en universel accepteret strategi til at screene 
den europæiske befolkning for at identificere personer med osteoporose eller dem med højest risiko for at 
få knoglebrud. I Danmark og flere andre lande anvendes en case-finding strategi til at identificere personer 
med mulig osteoporose, hvor personer med en eller flere risikofaktorer for osteoporose anbefales henvist 
til DXA skanning for videre udredning. Denne strategi virker dog ikke efter hensigten, da osteoporose stadig 
er under-diagnosticeret og under-behandlet. Derfor er nye strategier nødvendige på osteoporose området 
for at nedbringe det store antal af osteoporotiske knoglebrud, der må forventes at komme i fremtiden, 
blandt andet på grund af, at verdens befolkning bliver ældre og ældre. Der er en stor udfordring i at finde 
de personer med øget risiko for osteoporotiske knoglebrud, men risikovurderingsværktøjer kan muligvis 
bidrage til at identificere personer med højest risiko for osteoporotiske knoglebrud. 
Det overordnede formål med denne ph.d. afhandling var at undersøge om risikovurderingsværktøjer 
potentielt kan bruges i den kliniske håndtering af osteoporose til at identificere de kvinder med højest 
risiko for osteoporotiske knoglebrud. Formålet blev opnået ved specifikke formål i 4 individuelle artikler. I 
artikel I evaluerede vi om WHOs FRAX® uden BMD var egnet til danske kvinder. I artikel II, undersøgte vi 
prævalensen af risikofaktorer for osteoporotiske knoglebrud og brugen af DXA hos danske kvinder i relation 
til alder, risikofaktorer, afstand til DXA klinik og socioøkonomiske faktorer. I artikel III var formålet at 
sammenligne FRAX® og simplere risikovurderingsværktøjers styrke i forhold til deres evne til at prædiktere 
knoglebrud. I artikel IV udførte vi et systematisk review, hvor vi sammenlignede styrken af de validerede og 
pålidelige risikovurderingsværktøjer, der findes til at identificere kvinder med højest risiko for knoglebrud.  
Til denne afhandling udviklede og validerede vi et spørgeskema omhandlende risikofaktorer for 
osteoporose ud fra FRAX®. Afhandlingen er primært baseret på data fra dette spørgeskema, samt fra data 
fra danske registre og publicerede artikler om osteoporotiske frakturer og risikovurderingsværktøjer. 
Afhandlingen indeholder 3 populationsbaserede studier; 2 tværsnitsstudier og et prospektivt studie. Til at 
analysere data blev der anvendt forskellige statistiske metoder passende til de forskellige formål i de 
enkelte studier: Chi2 test, forskellige regressionsanalyser, overlevelsesanalyse samt ROC of Harrell´s C 
analyse. Til det systematiske review fulgte vi vejledningerne fra PRISMA gruppen for afrapportering af 
systematiske review og meta-analyser og anvendte QUADAS checklisten til at vurdere den metodologiske 
kvalitet af studierne.  
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Vi sendte spørgeskemaet til 5000 tilfældigt udtrukket kvinder fra det danske CPR register i alderen 40 til 90 
år bosiddende i Region Syddanmark. Vi fik svar fra 4194 (84%) kvinder, og 3860 (77%) udfyldte 
spørgeskemaet. Knoglebrudsrisikoen blev udregnet ud fra de forskellige risikovurderingsværktøjer som 
f.eks. FRAX®. 
Resultaterne viste, at FRAX® uden BMD virker til at være vel kalibreret til danske kvinder i forhold til 
hoftebrudsrisikoen, da både den forventede 10-år hoftebrudsrisiko udregnet af FRAX® (uden BMD) og den 
observerede knoglebrudsrisiko ud fra alders-specifikke hoftebrudsrater fra Landspatientregistret og 
overlevelsestabeller fra Danmark Statistisk næsten var identiske, henholdsvis 7,9% og 7,6%. 
Vi fandt, at 37,4% af kvinderne ikke havde nogen risikofaktorer for osteoporose, mens 62,6% havde en eller 
flere risikofaktorer. 10,3% af alle kvinder uden nogle risikofaktorer havde fået foretaget en DXA skanning, 
mens kun 36,3% af alle kvinder med 3 eller flere risikofaktorer havde fået foretaget en DXA skanning. 
Studiet viste således et relativt højt forbrug af DXA skanning ved lavrisiko kvinder og en relativt lavt 
dækning af kvinder med flere risikofaktorer. Dette støtter tidligere fund omkring, at case-finding strategien 
ikke virker efter hensigten. Studiet viste yderligere, at afstand til DXA klinikker, patient alder og en række 
socioøkonomiske faktorer var associerede med brugen af DXA skanning. 
Kvinderne blev fuldt gennem Landpatientregistret, og i løbet af 3 år havde 4% af kvinderne pådraget sig et 
osteoporotisk knoglebrud. I sammenligningen af FRAX® med de simplere risikovurderingsværktøjer blev der 
ikke fundet nogen forskel i styrken til at prædiktere fremtidige knoglebrud. AUC værdierne for FRAX® og 
OST2, ORAI3, OSIRIS4, SCORE5 samt alder alene var mellem 0,703 og 0,722 (p=0,86). 
I artikel IV identificerede vi 48 risikovurderingsværktøjer til at prædiktere osteoporotiske knoglebrud; kun 
20 af disse var eksternt valideret. Heraf var 8 værktøjer udviklet til at identificere kvinder med lav BMD og 
12 værktøjer udviklet til at identificere kvinder med øget risiko for knoglebrud. Kun 6 værktøjer var 
valideret mere end en gang i en populationsbaseret kohorte med en god metodologisk kvalitet. Ingen af 
værktøjerne klarede sig gentagende gange bedre end andre, og de simplere værktøjer (f.eks. OST, ORAI and 
Garven) klarede sig lige så godt eller endda bedre end de mere komplekse værktøjer (f.eks. SCORE, FRAX® 
and Qfracture). Ingen af studierne kunne vise effektiviteten af værktøjerne i forhold til at selektere 
patienter til behandling og derigennem forbedre et knoglebrudsudfald. 
Alt i alt viser afhandlingen, at risikovurderingsværktøjer potentielt kan bruges i den kliniske håndtering af 
osteoporose til at identificere kvinder med højest risiko for knoglebrud i stedet for den nuværende case-
                                                          
2 Osteoporosis Self-assessment Tool, 3 Osteoporosis Risk Assessment Instrument, 4 OSteoporosis Index Risk, 5 Simple Calculated Risk Estimation 
Score 
PhD Thesis                                                         The use of risk assessment tools in the clinical management of osteoporosis 
~ 8 ~ 
 
finding strategi, der bruges i Danmark og flere andre steder i verden. FRAX® er det eneste værktøj som 
allerede er integreret i flere nationale guidelines, men denne afhandling viser, at FRAX® ikke virker bedre 
end simplere værktøjer til at prædiktere osteoporotiske knoglebrud. Vores fund indikerer at simplere 
værktøjer med færre risikofaktorer, som ville være nemmere at bruge i klinisk praksis af lægen eller 
patienten selv, ligeså godt kan benyttes i stedet for FRAX® i håndteringen af osteoporose. Dog har ingen 
studier endnu valideret disse simplere værktøjer i et prospektivt randomiseret design. Der anbefales derfor, 
at fremtidig forskning sætter mere fokus på at validere disse simplere værktøjer (f.eks. Garvan) i 
randomiserede studier i populationsbaserede kohorter.   
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1. Introduction 
 
1.1 Osteoporosis  
Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue (1). The decreased bone strength results in an increased risk of fractures. The 
clinical significance of osteoporosis is occurrence of fractures, and in the absence of fracture, osteoporosis 
is asymptomatic. Low bone mineral density (BMD) increases the risk of fractures and is in turn the result of 
specific risk factors for osteoporosis such as prior fracture, smoking, age and genetics. The more risk factors 
for osteoporosis, the greater the risk of an osteoporotic fracture. Some risk factors such as low muscle 
strength and excessive alcohol intake do not affect BMD but increase the risk of fracture through other 
mechanisms e.g. by increasing the risk of falls.  
It is noteworthy that individuals with several risk factors may never experience an osteoporotic fracture 
(even though they have low BMD) and therefore never seek medical attention, despite having 
osteoporosis.  
 
1.1.1 Prevalence  
Osteoporosis is most common in white women, and especially postmenopausal women, and increases with 
age (2). In Denmark, approximately 40% of women and 18% of men above the age of 50 years have 
osteoporosis (3;4).  
Approximately 11,000 hip fractures (5), 7,000 forearm fractures and 2,000 clinical vertebral fractures occur 
every year in Denmark (3). Osteoporosis results in nearly 9 million fractures annually worldwide (6). Large 
geographic differences exist in hip fracture incidence, where Europe and North America have the highest 
incidences (6), and age- and sex adjusted hip fracture rates are higher in northern Europe than southern 
Europe (7). Recent, a study found that Denmark had the highest incidence of hip fracture in an 
international comparison (574/100,000 person-years in women) (8). Although the incidence of hip fracture 
is decreasing in Denmark (9) and age specific hip fracture rates from the Danish National Register 
decreased from 5.7/1000 per year in 2004 to 5.2/1000 per year in 2011 (Figure 1), the burden of fractures 
remains substantial.  
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Figure 1: Age-specific hip fracture rates in Danish women in 2004 and 2011 stratified by 5-year age 
intervals 
 
 
1.1.2 Diagnosis 
Osteoporosis is asymptomatic until fracture occurs, but can be diagnosed using dual-energy X-ray 
absorptiometry (DXA) that measures the bone mineral density (BMD) (10). The World Health Organization 
(WHO) bases the diagnosis of osteoporosis on the measured BMD, expressed as a T-score (in hip or lumbar 
spine). Osteoporosis is diagnosed when the BMD value is more than 2.5 standard deviations below the 
mean BMD of young adults at their peak bone mass (1), i.e. a T-score less than or equal to -2.5 SD (Table 1).  
Table 1: WHO diagnostic criteria for osteoporosis based on T-score at the spine, hip or distal forearm 
Diagnosis BMD measured by DXA 
Normal BMD T-score of -1 SD or above 
Osteopenia T-score between -1 and -2.5 SD 
Osteoporosis T-score of -2.5 SD or below 
Established (severe) osteoporosis T-score of -2.5 SD or below with one or more associated fractures 
 
DXA is widely used to measure BMD at the hip and lumbar spine and is considered the ”gold standard” for 
identifying persons at high risk of osteoporotic fracture, for diagnosis and for monitoring treatment (10;11). 
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The availability of DXA scanners varies from country to country, but it is estimated that approximately 11 
DXA scanners are required per million of the general population (12). Denmark has around 15 DXA 
units/million inhabitants (11) with 23 DXA clinics spread throughout the country (13), several of which have 
more than one DXA scanner. There are 7 DXA clinics in the Region of Southern Denmark (6 DXA clinics in 
2009). 
Central DXA (i.e. scanning of the hip or lumbar region) is unavailable in many countries and regions, and 
long distances to DXA clinics are strongly associated with lower use of DXA testing (14). The maximum 
distance to the nearest DXA clinic is 100 km in Denmark, and for the majority of the population the distance 
is less than 30 km (Figure 2). 
 
Figure 2: Map of the Region of Southern Denmark showing DXA clinics (black spots) in 2009 
 
 
In Denmark, an increasing number of individuals were scanned during the years 2002-2012 (from 6,324 to 
70,274, respectively). This number covers both new referred individuals and control scans (Figure 3). 
Approximately 50% of the patients seen at the DXA clinic in Odense, Denmark, were new referral. So the 
increasing number of scans perform in Denmark may to some extend be explained by an increase in follow-
up scans. 
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Figure 3: DXA scans per year in Denmark from 2002 to 2012  
 
 
Studies in Denmark (15;16) and other countries (17-19) show that few patients with hip fracture are 
offered DXA scan or treatment for osteoporosis. Gardner et al. (18) found that less than 30% were 
discharged with a prescription for medication targeting osteopenia (either supplemental calcium or an 
antiosteoporotic medication) and Aboyoussef et al. (17) found that only 27% of patients with fragility 
fracture were diagnosed with osteoporosis or osteopenia within 6 months of the fracture. Wiboe et al. (16) 
showed in 2002 that only 16% of Danish patients were started on osteoporosis preventative therapy after a 
hip fracture.   
Other Danish studies also indicate that osteoporosis is underdiagnosed and undertreated (3) and that DXA 
referrals are not used optimally. Frost et al. (20) found that DXA had been performed in only 10% of men 
with at least three risk factors for osteoporosis, while one-third of those with previous DXA had no risk 
factors.   
Although DXA scanning is used more frequently in Denmark, many patients thus remain undiagnosed, 
questioning the efficiency of the current case-finding strategy. 
 
1.1.3 Fractures 
Fracture of the vertebrae (spine), proximal femur (hip) and distal forearm (wrist) have long been regarded 
as the typical osteoporotic fractures. The effect of osteoporosis on the skeleton is systemic, however, and 
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individuals with low BMD have an increased risk of almost all types of fracture (21). Osteoporotic fractures 
(also known as fragility fractures) are fractures that result from mechanical forces that would not ordinarily 
cause a fracture. Several definitions of osteoporotic fracture exist. The WHO definition is a fracture 
resulting from forces equivalent to a fall from a standing height or less (1). Kanis et al. (22) defined 
osteoporotic fractures as occurring at a site associated with low BMD and with increased incidence after 
the age of 50 years – thus adding fractures of the humerus, other femoral sites, rib, pelvis, clavicle, scapula, 
sternum, tibia and fibula to the list of osteoporotic fractures (22). The studies in this thesis refer only to the 
typical osteoporotic fractures (i.e. of the spine, hip and wrist). 
The incidence of fragility fractures increases markedly with age, though the rate differs for different 
fracture types. This is most evident for forearm and hip fractures, where forearm fractures account for a 
greater proportion of fractures at younger ages, while hip fractures are rare at 50 years of age but are the 
predominant osteoporotic fracture from the age of 75 years. In women, the median age for distal forearm 
fractures is around 65 years and for hip fracture, 80 years (23). 
Approximately 11,000 Danish patients are hospitalized with hip fracture each year. Most (about 85%) also 
have osteoporosis and have a very high risk of new fractures (5). In the presence of a prior fracture, 
individuals are almost twice as likely to have a second or further fracture compared to those who are 
fracture-free (21). A Danish study found that within one year after hip fracture, 9% of patients will have a 
new hip fracture and 36% will have a fracture in another part of the body. After five years, 20% will have 
had a new hip fracture and 57% another fracture (5;24). 
Osteoporotic fractures are a major public health problem and it is important to prevent future fracture in 
individuals who already have suffered a fracture. In theory this may be achieved through e.g. fracture 
prevention program and by improving methods to identify individuals at increased risk of osteoporotic 
fracture. 
1.1.4 Personal and economic consequences of osteoporotic fractures 
Osteoporotic fractures are a major cause of morbidity in the population. Hip fractures are regarded as the 
most severe of the osteoporotic fractures; they cause acute pain, hospitalization and loss of function. 
Recovery is slow and rehabilitation is often incomplete, and many patients become permanently 
institutionalized in nursing homes (11). Osteoporotic fractures can also have consequences for the 
individual in the form of chronic pain, reduced activities of daily living (25) and increased mortality, with the 
exception of forearm fractures (26). In 2010, the number of deaths related to osteoporotic fractures was 
estimated at 43,000 in the European Union. Approximately 50% of fracture-related deaths in women were 
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due to hip fractures (11). Osteoporosis accounted for more disability and life-years lost than e.g. 
rheumatoid arthritis, cancer (with the exception of lung cancer) and Parkinson’s disease, but less than e.g. 
chronic obstructive pulmonary disease and ischemic heart disease (6;11;27). 
Osteoporotic fractures are associated with significant societal costs (28), especially due to the high cost of  
hip fractures with often long hospital stays (29), surgical treatment and rehabilitation services (5). In 
Denmark, the total cost for treatment, care, and rehabilitation of a hip fracture is estimated to be 96,000 
DKK (approx. 17,000 USD) in the first years and 280,000 DKK (approx. 49,000 USD) in the first ten years 
after a hip fracture (5). For 27 EU countries, the economic burden of osteoporotic fracture is estimated to 
be € 38.7 billion (11).  
The consequences of osteoporotic fracture are high for both the individual and society. The societal costs 
are expected to increase markedly in the future, partly due to increased longevity of the population. While 
the total European population will not increase markedly over the next 25 years, the proportion of elderly 
will increase by 33% (23). This poses challenges to public health systems including general practitioners 
physicians. 
1.1.5 Fracture prevention 
In theory, prevention of osteoporotic fractures may focus on achieving a high peak bone mass, maintaining 
or increasing bone mass or preventing falls.  
Lifestyle interventions include recommendations for cessation of tobacco smoking, avoidance of excessive 
alcohol intake, physical activity, fall prevention and an adequate intake of calcium and vitamin D. Smoking 
cessation increases BMD (30;31), reduction of alcohol intake to maximum 2 drinks a day would decrease 
the risk of falling (32), physical activity can improve agility, strength, posture and balance, which also can 
reduce the risk of fall and fracture (33-35). Falls prevention could also include home safety assessment and 
correction of nutritional deficiencies (36). Providing adequate daily calcium and vitamin D is an inexpensive 
way to help reduce fracture risk. Controlled clinical trials have demonstrated that the combination of 
supplemental calcium and vitamin D can reduce the risk of fracture (37-40).  
Several pharmaceutical therapies also decrease the risk of fracture. Randomized, placebo-controlled clinical 
trials have shown that treatment with estrogen (41), bisphosphonates (42), raloxifene (43), strontium 
ranelate (44), parathyroid hormone (45;46) and denosumab (47) reduces the incidence of fractures by 15-
80% depending on the specific drug, skeletal site and study population. Most patients (approximately 90%) 
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with osteoporosis can be treated with oral bisphosphonates (e.g. alendronate and risedronate) that are 
now available as generics at affordable price. 
It is unfortunate that osteoporosis is undertreated as appropriate treatment can prevent future fractures, 
thus avoiding reductions in functional ability and quality of life.  
 
1.2 Risk factors for osteoporotic fracture 
Osteoporotic fractures are a result of low BMD and falls. Numerous risk factors for osteoporotic fractures 
have been identified and can be divided into modifiable and non-modifiable factors (Figure 4). Modifiable 
factors include smoking (30;31), alcohol intake (48;49) and low Body mass index (BMI) (50;51). Non-
modifiable factors include age (50;52), sex (7;50), genetics (53;54), prior facture (21;55), and prior 
glucocorticoid use (50;55). Falls are a risk factor for osteoporotic fracture (56;57) and can be either 
modifiable or non-modifiable depending on the reason for the fall; e.g. poor muscle strength (55) and 
vision impairment (58) may be modifiable, but age is non-modifiable. 
Figure 4: Examples of modifiable and non-modifiable risk factors for osteoporotic fracture 
      Modifiable risk factors                     Non-modifiable risk factors 
 
 
 
 
 
 
 
 
 
 
Low BMD is a risk factor for osteoporotic fracture as individuals with low BMD have progressively higher 
risk of fracture. Most fracture types are more frequent in women with low BMD, although BMD measured 
at the proximal femur appears to be more strongly related to risk of hip fracture than BMD measured at 
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other sites (59;60). Many risk factors affect BMD, such as smoking and glucocorticoid use, while other risk 
factors such as falls are related to risk of fracture but not to BMD.  
Some risk factors vary with age. The risk of falling and the risk of fracture both increase with age. Age is 
independent of BMD and, for any BMD, fracture risk is much higher in the elderly than in the young (11). 
Poor balance and lower muscles strength in the elderly appear to contribute to the increased risk of falls 
and subsequent fractures (23). Some risk factors are strong risk factors for hip fracture but not necessary 
for other osteoporotic fractures. For instance are fall a risk factors for hip fracture but not for vertebral 
fracture (61). Other studies have shown that weight loss were a risk factor for hip fracture but did not 
predict other osteoporotic fractures (62).  
Meta-analyses undertaken to identify risk factors for osteoporotic fracture show that prior fracture is a risk 
factor that is strongly associated with future fracture. In the presence of a prior fracture, individuals are 
thus almost twice as likely to have a second or further fracture compared to those who are fracture-free 
(21;63). Genetics appear to play a large part in the determination of bone mass and fracture risk. A family 
history of fragility fractures is a significant risk factor that is largely independent of BMD (53). A low BMI 
increased the risk of hip fracture two fold when comparing individuals with a BMI of 20 kg/m2 and 25 kg/m2 
(51). Smoking increases the risk for hip fracture up to 1.5 times and is a risk factor that is in part dependent 
on BMD (30). Glucocorticoids are an important cause of osteoporosis, and oral glucocorticoid treatment 
with more than 5 mg prednisolone (or equivalent) daily reduces bone mineral density and rapidly increases 
the risk of fracture during the treatment period (64). Alcohol intake of three or more units daily is 
associated with a dose-dependent increase in fracture risk (49). Many secondary causes of osteoporosis are 
also associated with increased fracture risk, e.g. inflammatory bowel disease and endocrine disorders (50). 
Thus, a limited number of easily identifiable risk factors seem to be able to identify women with low BMD 
and high risk of fracture. Thus, it seems that age, prior fracture and family history are strong predictors for 
osteoporotic fracture. Focusing on individuals with high risk seems as an obvious strategy for decreasing 
the number of osteoporotic fractures in the future. 
 
1.3 Risk assessment tools 
Several risk assessment tools have been developed with the aim of providing a single estimate of fracture 
risk for an individual. Recently developed tools that calculate a patient´s 5- year or 10-year risk of fracture 
include the Fracture Risk Assessment Tool (FRAX®) (65), Qfracture algorithm (66) and Garvan Fracture Risk 
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Calculator (67;68). More tools have been developed to predict fracture, but there are also several tools 
developed to predict low BMD (69;70). A common feature of these tools is that they aim to stratify 
individuals into risk categories for osteoporosis or fracture. These tools differ in the number of risk factors 
included and the weighting of each risk factor in the algorithm. Except for the BWC tool (which has weight 
as the only factor), all the tools include age. The simplest tools include one or two risk factors, e.g. BWC 
(71) and OST3 (72;73), while the updated version of the Qfracture (74) includes 31 risk factors.  
The exact aim of the tools differs, and their potential uses are thus quite varied (Figure 5). Some of the 
tools could help clinicians target BMD measurement to women at high-risk e.g. OST3 (72;73), some could be 
used as screening instruments e.g. SCORE4 (75), some could aid in case-finding for further assessment e.g. 
DXA scanning (76), while others e.g. FRAX® can be used for identifying patients for treatment (77). The 
tools may also be useful in patient consultations to assist discussions about whether the patient should 
undergo further DXA scanning or start up with osteoporotic medication. The tools could also be used by 
patients themselves to assess their risk of future osteoporotic fracture, as many tools are internet-based 
and freely available. The risk estimates provided by the tools could prompt the patient to consult their 
general practitioner for further assessment or treatment. 
 
Figure 5: Potential use of risk assessment tools  
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Several studies have compared the various assessment tools with respect to their ability to identify 
individuals at increased risk of fracture or low BMD. Most of these studies concluded that the simpler tools 
perform as well as the more complex tools (typically FRAX®) in predicting fractures (78-86).  
In summary, while the risk assessment tools have not yet found broad acceptance, it is remarkable that 
FRAX® is increasingly used and has been incorporated into national guidelines (36;77;87) and are used for 
clinical decisions regarding pharmaceutical therapy.     
 
1.4 Guidelines and recommendations for identifying individuals at high risk   
At present, there is no universally accepted policy for population screening in Europe to identify patients 
with osteoporosis or those at high risk of fracture (11).  
In Denmark (as in other countries), a case-finding strategy has been adopted to identify individuals with 
increased risk of osteoporosis, whereby individuals with one or more risk factors for osteoporotic fracture 
or individuals with a low energy fracture may be referred for a DXA scan by their general practitioner (GP) 
(4). According to the guidelines issued by the Danish Bone Society (DKMS), reimbursement of anti-
osteoporotic medication is determined by DXA results unless hip or spine fracture is present (4). Guidelines and 
recommendations in other countries differ somewhat; some recommend screening of the population, 
while others recommend DXA scanning of specific groups of individuals (Table 2). 
The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic 
Aspects of Osteoporosis and Osteoarthritis (ESCEO) do not officially endorse national or regional guidelines. 
This is because osteoporosis prevalence and various aspects of the prevention, diagnosis and treatment of 
fractures are country- or region-specific. These societies have, however, updated their overall European 
guidance for the diagnosis and management of osteoporosis in postmenopausal women (11), by including 
three alternative assessment scenarios depending on access to DXA. Common to these three scenarios is 
that women with prior fragility fracture should be considered for treatment, and all scenarios apply FRAX® 
to determine intervention threshold. These are age-specific recommendations (11). Nearly identical 
guidelines are issued in the UK (NOGG, National Osteoporosis Guideline Group) a couple of years before. 
The U.S. Preventive Services Task Force (USPSTF) recommends screening with DXA for all women aged 65 
years and older, and in women below 65 years with increased risk of fracture (whose 10-year fracture risk is 
equal to or greater than that of a 65-year-old white woman without additional risk factors; 9.3% based on 
FRAX® calculation). Diagnosis and treatment are determined from the DXA result (88).  
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The US National Osteoporosis Foundation (NOF) also recommends DXA testing in women above 65 years 
and women aged 50-65 years with a high risk factor profile (36). In the newly updated 2013 version, NOF 
further recommends vertebral imaging to diagnose vertebral fracture in various risk groups, such as women 
65+ years if T-score is ≤-1.5, women aged 70+ years regardless of T-score, and postmenopausal women 
with low energy fracture or height loss (36).  
Table 2: Strategies and guidelines for identifying individuals at risk of osteoporosis or fracture 
 Recommendation Description of assessment Treatment 
DK – DKMS (4) Case-finding Individuals with one or more risk factors for 
osteoporotic fracture or individuals with a low 
energy fracture may be referred for a DXA scan 
by their general practitioner 
National board of health reimburses 
anti-osteoporotic medication based 
on DXA results and the presence of 
clinical risk factors, unless hip or 
spine fracture is present. 
IOF – 
European (11)  
European guidance If clinical risk factors present, estimate the 
FRAX® 10-year probability of major osteoporotic 
fracture 
 
Three risk assessment scenarios that depend on 
the access to DXA. 
If probability > intervention 
threshold, then treat 
or 
Treat if previous fragility fractures.  
UK –NOGG 
(87) 
Case-finding If clinical risk factors present, estimate the 
FRAX® 10-year probability of major osteoporotic 
fracture with or without BMD 
If probability > intervention 
threshold, then treat 
or 
Treat if previous fragility fractures.  
US – USPSTF 
(88) 
Screening DXA in all women ≥65 years and in women  <65 
years with increased risk of fracture (whose 10-
year fracture risk is equal to or greater than that 
of a 65-year-old white women without 
additional risk factors; 9.3% based on FRAX 
calculation) 
Diagnosis and treatment are 
determined from DXA result.   
US – NOF (36) DXA-testing 
 
 
Vertebral imaging 
In women above 65 years and women aged 50-
65 years with high risk factor profile. 
 
In various risk groups as e.g. women 65+ if T-
score is ≤-1.5, women aged 70+ years regardless 
of T-score, postmenopausal women with low 
energy fracture or height loss. 
Treatment of individuals with: 
1) Hip or vertebral fractures 
2) Low BMD (T-score ≤ -2.5)  
3) Postmenopausal women and men 
aged 50+ years with low bone mass (T-
score between -1.0 and -2.5, osteopenia) 
at the femoral neck or spine and a FRAX 
10-year hip fracture probability ≥3% or a 
FRAX 10-year major osteoporotic fracture 
probability ≥20%. 
Germany – 
Dachverband 
Osteopologie 
(89) 
DXA-testing 
Case-finding 
In all women aged ≥70 years. 
In women <70 years is fracture ± clinical risk 
factors used to select individuals for diagnostic 
assessment. 
Vertebral fracture + T-score ≤−2 or  
10-year probability of vertebral or 
hip fracture of 30% (equivalent to a 
15% 10-year probability for major 
osteoporotic fractures) + T-score ≤−2 
SD. 
Sweden – 
Socialstyrelsen 
(90) 
DXA-testing and 
case-finding 
If osteoporosis is suspected, FRAX calculation 
and results from DXA are used to determine 
whether the person is high risk and thus should 
begin treatment 
 
 
Persons with T-score ≤- 2 + FRAX 
≥30%  
or hip or vertebral fracture. 
Treatment not recommended for 
persons without fracture and a T-
score -2.5 + FRAX≤20%. 
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NOF recommends treatment of individuals with an increased risk of fracture based on the FRAX®. This 
includes postmenopausal women and men aged 50 years and older with low bone mass (osteopenia i.e. T-
score between -1.0 and -2.5) at the femoral neck or spine and a 10-year hip fracture probability ≥3% or a 
10-year major osteoporotic fracture probability ≥20% as calculated by the FRAX® tool (36). 
In Germany, the DVO guidelines (89) recommends DXA testing for all women 70+ years and for women 
below 70 years is fracture and clinical risk factors used to select individuals for diagnostic assessment. 
Comparisons of these strategies for identifying individuals at high risk (91-97) have led to differing 
conclusions regarding effectiveness, fracture outcome and treatment recommendations. Furthermore, 
prospective randomized studies have not yet been undertaken to determine effectiveness and cost-
effectiveness, so it remains unclear which strategy would perform best in the clinical management of 
osteoporosis. Osteoporosis is underdiagnosed in Denmark (as probably elsewhere) and new strategies are 
needed to reduce the high incidence of osteoporotic fractures that is expected in the future due to 
population aging (12). Targeting the right individuals at increased risk of osteoporotic fracture is an 
important challenge, and risk assessment tools may contribute to health care decision-making by 
identifying those individuals with highest risk of osteoporotic fracture. 
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2. Aims and hypothesis 
2.1 Aims 
The overall aim of the thesis was to investigate the potential use of risk assessment tools in the clinical 
management of osteoporosis to identify women at highest risk of fracture. Specific objectives were 
addressed in the four papers:  
I. To evaluate the performance of FRAX® without BMD in Danish women. 
II. To determine the relationship between prevalence of risk factors for fracture and the use of DXA scans in 
Danish women in relation to distance to DXA clinic and socio-economic factors. 
III. To compare the power of FRAX® (without BMD) and simpler screening tools (OST4, ORAI5, OSIRIS6, 
SCORE7 and age alone) in predicting fractures. 
IV. To provide an overview of existing valid and reliable risk assessment tools to identify women at highest 
risk of fractures.  
 
2.1 Hypotheses 
The hypotheses in each of the four papers were: 
I. FRAX® (as calibrated to the Swedish population) is applicable to Danish women. 
II. Many women with well-defined risk factors and high risk of fracture are not referred for DXA, while many 
women with very low risk are scanned. We further hypothesized that specific barriers, e.g. greater distance 
to a DXA clinic and low social status, decrease the use of DXA. 
III. The more complex FRAX® tool (without BMD) is a better predictor of fracture than OST, ORAI, OSIRIS, 
SCORE or age alone. 
IV. Complex tools have a better predictive accuracy than simple tools in identifying women at increased risk 
of osteoporotic fracture.  
 
                                                          
4 Osteoporosis Self-assessment Tool, 5 Osteoporosis Risk Assessment Instrument, 6 OSteoporosis Index Risk, 7 Simple Calculated Risk Estimation 
Score 
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3. Methods and design 
The thesis is primarily based on questionnaire data and Danish national register data (papers I-III) and from 
the published literature on osteoporotic fractures and osteoporosis risk assessment tools (Paper IV).  
An overview of the data, methods, designs and analysis used is presented in Table 3. Further details are 
provided in the following sections. 
Table 3: Overview of study design and methodology in the four papers of this thesis 
 
 Paper I Paper II Paper III Paper IV 
Design Cross-sectional Cross-sectional Prospective Systematic review 
Data source Questionnaire 
Danish national 
registers 
Questionnaire 
Danish national 
registers 
Questionnaire 
Danish national 
registers 
Databases: PubMed, 
Embase, Cochrane, 
Web of Science  
Data 
 
Self-reported risk 
factors  
Demographics 
Age-specific hip 
fracture and 
mortality rates 
Self-reported risk 
factors   
Demographics 
Distance from 
participant to DXA 
facility 
Self-reported risk 
factors  
Registers: Incident 
fracture, death and 
emigration  
Published papers on 
externally validated 
tools to identify 
women with an 
increased risk of 
osteoporotic fracture 
Participants/ 
Units 
Women aged 40-90 
years 
N= 3,636 
Women aged 40-90 
years 
N= 3,860 
Women aged 40-
90 years 
N= 3,614 
76 papers 
Outcome Predicted and 
observed 10-year hip 
fracture risk 
History of DXA 
Distance to DXA 
Number of risk factors 
Incident fracture 
Fracture risk index 
Risk assessment tools 
Analysis Chi2-test Chi2-test 
Logistic regression 
Kaplan Meier 
Cox regression 
ROC 
Harrell´s C 
PRISMA 
QUADAS 
 
3.1 Development of questionnaire 
We developed a composite questionnaire including risk factors for osteoporosis from the WHO fracture risk 
assessment tool (FRAX®) and from other risk assessment tools such as OST, SCORE, ORAI and OSIRIS. The 
items were composed in such a way that it was still possible to calculate the fracture risk on the basis of 
each risk assessment tool. 
The questionnaire comprised items on body weight, body height, ethnicity, history of osteoporosis, history 
of DXA scans, personal and family history of fracture, smoking habits, consumption of alcohol, use of oral 
glucocorticoids and conditions associated with secondary osteoporosis (e.g. rheumatoid arthritis, 
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osteogenesis imperfecta, untreated hyperthyroidism, hypogonadism or premature menopause (<45 years), 
chronic malnutrition or malabsorption and chronic liver disease). The questionnaire could be completed in 
about 10 minutes. Further details are provided in Table 4 and the final questionnaire is found in Appendix 
1. 
Table 4: Content of questionnaire on risk factors for osteoporosis 
Question Possible answers 
Anthropometry  
What is your current body height? Digits 
What is your current body weight? Digits 
What is your ethnicity? European, Middle Eastern, African, 
Asian,  Latin American or “other” 
Osteoporosis  
Have your GP diagnosed you with osteoporosis? Yes, no, don’t know 
Are you currently taking any prescription medication for 
osteoporosis?  
Yes, no, don’t know 
Have you had a DXA-scan to check if you have osteoporosis? Yes, no, don’t know 
Fractures  
Have you had any bone fractures after turning 40 years? Yes, no, don’t know 
If yes: 
Age at fracture 
Which bone 
Cause of the fracture 
 
40-44, 45-49, 50+ 
Hip, spine, wrist, rib or “other” 
Fall at same level, traffic accident or 
fall from heights, lifts, “other” 
Has your mother or father had a hip fracture?  Yes, no, don’t know 
Have some of your relatives (parents or siblings) had a wrist, hip 
or spine fracture after they turned 50 years? 
Yes, no, don’t know 
Risk factors  
Have you experienced more than one fall during the last 12 
months, where the falls were not caused by an external factor e.g. 
being pushed or hit by something? 
Yes, no, don’t know 
Do you smoke? Current, once a week, once a month, 
ex-smoker, never 
Do you drink alcohol during the week?  Yes, no 
If yes:   
How many units to you drink on each day in a usual week? Digits 
Have you ever been treated with glucocorticoids?  
If yes: 
Was the treated with glucocorticoids through?  
If tablets: 
Was the dose 5 mg or above?  
If yes: 
What was the longest period (months/year) you were treated?  
Yes, no, don’t know 
 
Tablets, “other” 
 
Yes, no, don’t know 
 
Digits 
Menopause  
Have you reached menopause (have your menstrual periods 
stopped)?  
Yes, no, don’t know 
At what age did you have your last menstrual period?  <45 or ≥45 years 
What was the cause of your menopause? Natural, underwent hysterectomy, 
ovary removed, unknown cause 
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Have you taken any estrogen after menopause? Yes, no, don’t know 
Are you currently on any estrogen therapy? Yes, no, don’t know 
Secondary osteoporosis  
Has your GP or another doctor diagnosed you with any of the 
following conditions?  
(one answer for each of the following conditions) 
Osteoarthritis, rheumatoid arthritis, chronic liver disease, type 1 
diabetes, osteogenesis imperfecta, anorexia, chronic malnutrition 
or malabsorption, colitis ulcerosa or Crohns disease, 
hyperthyroidism, hypogonadism, primary hyperparathyroidism. 
Yes, no, don’t know 
Immobilization  
Have you ever been bedbound for more than one month?  Yes, no, don’t know 
If yes:  
What was your age? Digits 
Are you immobile to such a degree that you:  
Cannot walk more than 100 meters?  Yes, no 
Cannot do ordinary domestic work? Yes, no 
 
The questionnaire was designed so that it could be read by optical character recognition (OCR) using a 
Kodak i640 scanner and AnyDoc 5.0 software. Paulsen et al. (98) tested the accuracy of the OCR and found 
no statistical difference between OCR and double data entry by keyboard. We also tested the accuracy of 
the setup on our questionnaire by comparing it to manual data entry for 100 questionnaires and found no 
discrepancies.  
3.1.1 Validation of the questionnaire 
We validated the questionnaire in several steps. A pilot testing was performed in 200 women. First, 20 
women aged 40-90 years, stratified with four women in each decade, who attended the osteoporosis 
outpatient clinic were interviewed about how they interpreted each of the questionnaire items. KHR 
observed 20 additional women in the same age range when they were completing the questionnaire. 
Whenever a respondent stopped or took longer than expected to answer an item, she was afterwards 
asked whether she had had problems answering. The questionnaire items were adjusted accordingly and 
the same procedure was repeated with a further 20 women until there were no new suggestions for 
changes. The pilot version of the questionnaire was also tested on 40 women from the general population 
(excluding hospitalized patients and healthcare personnel). In a further step, the questionnaire was mailed 
to 100 women to test the quality of the answers (such as missing items and response rate) and to test the 
OCR setup. If any item was missing, the woman was interviewed by phone (KHR) about the reason. A total 
of 70 women returned the questionnaire. Finally, the reliability of the questionnaire was tested by mailing 
it to the same 70 women again: 69 women responded and a close correlation between the fracture risk 
estimates by FRAX® (Rho=0.979) was found. Agreement (kappa) varied from 0.643 to 1.00 between items, 
and was between 0.643 and 0.800 for only three items (rheumatoid arthritis, other diseases associated 
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with secondary osteoporosis and use of oral glucocorticoids). Most women gave different estimations of 
their weight and height in the two questionnaire rounds, typically differing by 1-2 kilogram or cm, 
respectively.   
 
3.1.2 Study population 
Regarding paper I-III, we included 5,000 women aged 40-90 years, living in the Region of Southern Denmark 
and randomly selected from the Danish civil Registration system. The self-administered questionnaire was 
issued by mail in March 2009 together with a pre-paid return envelope. Reminders were mailed to non-
respondents twice (in the beginning and the end of May). All women returning a questionnaire were 
included in the analysis.  
After first issuing, 59% of the women returned the questionnaire; the first and second reminding resulted in 
a respondent rate of 79% and 84%, respectively. Some of the women returned the questionnaire blank or 
phoned us explaining the reason for not completing the questionnaire (Table 5).  
 
Table 5: Number of particpants and response rate for the postal questionaire 
Issuing Completed the questionnaire 
Returned the 
questionnaire blank 
Too sick to 
participate Total respondents 
First posting 2,895 (58%) 30 17 2,942 (59%) 
First reminder 3,681 (74%) 242 22 3,945 (79%) 
Second reminder 3,860 (77%) 297 37 4,194 (84%) 
 
 
A flowchart of the study participants in papers I-III is presented in Figure 6.  
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Figure 6: Flow chart of study participants in papers I-III  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 5,000 women were equally stratified by decades. The youngest women had the highest response rate, 
where women aged 51-60 had a response rate of 88%. The lowest response rate was among those aged 81-
90 years, but even in this age group 50% returned a completed questionnaire (Table 6). 
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N = 5,000 (100%) 
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N = 4,194 (84 %) 
No response 
N=806 
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in paper 2: 
N = 3,860 (77 %) 
Complete questionnaire 
included in paper 1: 
N = 3,636 (73 %) 
Excluded 
Blank questionnaire  
N = 297 
Too sick to complete N= 37 
Questionnaires included 
in paper 3: 
N = 3,614 (72 %) 
Excluded 
1-3 missing items 
N = 224 
Excluded 
Treated for osteoporosis 
N = 246 
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Table 6: Study population and response rate by age in decades 
Age, years (N) 
Respondents returning 
the questionnaire 
N (%) 
Respondents with less 
than 3 missing items 
N (%) 
Respondent with no 
missing items 
N (%) 
40-50 (1,000) 818 (82) 809 (81) 791 (79) 
51-60 (1,000) 894 (89) 882 (88) 863 (86) 
61-70 (1,000) 895 (90) 854 (85) 808 (81) 
71-80 (1,000) 841 (84) 751 (75) 676 (68) 
81-90 (1,000) 748 (75) 564 (56) 498 (50) 
Total (5,000) 4,194 (84) 3,860 (77) 3,636 (73) 
 
3.1.3 Data control and editing  
Following OCR, the questionnaire data were entered into a database. Because the questionnaires were 
scanned, the data were checked for correct scanning and to identify and deal with potential errors. If the 
Kodak scanner was unable to identify whether a respondent had marked a question with one or two 
crosses, then the answer was coded with the value ”888” and manually checked against the original 
questionnaire to resolve the issue. Answers on “weight” and “height” were inspected for extreme or 
missing values. Likewise, all other answers were verified according to predetermined values (1=Yes; 2=No; 
3=don’t know or 999=missing). In the case of missing values or other uncertainty, respondents were 
phoned for the correct answer (except if they had responded “no” to further contact from the study 
group). Missing values were coded as 2=”No”. If the value of “height” or “weight” was missing, we were 
unable to calculate the risk index, and these women were thus excluded from the analysis (papers I-III). 
 
3.2 Register data   
The data in papers I-III on mortality, demographics and fracture rates for the 5,000 women came from 
Danish national registers. This was possible because all persons residing in Denmark are assigned with a 
unique and permanent ten-digit personal identification number. This identification number is consistent 
throughout all national Danish registers and can be used to link data from all public registers at an 
individual level (99).  
These data were merged with information on death and emigration from the civil registration system and 
with information on fracture and hip surgery from the National Patient Register (NPR). The NPR covers all 
patient records in Danish hospitals since 1977 and, since 1995, also all outpatient and emergency room 
visits. Records are available for any given International Classification Disease (ICD-10) code and surgical 
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procedure (100). The register has a high validity (101) and the accuracy of diagnosis of fractures has an 
accuracy of 97% (102).  
Demographic data on each participant were extracted from Statistics Denmark, and included civil status 
(single, married, divorced, widowed or civil partnership), ethnicity (Danish, immigrant or descendant of 
immigrant), income per year, socio-economic status (in working, pensioner, on social security 
or government benefits), education (highest level achieved). This information was primarily used in paper I 
and II. 
In paper I, we extracted age-specific hip fractures and mortality rates from NPR on all women age 40+ years 
in the year 2004. 
For paper III, we extracted data on incident fracture for the 5,000 women during the follow-up period from 
the date of completing the questionnaire until April 2012. Fractures were classified either as “osteoporotic 
fractures” (excluding fractures of fingers, toes, skull or face) (ICD-10 codes: S12, S22, S32, S42, S52, S72, 
S82, T08) and “major osteoporotic fractures” defined by FRAX® (i.e. hip, clinical vertebral, wrist or humerus 
fracture; ICD-10 codes are shown in Table 7). For any individuals, only the first fracture in each category 
was counted to avoid overestimating rates due to readmissions. Hip fractures were validated using surgical 
procedure codes for primary hip arthroplasty and osteosynthesis (NFB00-92 and NFJ00-92, respectively), 
while hip fractures without an appropriate surgical code were omitted. Follow-up information on death and 
emigration was also collected in April 2012. 
Table 7: ICD-10 fracture codes used for “major osteoporotic fractures” 
Fractures ICD-10 code 
Hip DS720, DS721, DS722 
Wrist DS525, DS526 
Humerus DS422, DS423 
Vertebral DS120, DS121, DS122, 
DS220, DS221, DS320, DT08A 
 
 
3.3 Risk assessment tools 
The data from the questionnaire were used to calculate fracture risk of different risk assessment tools on 
each woman.  
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3.3.1 The Fracture Risk Assessment tool (FRAX®) 
FRAX® was developed under the auspices of the WHO and launched in 2008. FRAX® is a computer-based 
algorithm that calculates the 10-year probability of a major osteoporotic fracture (hip, clinical spine, 
humerus or wrist) and the 10-year probability of hip fracture in individuals aged 40-90 years. Fracture 
probability is computed taking both the risk of fracture and the risk of death into account (65). 
The fracture risk is calculated from age, body mass index and dichotomized risk factors comprising fragility 
fracture, parental history of hip fracture, current tobacco smoking, ever use of long-term oral 
glucocorticoids, rheumatoid arthritis, other causes of secondary osteoporosis and alcohol consumption. 
Femoral neck BMD is an optional input to enhance fracture risk prediction (65).  
FRAX® was developed using data from 9 population-based cohorts from Europe, North America, Asia, and 
Australia (65;103) and was validated in 11 independent, population-based prospective studied cohorts with 
over a million person-years of observation (65). It is currently available in 50 models for 45 countries and 
the website has been translated into 19 languages (FRAX® version 3.6) (104). In the absence of a FRAX® 
model for a particular country, a surrogate country in the same risk category may be used (105).  
The detailed algorithm for FRAX® is still not in the public domain, but it is possible to calculate the 10-year 
probability of fracture on an individual level using the FRAX® website (106). Thus, in papers I-III the FRAX® 
value was calculated using a programmed call of the FRAX® website (107). 
In papers I-III, we calculated the 10-year probability of fracture for the women who returned the 
questionnaire. The Swedish version of FRAX® (version 3.1) was used in papers I and II as no Danish version 
was available at that time (108) and it was only calculated for women returning a fully completed 
questionnaire. In paper I, the fracture risk was also calculated with the UK FRAX® version. In paper III,  the 
fracture risk for the same women was recalculated with the Danish version (version 3.4) and we further 
calculated the fracture risk for women having 1-3 missing items in the questionnaire, where the missing 
items were scored as a “no”. FRAX® was not calculated if data on height or weight were missing. 
In paper III, the risk score was classified as either high or low risk of fracture. We adopted the high-risk 
threshold used by the National Osteoporosis Foundation (NOF): 10-year probability of major osteoporotic 
fracture ≥20% (36). 
3.3.2 Calculation of fracture risk using tools to predict low BMD 
In paper III, the individual fracture risk was also calculated from OST, ORAI, OSIRIS and SCORE. These tools 
are designed to identify individuals at increased risk of having low BMD.  
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OST is the simplest tool and includes only age and weight (73). ORAI also includes estrogen use (109), 
OSIRIS adds non-traumatic fracture in the algorithm (110), while SCORE also includes rheumatoid arthritis 
and race (75). The scoring systems for included risk factors and the cut-offs for high risk are shown in Table 
8. The cut-offs for high and low risks are based on the suggestions of the respective developers and from 
validation studies of the tools in Caucasian populations (75;109;111;112). The definitions of low BMD in the 
tools vary slightly: while SCORE and ORAI use T-scores ≤-2.0 as cut-off, OST and OSIRIS used T-scores ≤-2.5 
(Table 8). 
All the tools were developed in women and then validated in independent cohorts; the performance of the 
tools being similar in the development and validation cohorts (113-116). OST has been validated in both 
men (117) and women (116;118); validation studies of the other tools included only women. 
Table 8: Scoring system for included risk factors and cut-off for high risk category in the risk assessment 
tools; OST, ORAI, OSIRIS and SCORE 
Risk factor Risk assessment tools 
 
OST (73) ORAI (109) OSIRIS (110) SCORE (75) 
 
Age 0.2*(weight (kg) 
-age (yrs)) 
+15 >75 yrs - 0.2*age (yrs) +3*first digit of age 
 +9 65-74 yrs 
 +5 55-64 yrs 
Weight +9 <60 kg - 0.2*weight (kg) -0.1*weight (lb)/10 
truncated to integer  +3 60-70 kg 
Estrogen use - +2  if not currently used +2 if currently used +1 if never 
Non-traumatic fracture - - -2 +4*fracture^  
Maximum +12 
Rheumatoid arthritis - - - +4 
Non-black race - - - +5 
Cut-off for high risk# 
Target T-score outcome 
< 2 ≥ 9 ≤ 1 ≥ 6 
TFN ≤-2.5 TFN or TLs ≤-2.0 TFN , TLs or TTH ≤-2.5 TFN  ≤-2.0 
^Rib, hip, wrist after age 45 years. 
# Suggested by the developer of the tools. 
FN = Femoral neck, LS=lumber spine, TH= Total hip  
3.4 Statistical methods 
Various statistical analyses were conducted in papers I-III, as appropriate to the study design and aim. 
Further details are provided in the individual papers. Statistical significance was set at p-values below 0.05. 
Statistical analyses were performed using SPSS statistics 17.0 in paper I and paper II and using STATA 12 in 
paper III.  
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In paper I, the chi2-test was used to evaluate the observed and predicted 10-year hip fracture risk both in 
the whole study population and in the age strata to test whether the Swedish version performed similarly 
in different age groups. The predicted 10-year hip fracture risk was calculated by individual risk scoring (as 
described in section 3.3.1). The observed risk was calculated as the expected total number of hip fractures 
in the total Danish population aged 40-90 years in 2004 (𝑣): 
𝑁ℎ𝑖𝑝(𝑡𝑜𝑡𝑎𝑙) = � 𝑁ℎ𝑖𝑝,10𝑦(𝑣)90
𝑣=40
 
where 𝑁ℎ𝑖𝑝,10𝑦(𝑣) signifies the expected number of hip fractures over 10 years for each start age cohort, 
e.g. 40 years old, 41 years old etc,, thus: 
𝑁ℎ𝑖𝑝,10𝑦(𝑣) = � 𝑃ℎ𝑖𝑝(𝑖, 𝑣) × 𝑁𝑎𝑡 𝑟𝑖𝑠𝑘 (𝑖, 𝑣)10𝑦
𝑖=1𝑦
 
where 𝑁𝑎𝑡 𝑟𝑖𝑠𝑘 (𝑖, 𝑣) is the remaining at-risk population after subtracting the number of expected deaths in 
start age cohort 𝑣 in year number i. 𝑃ℎ𝑖𝑝(𝑖, 𝑣)R  rates are the age-specific population hip fracture rates from 
NPR. We calculated the cumulative 10-year hip fracture risk for each age stratum as the sum of the 
predicted and observed risk, respectively.  
The chi2-test was also applied in paper II to test the different age groups (<65 and ≥65 years). The Z test was 
used to test equal proportions in comparing the two age groups. Logistic regression analysis was also used 
to evaluate differences between women with or without a history of DXA scan. All study variables were 
entered into the logistic regression and comprised nominal data, ordinal data as well as numeric variables 
categorized into appropriate intervals or dichotomized into yes/no. The analysis was made with and 
without stepwise regression, but only the results without stepwise regression were shown in the paper. 
The Homer-Lemeshow goodness-of-fit test was used to assess the fit of the model to the data (119).  
In paper III, the chi2-test was applied to test the difference in baseline characteristics of women with and 
without fractures during follow-up. Receiver operating characteristic (ROC) curves using C-statistics 
estimated from logistic regression was used to assess the ability of each tool to discriminate between 
women with or without incident fractures. Each point on the ROC curve marks the sensitivity and 
corresponding value of [1-specificity] for a given cut-off point in the risk tool. The AUC is an overall estimate 
of the accuracy of the risk tool to identify women with incident fracture. The area may vary from 0 to 1, 
where AUC statistics of 0.50 do not perform better than chance alone, while tools with higher AUC statistics 
perform better than chance. In order to adjust for censored women and to take time to event (fracture) 
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into consideration, we estimated the Harrell´s C index using Cox regression modelling. Harrell´s C is an 
analogue to AUC in a survival setting (120). In the performance comparison of the different tools we used 
the “roccomp” procedure in STATA to compare the AUC values between FRAX® and simpler tools. The 
agreement between the tools as to how well each tool assigned the women into risk quartiles was tested 
by using weighted kappa statistic. The data in paper III, were also analyzed using survival analysis to 
examine the performance of different risk assessment tools and incident fractures. The women were 
censored at the time of incident fracture, death or emigration. The cumulative incidence of fracture was 
calculated using Kaplan-Meier survival analysis divided into high and low risk of fractures. Since death may 
not occur independently from incident fracture, we did competing risk regressions analysis as an alternative 
to the Kaplan Meier curves to assess the influence of censorings that were not independent of occurrence 
of fracture.  
3.4.1 Assessment of methodological quality in the systematic review 
Paper IV was a systematic review, where Reference Manager was used to handle the identified articles. We 
followed the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Group (121). PRISMA is an update of the QUOROM (Quality Of Reporting Of Meta-
analyses) guidelines from 2009. The aim of the PRISMA statement is to help authors improve the reporting 
of systematic reviews and meta-analyses, and consists of a 27-item checklist (that includes items on the 
title, abstract, methods, results, discussion and funding) and a four-phase flow diagram (121). 
To assess the methodological quality of the studies, we applied the Quality Assessment Tool for Diagnostic 
Accuracy Studies (QUADAS) checklist (Appendix 2, S3 and S4) as recommended by the Cochrane Handbook 
for Systematic Reviews of Diagnostic Test Accuracy (122). The QUADAS tool for systematic reviews of 
diagnostic accuracy studies was developed in 2003. The tool includes 14 items assessing risk of bias, 
sources of variation (applicability), and reporting quality; each item is rated “yes”, “no”, or “unclear”. The 
QUADAS tool includes guidelines for scoring each of the included items (123). We added additional items 
specific to this review, and modified some of the original items to fit the review as suggested by the 
developers of QUADAS (124). 
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4. Results 
A short summary of the results from the four published papers is presented in the following sections. 
4.1 Study I: Fracture risk assessed by Fracture Risk Assessment Tool (FRAX®) compared 
with fracture risk derived from population fracture rates 
The analyses described in paper I included the 3,636 women (73%) that had responded to all the items in 
the questionnaire. The predicted 10-year hip fracture risk calculated by the Swedish version of FRAX® 
(without BMD) was 7.6% for the sample as a whole. When stratified by age, the predicted 10-year hip 
fracture risk ranged from 0.3% at the age of 40-50 years to 25% at 81-90 years. The observed fracture risk 
based on age-specific hip fracture rates from NPR and survival tables from Statistics Denmark was 7.6% 
(range 0.4% to 24%). There were no statistically significant differences between predicted and observed 
risk either in the sample as whole or in each age stratum. The Swedish version of FRAX® without BMD thus 
appears well calibrated for Danish women as regards hip fracture risk.  
Post-hoc analyses omitting some items or some subgroups gave similar results (Table 9). However, when 
fracture risk was recalculated using the UK version of FRAX®, the “predicted” risk was significant lower than 
the corresponding “observed” risk.   
Table 9: Post-hoc analyses of the 10-year probability of hip fracture (“predicted” and “observed”)   
 FRAX® (S) National hospital discharge register p (χ²) 
 "Predicted" risk "Observed" risk 
All respondents 277/3,636 (7.6%) 275/3,636 (7.6%) 0.918 
UK version  189/3,636 (5.2%) 275/3,636 (7.6%) <0.001 
Omitting premature menopause 262/3,636 (7.2%) 275/3,636 (7.6%) 0.556 
Only postmenopausal 273/2,885 (9.5%) 270/2,885 (9.4%) 0.892 
Omitting “don’t know” answers 225/3,072 (7.3%) 223/3,072 (7.3%) 0.940 
Only premenopausal women 4.8/751 (0.6%) 5.5/751(0.7%) 0.813 
 
4.1.1 Comparison of respondents and non-respondents 
Compared to non-respondents, respondents had higher annual income, were more likely to be employed, 
married and born in Denmark (Table 10).  There were a greater proportion of pensioners among the non-
respondents. 
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Table 10: Characteristics of respondents and non-respondents in paper I 
 Respondent Non-respondent p (χ²) 
Annual income (DKK) 210,432 164,301 < 0.001 
Employed 43% 19% < 0.001 
Pensioner 62% 76% < 0.001 
Widow 22% 40% < 0.001 
Married 62% 37% < 0.001 
Danish 96% 92% < 0.001 
 
4.1.2 The Danish version of FRAX® compared with national register rates 
When the Danish version of FRAX® was released (after the publication of paper I), we compared results 
using the Danish version of FRAX® with data from national registers (Table 11). We found no statistically 
significant differences between predicted and observed hip fracture risks. 
 
Table 11: 10-year hip fracture (”predicted” and ”observed”) using the Danish version of FRAX 
10-year hip fracture risk, N and % 
Age FRAX® (DK) "Predicted" risk 
National hospital 
discharge register (DK) 
"Observed" risk 
p (χ²) 
40-50 3/791 (0.3%) 3/791 (0.4%) 0.872 
51-60 13/863 (1.5%) 12/863 (1.4%) 0.852 
61-70 38/808 (4.8%) 40/808 (4.9%) 0.892 
71-80 100/676 (14.8%) 101/676 (14.9%) 0.949 
81-90 133/498 (26.8%) 120/498 (24.0%) 0.322 
40-90 288/3,636 (7.9%) 275/3,636 (7.6%) 0.573 
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4.2 Study II: Prevalence of risk factors for fractures and use of DXA scanning in Danish 
women. A regional population-based study 
The analyses described in paper II, included the 3,860 women who returned the questionnaire with less 
than three missing items. Of these, 664 (17.2%) had a history of DXA scan – of whom 71% were over 65 
years old (Figure 7). 
Figure 7: The distribution of 664 women with a history of DXA scan according to age 
 
 
Table 12 shows the prevalence of self-reported risk factors for osteoporosis and the percentage of women 
with each risk factor who had a history of DXA. The most frequent risk factors were conditions associated 
with secondary osteoporosis (21%), smoking (21%), age above 80 years (16%) and history of low energy 
fracture (12%). In women with a history of low-energy fracture, 34% had a history of DXA compared with 
52% of women with a history of oral glucocorticoid therapy. 
Of the 443 women with a history of low energy fracture, 101 had experienced two previous fractures, 38 
had three fractures, 11 had four fractures and 4 women had experienced 5 or more low-energy fractures 
(data not reported in paper II). In all, 701 (18%) women reported prevalent fractures at wrist, hip or 
vertebral in parents or siblings after the age of 50 years. Regarding the alcohol consumption, 76 (2%) 
women consumed an average of 3 units daily and 35 (1%) consumed four or more units daily. Finally, 174 
(4.5%) women had used oral glucocorticoids in a dose of at least 5 mg per day for a period of three months 
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or more, while 154 (4%) had used oral glucocorticoids for four months or more (data not reported in paper 
II). 
Table 12: Prevalence of risk factors in 3,860 women and history of DXA in women with each risk factor    
Risk factors 
Prevalence of risk factors 
N (column %) 
History of DXA in women with 
each risk factor 
Yes (row %) 
Conditions associated with 
secondary osteoporosis 811 (21.0) 221 (27.3) 
Current smoker 790 (20.5) 121 (15.3) 
Age above 80 years 613 (15.9) 140 (22.8) 
History of low energy fracture* 443 (11.5) 152 (34.3) 
Premature menopause (<45 years) 436 (11.3) 112 (25.7) 
Parental hip fracture 413 (10.7) 97 (23.4) 
History of falls** 267 (6.9) 82 (30.7) 
Use of oral glucocorticoids*** 174 (4.5) 91 (52.3) 
BMI <19 kg/m2 143 (3.7) 44 (30.9) 
Alcohol ≥ 3 units daily 76 (2.0) 19 (25.0) 
*Low energy fracture after age 40 years; **More than 1 fall in one year where the falls were not associated with external impact; 
*** Dosage > 5 mg for more than 3 months. 
In the study sample, 37.4% of the women had no risk factors while 62.6% had one or more risk factors. 
Those below 65 years were more likely to have no risk factors, while 76,6% of the women above 65 years 
have 3 or more risk factors (Figure 8). 
Figure 8: Number of prevalent risk factors stratified by age in 3,860 women 
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Of those women without any risk factor for osteoporosis, 10.3% had a history of DXA, while only 36.3% of 
women with three or more risk factors had a history of DXA (Figure 9). When stratifying the women 
according to age, history of DXA scan was positively related to number of prevalent risk factors, but still 
only 32% of women below 65 years with 3 or more risk factors had had a DXA scan, and 37.5% of the 
women above 65 years. The results indicate a relatively high use of DXA in low-risk women and a relatively 
low DXA coverage in women with multiple risk factors. 
Figure 9: Number of prevalent risk factors according to history of DXA scan in 3,860 
  
The FRAX® 10-year fracture risk was calculated, categorized into four groups (<15%, 15-19.9%, 20-24.9% 
and ≥25%) and then related to history of DXA scan. Increasing 10-year fracture risk was related to greater 
likelihood of previous DXA scan, where 8.7% of women with a risk below 15% had previous DXA compared 
to 30.2% of women with a 10-year fracture risk above 25%.  
History of DXA was also compared to the distance from the respondent’s home address to the nearest DXA 
facility (categorized into distances below 10 km, 10-29 km, 30-39 km and above 40 km). Greater distance to 
a DXA facility was associated with less likelihood of previous DXA such that 20.2% of women with less than 
10 km to the nearest scanner had a history of DXA compared to 11.5% of those with more than 40 km to 
the nearest scanner.  
The logistic regression analysis showed that several variables were significantly associated with a history of 
DXA, i.e. shorter distance to DXA clinic, use of oral glucocorticoids, higher 10-year fracture risk, age (65-79 
years), low BMI, history of falls, conditions associated with secondary osteoporosis, previous low energy 
fracture, living with a spouse and annual income (150,000-249,999 DKK).  
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4.3 Study III: Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE 
and age alone) to identify women with increased risk of fracture. A population-based 
prospective study 
The analyses described in paper III, were also based on the 3,860 women who returned the questionnaire 
with less than three missing items, but with an additional 246 women excluded because they had been 
diagnosed and treated for osteoporosis, leaving 3,614 women for analysis. The mean follow-up was 36 
months [30-37] (10,385 person-years). During follow-up, 156 (4%) women had a “major osteoporotic 
fracture”, 225 (6%) had an “osteoporotic fracture”, 174 (5%) died and 6 were lost to follow-up (Figure 10). 
The non-respondents suffered more fracture; 7% of the non-respondents had a “major osteoporotic 
fracture during follow-up. 
Figure 10: Flow-chart of participants in paper III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Women with incident fractures during follow-up differed from those without fracture, being older (mean 
age 73 ± 11 versus 63 ± 13 years, p=0.001), more likely to have history of fracture (22% versus 9%, p<0.001) 
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or of falls during the previous 12 months (14% versus 6%, p<0.001) or to have conditions related to 
secondary osteoporosis (26% versus 18%, p=0.011), and less frequently to currently use estrogen (3% 
versus 11%, p=0.001).  
We found no significant difference between the different tools or age alone in the predictive ability to 
identify incident fracture based on AUC and Harrell´s C values. The AUC values ranged from 0.703–0.722, 
indicating that the tools were modest predictors of incident fracture (Figure 11). Kaplan-Meier analysis and 
competing-risk regression also showed very similar results between tools or age alone. 
Figure 11: AUC for ROC analyses between various risk assessment tools and age alone, n=3,614 women 
 
Kappa analysis showed that agreement in categorization of women according to quartiles of risk was 
moderate. With regards to identifying women at highest risk, however, approximately 80% of the women 
classified in the top quartiles by FRAX® were also categorized as high risk by all the other tools. This 
indicates that virtually the same women would meet the threshold for treatment regardless of the tool 
used. 
4.3.1 Methodological quality of paper III 
After submission of the manuscript for publication, we assessed the methodological quality of the study 
using the modified QUADAS checklist (for tools predicting fractures) that was used in paper IV. We 
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concluded that the overall methodological quality of the study was good, since the paper scored positively 
on 8 of the 13 items, with only 2 negative items and 3 unclear items (Table 13). 
The reasons for the two negative items were that the data were based on self-reported risk factors and the 
follow-up period was less than 10 years. The uninterpretable results were considered to be unclear and we 
had not clearly in this paper accounted for missing data. Fracture data were also rated as unclear, as the 
register data were not verified against clinical notes or the women. 
Table 13: Methodological quality of paper III according to a modified QUADAS checklist to tools 
predicting fracture 
 yes No Unclear  
Representative sample X 
  Selection criteria described X 
  Tools described (a final model) X 
  Fracture collection verified 
  
X 
Possible to collect risk factors in clinical practice X 
  Uninterpretable results reported 
  
X 
Withdrawals from the study explained X 
  Data on risk factors from interview  
 
X 
 Participants adequately described X 
  No missing data 
  
X 
Study sample over 1000 subjects X 
  Over 100 fractures during follow-up  X 
  Time of follow-up 
 
X 
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4.4 Study IV: Risk assessment tools to identify women with increased risk of osteoporotic 
fractures. Complexity and simplicity? A systematic review 
The final electronic literature search for paper IV was untaken on August 18, 2012. We found 991 papers 
after removing duplicates. The first screening of title and abstract reduced the number for full-text 
screening to 188 papers. Two independent reviewers screened the 188 papers and further excluded 100 
papers due to irrelevant intervention, outcome or population and a single paper due to inability to retrieve 
the full text. A hand search and a search in Web of Science identified an additional 16 papers. On the basis 
of external validation criteria, 28 papers were excluded and 76 papers were included in the initial review.  
Twenty risk assessment tools had been externally validated – 8 tools to predict low BMD and 12 tools to 
predict fractures (Figure 12). There was considerable variation in the number of times each tool had been 
validated and the number of clinical risk factors included in the final algorithm. The simplest tools only 
included 1 or 2 risk factors, while the most complex included 31 risk factors. 
 
Figure 12: Flow chart of the systematic review and evaluation of risk assessment tools 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When the 20 tools were evaluated according to methodological quality of their studies (>60% on QUADAS) 
and external validation (more than once in a population-based setting), the number of relevant tools was 
reduced to six – three tools to predict low BMD (OST, ORAI, and SCORE) and three tools to predict fractures 
48 tools 
  
20 tools
8 tools 12 tools
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Predicting Low BMD
Proper methodological quality 
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(Garvan, FRAX® and Qfracture) (Figure 12). None of the tools had been examined for effectiveness in 
selecting patients for therapy and none had been prospectively tested in a population-based setting with a 
randomized design where they demonstrated improved fracture outcome. We are aware of two ongoing 
randomized studies in which patients are selected for DXA using FRAX® and with fractures as the primary 
outcome (125;126)(Holmberg and colleagues; The Risk-stratified Osteoporosis Strategy Evaluation Study 
[ROSE] (126)). 
The ability of the tools to differentiate between individuals with low or high risk of osteoporotic fractures 
was evaluated by comparing the AUC values. Figure 13 shows the results for the six tools with more than 
one validation study of acceptable methodological quality. The size of the circles reflects the number of 
women included in the studies, the number of risk factors included in the tools is shown on the x-axis and 
the AUC values are on the y-axis. The complexity of the tools did not appear to influence their 
discriminative power, and no tool performed consistently better than the others. Furthermore, the simple 
tools with fewer risk factors (OST, ORAI, GARVAN) often did as well or better than the more complex tools 
with more risk factors ( SCORE, FRAX®, Qfracture). 
 
Figure 13: Ability (AUC values) of six risk assessment tools to predict low BMD or fracture in relation to 
number of included risk factors and the sample size in validation studies 
 
OST = Osteoporosis Self-assessment Tool, ORAI = Osteoporosis Risk Assessment Instrument, SCORE = Simple Calculated Risk 
Estimation Score 
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6. Discussion  
The results of this thesis showed that the Swedish version of FRAX® without BMD was well calibrated for 
Danish women regarding hip fracture risk. Similar results were achieved using the Danish version of FRAX® 
when this became available. DXA appeared to have been performed on a relatively high number of low-risk 
women and a relatively low number of women with multiple risk factors. Distance to the DXA clinic, patient 
age, and a number of socio-economic factors influenced the use of DXA. 
The more complex tool FRAX® did not perform better in predicting fracture compared with simpler tools 
such as OST, ORAI, OSIRIS and SCORE or even age alone. Study quality was poor for most of the 48 existing 
tools for predicting fractures, and only six tools had been tested more than once in a population-based 
setting with acceptable methodological quality. None of the tools performed consistently better than the 
others. In general, simple tools (i.e. OST, ORAI and Garvan) often did as well or even better than more 
complex tools (i.e. SCORE, FRAX®, and Qfracture). The effectiveness of tools in selecting patients for 
therapy and thus improving fracture outcomes has not yet been studied.  
6.1 Methodological considerations 
The main data source in the thesis was a self-completed questionnaire on clinical risk factors for 
osteoporosis sent by post to 5,000 women living in the Region of Southern Denmark. These women were 
randomly selected from the general population, but because the accompanying letter explained that the 
questionnaire included items on osteoporosis, it is conceivable that women at higher risk of osteoporosis 
were more motivated to return the questionnaire, potentially resulting in self-selection bias. Comparison of 
respondents and non-respondents using data from central registers revealed minor differences in age, 
fracture outcome and socio-economic status. Non-respondents were older, had more fractures during 
follow-up and had lower socio-economic status than respondents. Studies have shown that the proportion 
of people with unhealthy lifestyles (with a negative effect on bone health) is higher among individuals with 
lower socio-economic status (127), indicating that the women participating in the studies described in this 
thesis may have been healthier than the general population. 
The cross-sectional design in paper I enabled us to test whether FRAX® was well calibrated to the Danish 
population, but did not allow an assessment of the predictive power of FRAX®. Long-term prospective study 
designs are thus needed before FRAX® can be used in clinical practice at an individual level. We tested 
FRAX® in a prospective design in paper III, and Friis-Holmberg et al. (128) also tested FRAX® prospectively in 
a Danish population, but none of these studies have 10 years of follow-up, which is the time scale to which 
FRAX is calibrated. 
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The cross-sectional design in paper II was the best approach in that context, as the main focus was the 
relationship at a specific point in time between risk factors for fracture and the use of DXA scans. Distance 
to the DXA clinic was estimated using the home address that the questionnaire was mailed to. We did not 
have the date of the DXA scan and so cannot exclude the possibility that some women had moved since the 
DXA scan and thus had an incorrect estimate for distance to a DXA facility. This distance could be measured 
more precisely in a prospective study design. 
A prospective design was used in paper III to evaluate incident fracture rates over time in relation to risk of 
fracture assessed by different risk assessment tools. The linkage of the questionnaire data to the national 
patient register (NPR) ensured nearly complete follow-up with quite accurate information on the amount of 
time each person had been at risk of fracture. This register is considered to be one of the most 
comprehensive databases internationally (100) and has a high validity regarding diagnostic codes (101). The 
major osteoporotic fractures are defined as by FRAX® (i.e. hip, wrist, humerus and vertebral fractures) 
(106). These fracture types were chosen because they are the most frequent and are closely related to 
osteoporosis (7). We were able to retrieve the number of fractures on the basis on the ICD-10 codes in the 
NPR, but it was not possible to validate whether a given fracture was caused by low-energy trauma – thus 
the QUADAS checklist item on fracture collection was coded as unclear as we could not exclude the 
possibility that some of the fractures included in paper III were not osteoporotic. Furthermore, probably 
only a small number of vertebral fractures are included in the NPR, because many vertebral fractures are 
asymptomatic or associated with only a few, uncharacteristic symptoms and thus remain undiagnosed in 
hospital registers (1). Completion of the questionnaire may have prompted some of the women to contact 
their GP for further advice. This may in turn have resulted in some of them starting anti-osteoporosis 
medication during follow-up, and some fractures might have been prevented. This might explain the 
observation that respondents had fewer fractures during follow-up than non-respondents.  
One of the main limitations in paper III was the duration of the follow-up. However, we took time to event 
into account in our analyses and similar studies have shown that the efficacy of fracture prediction is 
independent of the duration of follow-up (78;80;84;129). After the publication of paper III, we evaluated its 
methodological quality and concluded that the uninterpretable results were not clearly reported and nor 
did we explain how we handled missing data. Though not explicitly stated in paper III, missing answers in 
the questionnaire were coded as 2=”No” in the calculation of the fracture risk index. In other words, 
unstated risk factors were assumed to be absent. We believe this is the most realistic representation of the 
clinical use of FRAX. If data were missing on height and weight, the mean values for the study population 
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were used. This could potentially have led to misclassification and thus underestimation of the real fracture 
risk among the women.  
6.2 FRAX® 
The FRAX® tool was used in all four papers of this thesis, though with different approaches. FRAX® is limited 
by a number of inherent features. First, it does not take into account “dose response” for several risk 
factors (e.g. number of fractures, amount of glucocorticoid use). Second, FRAX® uses the T-score of the 
femoral neck BMD only and does allow entry of DXA data from multiple skeletal sites. Third, FRAX does not 
adjust for severity of diseases potentially causing secondary osteoporosis (e.g. rheumatoid arthritis). 
Finally, several well-known risk factors for fracture are not included in the FRAX® algorithm such as falls, 
bone turnover markers, fracture in siblings and non-hip fractures in parents (104;130).  
In our study population, 23% and 9% of the women with a history of low-energy fracture had two or more 
low-energy fractures and three or more low-energy fractures, respectively. In reality, but not captured by 
FRAX®, these women are at a higher risk of fracture as two prior fractures carry a much higher risk of 
fracture than a single prior fracture (131). In contrast to FRAX®, other algorithms do include the number of 
prior fractures, for example SCORE (75) and Garvan (67;68). 
Regarding prior glucocorticoid use, FRAX® assumes an average risk for an average dose of 5 mg daily and an 
average duration of three months (65), even though dose response is evident for glucocorticoid exposure 
(132). In our study, 174 women had used oral glucocorticoid for three months or more; however 154 of 
these had used oral glucocorticoids for at least four months and thus had an even higher fracture risk that 
was not reflected in the FRAX® result.   
Dose response is also evident for alcohol intake (49), and the FRAX® algorithm accommodates three or 
more units daily (as a “yes”). While 76 women in our study were in this category, 35 of them consumed 
more than four units daily.  
FRAX® includes an item on history of hip fracture in the patient’s parents. However, parental history of 
fracture at other skeletal sites and fractures in siblings are also risk factors (53;133). In our study, 413 
women reported a parental hip fracture, while 701 women reported fracture in wrist, hip or vertebrae in 
parents or siblings. Again, omission of these factors may result in FRAX® underestimating the fracture risk. 
A further criticism of the FRAX® tool is the lack of consideration of falls or risk of falls in predicting fractures. 
Masud et al. (134) have strongly recommended that falls should be incorporated into FRAX®, as falls are 
strongly associated with fracture risk (135). FRAX® underestimates fracture risk in individuals who have 
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with a history of falls that exceeds the population average – such as the 77 women in our study who had 
prior falls and no other risk factor that could increase their fracture risk calculated by FRAX®. Prior falls are 
included in some other algorithms, such as Garvan and Qfracture. In paper III, we were unable to calculate 
fracture risk using these tools, however, as Qfracture includes a number risk factors not addressed by our 
questionnaire and Garvan requires information on the number of falls over the last 12 months. These two 
tools were not available when we developed and validated our questionnaire and thus their items could 
not be taken into consideration. Despite this, the 10-year fracture risk for a woman in our study with a 
history of at least two falls and no other risk factors would be considerably higher calculated by Garvan 
than by FRAX®. For example a woman aged 81 years with a weight of 60 kg would have a 10-year risk of 
major osteoporotic fracture of 28% on FRAX® and 40% on Garvan. Similarly, she would have a 10-year risk 
of hip fracture of 12% on FRAX® and 19% on Garvan.  
A further limitation of FRAX® is that it only includes T-score at the femoral neck, even though lumbar spine 
BMD is frequently measured by DXA and indeed incorporated into several clinical guidelines (36;136;137). 
We did not measure BMD and are aware of this as a potential limitation in our studies. In paper III, we 
discussed that studies including FRAX® with BMD only had a slightly higher AUC than FRAX® without BMD 
(78;80;129;138). 
The FRAX® tool is constructed for different countries using a generalized risk model and national hip 
fracture and mortality rates. The FRAX® model is currently available for 45 countries (104). It is remarkable, 
however, that when high-quality national hip fracture data are unavailable, FRAX® recommends the use of 
hip fracture incidence rates from a “surrogate country” alongside the target country mortality rates (104). 
No validation of newly calibrated models is made before they are publicized, and only few subsequent 
FRAX® publications have evaluated the calibration process (139). 
The underlying equations used in FRAX® have never been published or placed in the public domain (140) 
and its calculations are somewhat of a black box. Some authors have noted disappointment that FRAX® in 
an era of reproducible research and transparent reporting have failed to deliver on either (140). We found 
in paper IV that the methodological quality of the development and validation cohort was poor and that 
insufficient information is available for objective evaluation of FRAX®. Actually, FRAX® was omitted from a 
systematic review of fracture risk tools due to these reservations (70).  
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6.3 Choice of risk assessment tool  
In paper IV, we demonstrated that only six of the many published tools were validated in studies of good 
methodological quality. In papers III and IV, we found that simple tools do just as well as FRAX®. Several 
other studies support these findings (78;80;85;86). 
The fracture risk calculation tools that are available online include FRAX® (65), Garvan (67;68) and 
Qfracture (74). In paper IV, Garvan performed as well as FRAX® in fracture prediction despite including only 
four clinical risk factors and BMD or bodyweight. An important difference between Garvan and FRAX® is the 
time frame for risk estimation and the approach to the competing risk of mortality. The Garvan calculator 
estimates 5- and 10-year risk of fracture, while FRAX® only estimates 10-year risk of fracture. FRAX® takes 
account of the competing risk of mortality, however (61;141). Several validation studies (78;84;85;142) and 
a newly published review (61) of FRAX® suggest that the FRAX® model underestimates the risk of fracture. 
The 10-year fracture risk in elderly individuals is substantially lower when calculated by FRAX® compared to 
Garvan. This has led Bolland et al. (141) to suggest that for elderly people, clinicians should use risk 
assessment tools that provide fracture risk estimated for shorter time periods (e.g. Garvan). The Garvan 
tool should also be easier to use due to fewer risk factors included in the algorithm. Like FRAX®, however, 
Garvan should be externally validated in prospective randomized studies before clinical implementation.  
 
6.4 Clinical use of risk assessment tools 
A risk assessment tool has many potential uses in screening, case-finding and guiding treatment and may 
be appropriate for use by the GP and/or patients themselves. Although all the tools aim to stratify 
individuals according to risk of osteoporotic fracture, we showed (in paper IV) that only FRAX® has found 
broader acceptance. Methodological weaknesses of tool development could be one explanation, as most 
tools have not been subject to proper external validation – and none have been prospectively validated in 
randomized studies. Moons et al. (143) suggested for the need for “impact studies” after the validation of a 
model and before implementation in clinical practice. Impact studies attempt to compare the effect of a 
prediction model on clinician behavior (i.e. changing therapeutic decisions, acceptability), cost-
effectiveness or patient outcomes against a system without the prediction model (143). While impact 
studies are the ultimate test and evaluation of a prediction model, we are not aware of any impact studies 
on osteoporosis risk assessment tools. 
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Although clinical management of osteoporosis aims at reducing the incidence of fractures, there is no 
consensus on which high-risk patients should be targeted – those with more immediate high risk (e.g. 
within the next 5 years) or those with high risk over the remaining lifetime.   
Only a single risk assessment tool (FRAX®) is currently incorporated in national osteoporosis guidelines 
(36;87). It is stated that FRAX® should not be considered as a gold standard in patient assessment, but 
rather as a reference platform. It is interesting that FRAX® is recommended for clinical decisions on further 
DXA testing as well as treatment, even though FRAX® has not been tested in independent prospective 
randomized studies. There is, however, no consensus on how to approve a risk assessment tool for clinical 
use. This is in contrast to the detailed and strict rules regarding approval of new drugs (144) and CE labeling 
of medical equipment (145). 
A number of studies have compared national strategies for osteoporosis case-finding and treatment 
recommendations, but have come to different conclusions (91-97). The most recent study after the 
inclusion of FRAX® in national guidelines is that by Bolland et al. (91), who found very different outcomes 
according to whether UK (87) or US (146) osteoporosis treatment guidelines were applied. The study 
included 1,471 healthy older women with a mean age of 74 years and mean follow-up of 4.4 years. While 
the NOGG guidelines predicted only a minority of fracture cases, the NOF guidelines predicted the majority 
of fracture cases (91). Applying the NOF guidelines resulted in recommendation for treatment in almost 
half of the patients (and about two-thirds of the women who subsequently experienced a fracture), while 
applying the NOGG guidelines resulted in recommendation for treatment in 21% (and one-third of the 
women who subsequently experienced a fracture). Furthermore, the NOGG guidelines recommend 
treatment of younger people at low absolute risk, but older people with high absolute risk are denied the 
benefits of effective therapies (91).    
Kanis et al. (11) have published new European guidelines for the management of osteoporosis in 
postmenopausal women, based on an update of the International Osteoporosis Foundation and European 
Society for Clinical and Economic aspects of Osteoporosis and Osteoarthritis guidelines from 2008 to 
further a cohesive approach to the management of osteoporosis in Europe (11). If a country like Denmark 
provides good access to DXA scanner the recommendations are remarkable identical to the NOGG 
guidelines with an age-specific recommendation. If these guidelines were recommended for the Danish 
population, we would have the same concern as other authors (61;141), namely that the results would be 
under-treatment of older people at high risk of fracture, because of the 10-year time frame and 
adjustments for mortality risk. Further over-treatment of younger people, since studies have shown that 
the NOGG guidelines recommends treatment of younger people at low absolute risk (141).  
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We are aware of two ongoing population based randomized studies to evaluate strategies for population 
screening that includes decision tools, including FRAX®: The English study SCOOP (125) and the Danish 
study ROSE (the Risk-stratified Osteoporosis Strategy Evaluation) (126). The SCOOP study includes 
approximately 12,000 women aged 70-85 years randomized to either questionnaire-based screening or 
standard care. The ROSE study includes 35,000 women aged 65 to 80 years and is evaluating the 
effectiveness of a two-step screening strategy. Outcome variables include effectiveness in terms of 
prevention, incident clinical fractures, cost-effectiveness, participation rate and patient preferences. 
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7. Main conclusions 
The results from the four papers presented in this thesis show that risk assessment tools could be 
potentially useful in the clinical management of osteoporosis to identify women at highest risk of fracture.  
In paper I, we demonstrated that the Swedish version of FRAX® without BMD was well calibrated for Danish 
women with regard to hip fracture risk. Similar results were achieved using the Danish version of FRAX® 
when this became available.  
The findings in paper II suggest that the current case-finding strategy does not perform as intended. We 
found a relatively high use of DXA in low-risk women and a relatively low coverage in women with multiple 
risk factors. Moreover, we found that distance to DXA clinic, patient age, and several socio-economic 
factors influenced the use of DXA and thus need to be considered in future strategies for the management 
of osteoporosis. 
Papers III and IV both showed that simpler risk assessment tools perform as well or even better than more 
complex tools. Paper III described a prospective study with follow-up over three years and using self-
reported clinical risk factors. The more complex tool FRAX® did not predict fracture risk better than simpler 
tools such as OST, ORAI, OSIRIS and SCORE or even age alone.  
Paper IV was a systematic review that revealed the high number of risk assessment tools that have been 
developed. Only 20 of the 48 tools for prediction of osteoporotic fractures have been externally validated, 
however, where eight tools aimed to identify individuals at risk of low BMD and 12 tools aimed to identify 
individuals with an increased risk of fracture. Only six tools have been tested more than once in a 
population-based setting with acceptable methodological quality. None of the tools performed consistently 
better than the others and simple tools (i.e. OST, ORAI, and Garvan) often did as well or better than more 
complex tools (i.e. SCORE, FRAX®, and Qfracture). We did not find any studies evaluating the effectiveness 
of tools in selecting patients for therapy and thus improving fracture outcomes. 
The primary conclusion of this thesis is that risk assessment tools could be useful in the clinical 
management of osteoporosis to identify women with increased risk of osteoporotic fracture. Furthermore, 
simpler tools with fewer risk factors would be easier to use in clinical practice by the GP or the patient 
herself and may be just as effective as more complex tools such as FRAX®. Still, none of these simpler tools, 
however, have been validated in prospective, randomized studies.  
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8. Future perspectives  
This thesis has shown that risk assessment tools can potentially be useful in the clinical management of 
osteoporosis to identify individuals at increased risk. At the present time, however, there are still 
challenges to be solved by future research. 
Risk assessment tools can assist health care providers to identify women at increased risk but will not 
identify all individuals with osteoporosis. Nor will they be able to predict exactly which individuals will 
experience a fracture in the years ahead. Studies that could chart the likelihood of fractures over time 
would be of great interest and could contribute to data from assessment tools that aim to predict risk over 
certain periods, e.g. the 10-year risk of fracture.  
Since FRAX® already are implemented into several guidelines, it will be interesting to follow the finding 
from the two randomized studies in some years (125;126), The results of this thesis suggest, however, that 
more focus should be put on validating simpler tools (e.g. Garvan) in high-quality randomized studies with 
population-based samples or cohorts with different case mixes, thus not concentrating on FRAX® alone.  
No regulations currently exist on which decision tools may be implemented in clinical medicine. We 
propose that such tools are subjected to Health Technology Assessment (HTA) before implementation into 
guidelines. This type of assessment would ensure systematic and comprehensive evaluation of 
performance and safety and would include analyses of the tool’s effects on clinical and patient outcome as 
well as organizational and economic aspects. 
Some guidelines recommend that individuals with FRAX® probabilities over a certain age-dependent 
threshold should be offered treatment. We question the evidence for these recommendations and 
encourage studies to monitor treatment decisions based on FRAX®. Because our research suggests that 
simpler tools do just as well as more complex tools, we would also recommend the monitoring of 
treatment decisions based on simpler tools such as Garvan. 
In Denmark, the diagnosis of osteoporosis and the treatment decision rely primarily on the result of DXA 
scans, although clinical risk factors are considered and are required for treatment reimbursement in 
patients without a low-energy fracture. The findings of this thesis show that a relatively high number of 
low-risk patients are referred for DXA, suggesting a sub-optimal use of the resources at DXA clinics. The use 
of a risk assessment tool in case-finding strategies may improve the use of DXA resources.  
A further avenue for research is the role of risk assessment tools in communicating risk of osteoporosis or 
fracture. Explanation of risk and its implications is often challenging and is not always understood by 
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patients and health care personnel. Abrahamsen et al. (147) have speculated that back-transformation of 
risks to a risk age could give a clearer message, but this approach has yet to be tested. Smoking is one of 
several modifiable risk factors for osteoporosis and it maybe that “risk” illustrated by a risk assessment tool 
could be used by the general practitioner when advising and assisting patients to stop smoking.  
Current tools use a set of risk factors to predict the 5-year or 10-year risk of any fracture, i.e. without 
specifying the site of fracture, because it is assumed that the same set of risk factors is associated with all 
fractures. This assumption is incorrect, however, because risk factors for hip fracture are not necessarily 
the same as risk factors for vertebral fracture (61). It would be useful to have this in mind when existing 
tools are being refining or new tools are being developed. 
The availability of electronic case records and access to reliable databases should allow the inclusion of 
register-based risk assessment tools that automatically assess the patient’s risk of osteoporotic fracture. 
Such ”pop-up” menus could prompt the doctor to expand the medical history to explore risk factors for 
osteoporosis and may facilitate clinical decision-making.  
A further unexplored area in the management of osteoporosis is the possibility of empowering patients 
through the use of risk assessment tools. Several tools are freely available on the Internet, giving patients 
the opportunity to see for themselves whether they are at increased risk of osteoporotic fracture. This 
could have beneficial effects on referrals to DXA scanning.    
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Abstract
Purpose: To evaluate the performance of the Swedish version of Fracture Risk Assessment Tool (FRAX)) without bone mass
density (BMD) in a Danish population to examine the possibility of applying this version to Danish women. Methods: From
the Danish National Register of social security numbers, we randomly selected 5000 women living in the region of Southern
Denmark aged 4090 years to receive a mailed questionnaire concerning risk factors for osteoporosis based on FRAX. The
predicted 10-year probability of hip fractures was calculated for each woman returning a complete questionnaire using the
Swedish version of FRAX. The observed 10-year hip fracture risk was also calculated for each woman using age-specific hip
fracture rates from the National Hospital Discharge Register and National survival tables. Results: A total of 4194 (84%)
women responded to the questionnaire and 3636 (73%) gave complete information and were included in the analysis. Using
FRAX, the predicted 10-year fracture risk was 7.6%, ranging from 0.3 to 25.0% at the age of 4150 and 8190, respectively,
while the corresponding observed fracture risk was 7.6%, ranging from 0.4 to 24.0%, respectively and not significantly
different from the predicted risk (p¼ 0.92). Conclusions:The Swedish version of FRAXwithout BMD is applicable to
Danish women.
Key Words: Epidemiology, FRAX, hip fracture, risk factors, women
Introduction
Osteoporosis is a highly prevalent disease in women
leading to fractures, chronic pain, disability, and
increased mortality [1]. In Sweden, approximately
46% of all women will suffer from at least one
osteoporotic fracture from the age of 50 years [2].
Globally, the lifetime risk of hip fractures at the age of
50 years varies, as illustrated by 14% in women from
UK, 16.5% in women from Denmark, and 28.5%
in women from Sweden [3]. The diagnosis of
osteoporosis relies on the assessment of bone mass
density (BMD), usually by dual-energy X-ray
absorptiometry (DXA) of the spine and/or hip [4].
In Denmark as in many other countries, a case-
finding strategy is used to identify patients with
possible osteoporosis. Ideally, women with one or
more risk factors should be referred to a DXA-scan
by their general practitioner. This strategy, however,
seems to result in referral of only few high-risk
patients while many resources are used to examine
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women with low fracture risk [5]. Thus, osteoporosis
is under-diagnosed and under-treated in Denmark,
as is likely to be the case elsewhere [5].
Recently, the WHO Collaborating Centre for
Metabolic Bone Diseases at Sheffield developed the
Fracture Risk Assessment Tool (FRAX) to improve
the case-finding strategy and help general practi-
tioners in their daily practice to calculate the indi-
vidual risk of fracture in women and men in order to
identify the patients at highest risk of fractures [6,7].
FRAX uses clinical risk factors to predict the 10-year
probability of hip and other major osteoporotic
fractures in individual patients. The estimate can be
based on risk factors alone or using risk factors
together with femoral neck BMD. FRAX was con-
structed using information from data of nine popula-
tion-based cohorts from Europe, North America,
Asia, and Australia [8,9]. The National Osteoporosis
Foundation and the National Osteoporosis Society
have recently updated their guidelines and included
FRAX as a tool for case-finding on identifying
patients at high risk for fractures, for selecting
patients for DXA and for treatment decisions
[10,11].
The FRAX model is available in 17 different
countries; however, in many other countries includ-
ing Denmark, there is currently no national version of
the FRAX calculation tool. In the absence of a FRAX
model for a particular country, a surrogate country in
the same risk category may be used [7,12]. FRAX has
been validated in 11 independent population based
cohorts with a similar geographic distribution and
that did not participate in the model synthesis [9].
Among these there was a Danish study (the PERF
study), but of the clinical risk factor information, only
history of prior fracture was available on this study
[13].
The purpose of the present study was to evaluate
the performance of FRAX without BMD in Danish
women. We hypothesised that FRAX as calibrated to
the Swedish population would be applicable to
Denmark. We compared the fracture risk as assessed
by FRAX calculated from self-reported risk factors in
a random sample of the population with fracture risk
derived from population fracture rates and mortality
rates in Denmark.
Methods
Design
The study was designed as a population-based cross-
sectional study. Data was based on self-reported risk
factors from a random sample of the population.
Moreover, nationwide age-specific hip fracture rates
and survival tables from registers were used.
Participants
From the Danish National Register we randomly
selected 5000 women living in the region of
Southern Denmark, aged 4090 years, equally strat-
ified by decades. In the period of March–May
2009, a self-administered questionnaire concerning
risk factors for osteoporosis based on FRAX was
issued to this population. Reminders were mailed
to non-respondents twice. All women returning a
complete questionnaire were included in the analysis.
No other exclusion criteria were applied.
Signed and returned questionnaires were consid-
ered as informed consent to be included in the
analysis. All participants were anonymised and the
study was approved by the local ethical committee.
Questionnaire
The questionnaire comprised items on weight,
height, ethnicity, history of osteoporosis, personal
and family history of fracture, smoking habits, con-
sumption of alcohol, use of oral glucocorticoids, and
diseases associated with secondary osteoporosis (e.g.
rheumatoid arthritis, type l diabetes, osteogenesis
imperfecta, untreated long-standing hyperthyroid-
ism, hypogonadism or premature menopause (<45
years), chronic malnutrition or malabsorption, and
chronic liver disease). The questions were designed
to allow answering by simple ‘‘yes’’, ‘‘no’’, or ‘‘don’t
know’’ with the possibility to comment and could be
completed in about ten minutes.
The questionnaire was read by optical character
recognition (OCR), using a Kodak i640 scanner and
OCR for AnyDoc 5.0 software. The accuracy of this
setup was tested by concurrent manual feeding of
data from 100 questionnaires without any difference
in data registration.
A pilot version of the questionnaire was tested on
approximately 200 women. One author (KHR)
interviewed 20 women about how they understood
each item. Twenty additional women were inter-
viewed after completing the questionnaire and some
of the questions were adjusted accordingly. This
procedure was repeated until consistency was
achieved. The questionnaire was then mailed to
100 women to test the quality of the answers and to
estimate the participation rate. The reliability of the
questionnaire was also tested in 69 women returning
the questionnaire twice. A close correlation between
fracture risk estimates (Rho¼ 0.979) was found and
correspondence (kappa) varied from 0.643 to 1.00
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between items, with only three items between 0.643
and 0.800 (rheumatoid arthritis, other diseases asso-
ciated with secondary osteoporosis, and use of oral
glucocorticoids).
Register data
Denmark offers good possibilities for conducting
population based surveys since all Danish citizens are
assigned with a unique and permanent 10-digit social
security number at birth allowing valid linkage of
information at the individual level between all
national registries.
The National Discharge Register covers all in- and
outpatient records in Danish hospitals. Records are
available for any given International Classification of
Diseases code and surgical procedure [14]. The
register has a high validity [15] and the diagnosis of
fractures has previous been reported with accuracy of
97% [16]. We collected background population
demographics (i.e. civil status, income, and socio-
economic status) from Statistics Denmark on all the
5000 women invited to participate in the study. Also,
age-specific mortality rates were obtained from
Statistics Denmark.
Calculation of 10-year hip fracture risk
We calculated the 10-year hip fracture risk for the
study population in two different ways: predicted and
observed risks. Both estimates incorporate adjust-
ment for 10-year survival rates.
The predicted 10-year hip fracture risk was calcu-
lated by individual risk scoring using the Swedish
version of FRAX based on the self-reported risk
factors from the questionnaire using a programmed
call of the FRAX website [17].
The observed 10-year hip fracture risk was calcu-
lated by using age-specific hip fracture rates from the
National Hospital Discharge Register and survival
tables from Statistics Denmark. We obtained the
number of women discharged with hip fracture
(S720 and S721) in the calendar year 2004 stratified
by age (5-year intervals) [18]. This calendar year was
the latest available from the National Hospital
Discharge Register.
The observed 10-year hip fracture risk was calcu-
lated as the expected total number of hip fractures in
total age group (v) 40–90 years:
Nhip totalð Þ ¼
X90
v¼40
Nhip,10yðvÞ
where Nhip,10yðvÞ signifies the expected number of hip
fractures over 10 years for each start age cohort, e.g.
40 years old, 41 years old etc, therefore:
Nhip,10yðvÞ ¼
X10y
i¼1y
Phipði, vÞ Nat riskði, vÞ
where Nat riskði, vÞ is the remaining at-risk population
after subtracting the number of expected deaths in
start age cohort v in year number i. Phipði, vÞ rates are
shown in Table I.
We furthermore stratified the women according to
decades and calculated the cumulative 10-year hip
fracture risk for each age stratum as the sum of the
predicted risk and the sum of the observed risk,
respectively.
Statistical methods
Data are shown as meanSD or median (range) as
appropriate. Chi-squared test (one-sided) was
applied to test predicted and observed risk. p-values
<0.05 were considered statistically significant. No
Bonferroni adjustments were applied. Analyses were
performed using SPSS statistics 17.0.
Results
Respondent rate
The questionnaire was mailed to 5000 women and
4194 (84%) women responded to the questionnaire
(Figure 1). A total of 558 questionnaires were blank
or had at least one missing item and were excluded
from the analysis leaving 3636 (73%) available for
analysis.
Anthropometrics and prevalence of risk factors
Characteristics of the participants are shown in
Table II. The median age was 64 years,
body weight was 6914 kg, height 165 6 cm and
Table I. Age-specific hip fracture rates from the Danish National
Hospital Discharge Register, i.e. women discharged with the
diagnosis of hip fracture in the year 2004.
Age (years)
Hip fracture rate per
1000 per year
4044 0.11
4549 0.24
5054 0.46
5559 0.94
6064 1.49
6569 3.26
7074 6.49
7579 12.85
8084 22.57
85þ 42.90
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body mass index was 25.5 4.8 kg/m2. A relatively
high percentage (19.4%) of women had diseases or
conditions associated with secondary osteoporosis.
Especially the item ‘‘premature menopause (<45
years)’’ was responsible for the high fraction (11.3%)
of women who reported diseases potentially associ-
ated with secondary osteoporosis. A total of 11.5% of
the women had a fragility fracture after the age 40
years and 10.7% have a mother or a father that have
had a hip fracture. Smoking was very prevalent
(20.5%), 2% of the women drank more than three
units alcohol daily, and 4.5% of the women had used
oral glucocorticoids for at least 3 months with a
dose45 mg.
10-year fracture risk
Table III shows the predicted and the observed
10-year hip fracture risk. Using FRAX in the study
population, the predicted 10-year fracture risk was
7.6%, ranging from 0.3 to 25.0% at the age of 4150
and 8190, respectively, while the corresponding
observed fracture risk was 7.6%, ranging from 0.4 to
24.0%, respectively. No statistical significant differ-
ence was seen between predicted and observed risk in
the overall population in any age strata.
Sensitivity analysis
Sensitivity analysis was performed by reanalysing
data omitting the item ‘‘premature menopause’’ since
the fraction of the women answering ‘‘yes’’ to this
items was unexpectedly high. The predicted 10-year
fracture risk in the cohort changed from 7.6% to
7.2%; however, the difference between predicted and
observed risk in the overall population in any age
strata remained non-significant (data not shown).
Similarly, reanalysis recoding all ‘‘don’t know’’
responses to ‘‘no’’did not change the results (data not
shown). A total of 564 questionnaires contained
answers with ‘‘don’t know’’.
A total of 20% of the women in our study were pre-
menopausal. Reanalysis omitting these women did
not change the results (data not shown). Also,
reanalysis including pre-menopausal women only
gave similar results (data not shown).
Finally, we recalculated the predicted 10-year
fracture risk using the UK version of FRAX
(Table IV). In this case, the predicted 10-year
fracture risk was 5.2% significantly lower than the
corresponding observed fracture risk of 7.6%
(p< 0.001). At all decades, we found that the
Included
N=5000
Respondents
N=4194 (84%)
Complete
questionnaire N=3636
(73%)
No response
N=806
Excluded
Blank questionnaire N=297
To sick to complete N=37
1–3 missing items N=224
Figure 1. Flow-chart illustrating inclusion of participants.
Table II. Characteristics of the study population.
Characteristic N (%)
Respondents 3636 (73)
Post-menopausal 3100 (80.3)
Current smoker 790 (20.5)
History of low-energy fracturea 444 (11.5)
Hip 62 (1.6)
Spine 68 (1.8)
Wrist 246 (6.4)
Rib 23 (0.6)
Other 186 (4.8)
Parental hip fracture 413 (10.7)
Rheumatoid arthritis 209 (5.4)
Use of oral glucocorticoidsb 174 (4.5)
Body mass index <19 kg / m2 142 (3.7)
Alcohol43 units daily 76 (2.0)
Diseases associated with secondary osteoporosis 748 (19.4)
Premature menopause (<45 years) 436 (11.3)
Untreated longstanding hyperthyroidism 242 (6.3)
Type 1 diabetes 37 (1.0)
Osteogenesis imperfecta in aldults 24 (0.6)
Malabsorption 21 (0.5)
Chronic liver disease 17 (0.4)
Values are N (%).
aLow-energy fracture after age 40 years.
bDosage45 mg more than 3 months.
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predicted FRAX (UK) score was lower than the
observed rates derived from the Danish register data.
Comparison of respondents and non-respondents
A number of demographic and socio-demographic
were available both in respondents and non-respon-
dents. The youngest women had the highest respon-
dent rate; especially the women aged 5160 with a
respondent rate of 86%. The lowest rate was among
the 8190 years old women, but even in this age
group 50% returned a complete questionnaire.
Respondents had a higher mean income per year
(210,432 Danish Kroner (DKK) versus 164,301
DKK for non-respondents, p< 0.001). Also, 43%
of the respondents were employed compared with
only 19% of the non-respondents (p< 0.001). A
higher percentage of the non-respondents were pen-
sioners compared to the respondents (76% versus
62%, p< 0.001). The geographical distribution of
the women in the region of Southern Denmark was
the same in the respondents and non-respondents
group.
Discussion
Our study showed that hip fracture rates predicted by
FRAX were very similar to observed rates derived
from age-specific incidence rates and mortality rates
from the Danish National Hospital Discharge
Register and national survival tables.
Our results also suggest that the difference between
Sweden and Denmark regarding the frequency of
fractures is largely explained by differences in age
distribution and prevalence of the risk factors, e.g.
smoking, included in the FRAX algorithm. In this
study we found that 21% of the women were smokers
compared with 22% in the background population in
Denmark above 15 years [19]. In Sweden, smoking is
less prevalent, i.e. 15% of the women above 15 years
[20], and in one of the primary cohorts from Sweden
only 8.2% of the women were smokers [21]. Indeed,
the gradients of fracture risk used in the FRAX tool
were validated in independent cohorts to ensure
robustness of the algorithm regarding these [22].
Some of the large variation in age- and sex-specific
fracture risk between countries [3], however, may
be due to differences in the prevalence of risk factors
not included in FRAX (e.g. genetics, diet, and
exercise). Our approach using data on risk factors
in a random sample of the population in conjunction
with register data on fracture and mortality rates
provides a means to validate FRAX irrespective of the
existence of such unknown factors. In absence of
local historical cohorts with long-time follow-up, our
approach is a realistic alternative to a 10-year obser-
vational study.
Table III. Ten-year probability of hip fractures: predicted (using the Swedish version of FRAX) and observed (from the National Hospital
Discharge Register).
Age (years) Predicted Observed p (2)
4050 3/791 (0.3) 3/791 (0.4) 0.858
5160 12/863 (1.4) 12/863 (1.4) 0.939
6170 37/808 (4.5) 40/808 (4.9) 0.724
7180 104/676 (15.3) 101/676 (14.9) 0.833
8190 123/498 (25.0) 120/498 (24.0) 0.805
4090 277/3636 (7.6) 275/3636 (7.6) 0.918
Values are n/total (%).
Table IV. Ten-year probability of hip fractures: predicted (using the UK version of FRAX) and observed (from the National Hospital
Discharge Register).
Age (years) Predicted Observed p (2)
4050 2/791 (0.3) 3/791 (0.4) 0.635
5160 8/863 (0.9) 12/863 (1.4) 0.309
6170 23/808 (2.8) 40/808 (4.9) 0.032
7180 60/676 (8.9) 101/676 (14.9) 0.001
8190 96/498 (19.3) 120/498 (24.0) 0.073
4090 189/3636 (5.2) 275/3636 (7.6) <0.001
Values are n/total (%).
316 K. H. Rubin et al.
We used the Swedish version of the FRAX calcu-
lation tool since both Denmark and Sweden are
categorised as countries with ‘‘very high’’ probability
ratios of fractures [3]. Even though the age-specific
incidence of hip fracture is higher in Sweden com-
pared with Denmark [2] and life expectancy for
Danish women born between the two World Wars is
lower than for Swedish women [23], FRAX appears
well calibrated for Denmark as regards hip fracture
risk in women across a wide age range. This is not
surprising since the populations are similar with
regard to diets and living standard and also are
connected genetically. We also compared Denmark
and UK since lifetime hip fracture risk at 50 years is
similar in these countries [3]. At all decades, how-
ever, we found that the predicted FRAX (UK) was
lower than the observed rates derived from the
Danish register data (Table IV) suggesting that
factors not included in FRAX (e.g. genetics, diet,
or exercise) or mortality rates differ between these
countries.
Our questionnaire included items on a number of
diseases potentially associated with secondary osteo-
porosis exemplified on the FRAX website [24]. The
frequency of positive answers on these items was very
high (19.4%). This was explained by a high fre-
quency of ‘‘premature menopause’’ (11.3%). In
theory, this could lead to an overestimation of the
FRAX prediction; however, sensitivity analysis did
not support this idea (data not shown).
We designed our questionnaire with the options
‘‘yes’’, ‘‘no’’, or ‘‘don’t know’’ to ensure it to be
exhaustive and inclusive. In contrast, the FRAX
website only allows ‘‘yes’’ or ‘‘no’’. As demonstrated
by our sensitivity analysis, however, this approach
had little impact on the results and no impact on the
conclusion (data not shown).
We included women aged 40–90 years because this
is the age range covered by FRAX. Some of the
women were pre-menopausal but still included in the
analysis even though FRAX is only recommended for
use in post-menopausal women [8]. Results, how-
ever, were unchanged if analysis was restricted to
post-menopausal women (data not shown).
The FRAX tool was developed for professional use
by e.g. general practitioners. In this study we trans-
lated it into a self-administrated questionnaire and
73% of the respondents returned this completely
filled. Although, the number of non-completed
questionnaires was higher in the elderly (25%), the
approach worked very well. This suggests that
the FRAX tool could be developed into a tool for
the patients.
Our study has important strengths. First, it was
population based. Similarly, FRAX is based on
primary data from prospective population-based
cohorts [9]. Second, we had a high response rate
(84%) surpassing the primary studies included in the
development of FRAX. We even had a very high
response rate among the women aged 8090 years
(75%). In the analysis we had to exclude 25% of the
response from this group because of incomplete
answers, but still 50% of the women aged 8090
years returned a complete questionnaire. Third, the
questionnaire was validated in a large number of
women before its use and had a high reliability.
Moreover, the questionnaire was scanned to mini-
mise errors during data entry. Finally, we relied on
data from national registers since data on hip frac-
tures have a high accuracy, i.e. 97% [15,16].
Our study also has limitations. First, the data were
based on self-reported risk factors and thus poten-
tially prone to bias. Despite a high respondent rate,
we cannot completely exclude the possibility that
women at high risk of fracture were more motivated
to participate in this study. Indeed, comparison of
respondents and non-respondents revealed some
differences. Respondents were more often married,
less often widowed, had a higher income, and were
more often employed and less often pensioners.
Marriage status, income, or employment, however,
were considered strong risk factors for fracture.
Second, our study focussed on hip fractures since
ascertainment of this particular fracture in registers is
very reliable [16]. Third, we limited our study to
include hip fractures since virtually all patients with
such fracture are admitted to hospital while this is not
the case for ‘‘major osteoporotic fractures’’ which
include clinical spine fractures. Finally, the cross-
sectional design did not allow testing the predictive
power of FRAX at an individual level.
In conclusion, our study showed that the Swedish
version of FRAX without BMD appears to fit very
well to the Danish female population. The study
further demonstrates an approach for checking per-
formance of a particular FRAX model based on
questionnaires issued to a sample population com-
bined with age-specific fracture rates and mortality
rates.
Preliminary results were shown on the 7th Baltic
Bone and Cartilage Conference, Nyborg, Denmark,
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Abstract
Summary To determine the relationship between risk
factors and use of DXA scans. Our study showed a
relatively high use of DXA in low-risk women and the
relatively low coverage in women with multiple risk
factors. Moreover, distance to DXA clinics, age, and
socio-economic factors are associated with the use of
DXA.
Introduction To determine the relationship between risk
factors for fracture and use of DXA scans in Danish women
in relation to distance to DXA clinics and socio-economic
factors.
Methods From the Danish National Civil Register we
randomly selected 5,000 women aged 40–90 years living
in the region of Southern Denmark to receive a mailed
questionnaire concerning risk factors for fractures.
Results The respondents rate was 84% and 77% of the
invited population were available for analysis. A total of
10.3% of the women without risk factors and only 36%
of the women with three or more risk factors had a
history of DXA. The likelihood of a history of DXA
was higher with increasing FRAX(™) 10-year risk; i.e.,
8.7% and 30.2% in patients with a 10-year fracture risk
of 0–14.9% and 25–100%, respectively. In women with
less than 10 km to nearest DXA facility, 20.2% had a
history of DXA, while 11.5% of those with more than
40 km to the nearest scanner had a history of DXA.
Logistic regression analysis showed that distance,
fracture risk, oral glucocorticoids, low-energy fracture,
conditions associated with secondary osteoporosis, low
BMI, history of falls, age 65–79 years, spouse status,
and income were significantly associated with having a
history of DXA.
Conclusions Our study showed a relatively high use of
DXA in low-risk women and the relatively low coverage in
women with multiple risk factors. Moreover, distance to
DXA clinics, age, and a number of socio-economic factors
are associated with the use of DXA.
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Introduction
Osteoporosis is highly prevalent especially in post-
menopausal women [1] imposing considerable burdens on
the individual [2] and significant costs on the society [3].
The diagnosis of osteoporosis relies on the assessment of
bone mineral density (BMD), usually by central dual
energy X-ray absorptiometry (DXA) [4]. Worldwide,
recommendations and access to DXA vary greatly. The
US Preventive Services Task Force (USPSTF) recommends
DXA screening in all women aged 65+ as well as in women
60 to 64 years with increased risk of fracture [5]. National
Osteoporosis Foundation (NOF) recommends testing of all
women aged 65+ regardless of clinical risk factors, but also
women aged 50+ with clinical risk factors [6]. In contrast,
only patients with a history of fractures are advised to have
a DXA scan in Norway [7]. Similarly, based on 2005 data,
the access to DXA varies around Europe with 20 units/
million inhabitants in France and Portugal, 3.7 units/million
in UK and 9.4 units/million in Denmark [8].
Recently, the Fracture Risk Assessment Tool (FRAX®)
was developed to improve the case-finding strategy and
allow general practitioners (GPs) to calculate the individual
risk of fracture and thus identify the patients at highest risk
of fractures [9, 10]. FRAX uses clinical risk factors to
predict the 10-year-probability osteoporotic fractures in
individual patients. The NOF and the National Osteoporosis
Society (NOS) have recently updated their guidelines and
included FRAX as a tool to identify patients at high risk for
fractures and select patients for DXA and to assist in
treatment decisions [6, 11]. Also, FRAX has recently been
validated in a Danish study [12; manus submitted] as well
as in a UK study [13].
In Denmark, a case-finding strategy has been adopted by
the Danish Bone Society and other professional societies
[14, 15] recommending general practitioners to refer
women with one or more risk factors (see Appendix 1)
for DXA [16]. The Danish Medicine Agency adheres to
the same recommendations regarding reimbursement of
medication [16]. Despite universal coverage, no copayment
in Denmark, a relative good access to DXA clinics and
reimbursement of patients' medicine expenses, osteoporosis
is still under-diagnosed and under-treated in Denmark [17].
This questions the efficiency of the case-finding strategy.
The aim of the present study was to determine the
relationship between the prevalence of risk factors for
fracture and the use of DXA scans in Danish women in
relation to distance to DXA clinics and socio-economic
factors. We hypothesized that patients with well-defined
risk factors and high risk of fracture are not referred, while
many women with very low risk are scanned. We further
hypothesized that potential barriers, e.g., distance to DXA
clinics and low social status, decrease the use of DXA.
Methods
Design
In this population-based, cross-sectional study we included
5,000 women, aged 40–90 years, randomly selected from
the population of the region of Southern Denmark using the
Danish Civil Registration system. In the spring of 2009, the
women were mailed a self-administered questionnaire
concerning risk factors for fractures. Signed and returned
questionnaires were considered as informed consent to be
included in the analysis. All participants were anonymi-
mized and the study was approved by the Local Ethical
Committee.
This study was performed in Denmark, where the
general income tax funds the public healthcare system
providing universal coverage to the population. Hospital,
general practice, and specialist services are provided for
free at the point of use [18]. GPs act as gatekeepers and
refer patients to hospitals. DXA scans are provided with no
copayment. Patient with T score<−2.5 and with one or
more risk factors are eligible for reimbursement of the
expenses on osteoporosis medicine. Denmark has a total of
24 DXA clinics spread throughout the country. In 2005, at
least 36,367 DXA scans were performed [19]. The
maximum distance to the nearest DXA clinics is 100 km,
while for the majority of the population the distance is less
than 30 km.
Questionnaire
The questionnaire comprised items on body weight, body
height, history of osteoporosis, history of DXA scans,
personal and family history of fracture, smoking habits,
consumption of alcohol, use of oral glucocorticoids, and
conditions associated with secondary osteoporosis (e.g.
rheumatoid arthritis, osteogenesis imperfecta, untreated
hyperthyroidism, hypogonadism, or premature menopause
(<45 years), chronic malnutrition or malabsorption and
chronic liver disease). The questionnaire was validated and
reliability tested as previously reported [12; manus submitted].
The returned questionnaires were read by optical character
recognition (OCR) using a Kodak i640 scanner and OCR
for AnyDoc 5.0 as software. The accuracy of this setup
was tested by concurrent manual feeding of data from
100 questionnaires without discrepancies.
Calculation of FRAX
The 10-year probability of major osteoporotic fracture
value was calculated using the Swedish version of FRAX.
As previously demonstrated, this is applicable to Denmark
[12; manus submitted]. The calculation was based on the
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self-reported risk factors from the questionnaire and
performed by a programmed call of the FRAX website
[20].
Socioeconomic data
We obtained demographic data, i.e., civil status, income,
and socioeconomic status, from Statistics Denmark on each
participant.
Distance to DXA facilities
The Region of Southern Denmark comprises 835,375
inhabitants over 25 years (51% women). A total of six
DXA clinics including one private and five public clinics
have been open for referral for periods during the last
10 years. The maximum distance to a DXA clinic was
90 km. For each participant, we calculated the distance to
the nearest DXA facility using a programmed call of a
Danish route planner web site [20].
Statistical methods
Data are shown as mean ± SD or median (range) as
appropriate. Body Mass Index (BMI) was calculated
from self-reported body height and body weight (kg/m2).
Chi-square test (two-sided) was applied to test the
different in groups. Z test for equal proportions was
applied in comparing women <65 and ≥65 years. P values
below 0.05 were considered statistically significant.
Logistic regression analyses were performed with history
of DXA scans (yes/no) as the dependent variable. The
independent dichotomous variables were parental hip
fracture, history of low-energy fracture after the age of
40 years, history of falls, BMI≤19 kg/m2, smoking, alcohol
consumption of three or more units a day, menopause
before the age of 45 years, use of oral glucocorticoids at a
dosage above 5 mg for at least 3 months and conditions
associated with secondary osteoporosis. These cut-offs are
chosen, regarding to the FRAX calculation tools [21] and
to the Danish guidelines [16]. Categorical variables
included the 10-years probability of major osteoporotic
fracture. This variable was arbitrarily categorized into the
following intervals “0–14.9%”, “15–19.9%”, “20–24.9%”,
and “25–100%”. Age was categorized into less the
65 years, 65–79 years and above 80 years.
The demographic data were distance from home to the
nearest DXA clinic (categorical). This variable was
arbitrarily categorized into “<10 km”, “10–29 km”,
“30–39 km” and “≥40 km”.
The socioeconomic data included in the logistic regres-
sion were working status (work/not in work), spouse status
(married (living with a spouse)/living alone), ethnic
background (Danish/immigrant), and income (categorical).
Income were arbitrarily categorized into “<150,000 Dkk.”,
“150,000–249,999 Dkk.”, and “≥250,000 Dkk.”
All variables were entered into the logistic regression
analysis. We used the Homer–Lemeshow goodness-of-fit
test to assess the fit of the model to the data [22]. Statistical
analyses were performed using SPSS statistics 17.0.
Results
Respondent rate
The questionnaire was mailed to 5,000 women aged 40–
90 years and 4,194 (84%) women responded to the
questionnaire (Fig. 1). A total of 334 questionnaires were
blank or largely incomplete leaving 3,860 (77%) for
analysis. A total of 224 questionnaires had one to three
missing items. Thus, the FRAX calculation was only
performed on complete questionnaires (3,636 (73%)).
Anthropometrics and prevalence of risk factors
The median age of the women was 64 years. Self-
reported body weight was (mean ± SD) 69±14 kg, body
height 165±6 cm, and BMI 25.5±4.8 kg/m2. The
prevalence of risk factors is shown in Table 1. A total of
11.5% of the women had suffered a low-energy fracture
after the age 40 years, 10.7% have a mother or a father
with a history of hip fracture, 20.5% of the women were
current smokers, and 2% of the women had an alcohol
consumption of three or more units daily. A total of 4.5%
of the women had used oral glucocorticoids for at least
3 months in a dosage above 5 mg/day and 21% of women
reported diseases or conditions associated with secondary
Fig. 1 Flow chart illustrating inclusion of participants
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osteoporosis. “Immobilization more than 1 month” (10.5%)
and “untreated hyperthyroidism” (6.3%) were frequent con-
ditions associated with secondary osteoporosis reported by the
respondents.
Table 1 also shows the prevalence of risk factors
stratified in women above and below the age of 65 years.
A higher percentage of women above 65 years reported a
history of low-energy fracture (20.2% versus 4.0%, p<
0.001), a premature menopause (14.9% versus 8.2%, p<
0.001), a history of falls (10.0% versus 4.3%, p<0.001),
conditions associated with secondary osteoporosis (26.5%
versus 16.3%, p<0.001), use of oral glucocorticoids (6.8%
versus 2.5%, p<0.001) and a low BMI (4.9% versus 2.7%,
p=0.001) compared with women less than 65 years. In
contrast, smoking was more frequent in women less than
65 years (24.1% versus 16.1%, p<0.001).
Table 2 shows the number of prevalent risk factors. A
total of 37.4% of the participants had no risk factors
while 62.6% had one or more risk factors and 11.5% had
three or more risk factors. The prevalence of women
with several risk factors was higher in those above
65 years as compared with the younger women (19.2%
versus 4.9% had three or more risk factors, p<001, data
not shown).
Risk factors and history of DXA
Table 2 further shows that 664 (17.2%) of all women had a
history of DXA; of these 471 (70.9%) women were above
65 years.
A total 10.3% of all women without any risk factor
had a history of DXA. Women with several risk factors
were more likely to be DXA scanned; 21% of all women
with three or more risk factor had a history of DXA (not
shown) and 36.3% of all women with three or more risk
factors had a history of DXA. In women above the age
of 65 years, 19.2% with no risk factors had a history of
DXA while this was the case for 6.7% for women aged
less than 65 years (p<0.001).
A total of 22.4% of the women with a history of DXA
had no risk factors and 8.9% of the women without a
history of DXA had three or more risk factors (not shown).
Prevalence of risk factors and history of DXA
Table 1 further shows the percentage of women with a
history of DXA in those within each risk factor. In patients
with a history of low-energy fracture, 34.3% had a history
of DXA compared with 52.2% in patients with a history of
Table 1 Prevalence of self-reported risk factors for fracture in 3,860 women and history of DXA in women with each risk factor
Risk factors All women
(n=3,860)
(column%)
Prevalence of risk factors History of DXA in
women with each risk factors
Women
<65years
(n=2,087)
(column%)
women≥65years
(n=1,773)
(column%)
Chi-square test
(two-sided)
Yes (row%)
Current smoker 790 (20.5) 504 (24.1) 286 (16.1) <0.001 121 (15.3)
Age above 80 years 613 (15.9) NA 613 (34.6) NA 140 (22.8)
History of low-energy fracturea 443 (11.5) 84 (4.0) 359 (20.2) <0.001 152 (34.3)
Premature menopause (<45 years) 436 (11.3) 171 (8.2) 265 (14.9) <0.001 112 (25.7)
Parental hip fracture 413 (10.7) 208 (10.0) 205 (11.6) 0.110 97 (23.4)
History of fallsb 267 (6.9) 90 (4.3) 177 (10.0) <0.001 82 (30.7)
Use of oral glucocorticoidsc 174 (4.5) 53 (2.5) 121 (6.8) <0.001 91 (52.3)
BMI≤19 kg/m² 143 (3.7) 57 (2.7) 86 (4.9) 0.001 44 (30.8)
Alcohol≥3 units daily 76 (2.0) 33 (1.6) 43 (2.4) 0.060 19 (25.0)
Conditions associated with secondary osteoporosis 811 (21.0) 341 (16.3) 470 (26.5) <0.001 221 (27.3)
Immobilisation for more than 1 month 407 (10.5) 173 (8.3) 234 (13.2) <0.001 103 (25.3)
Untreated hyperthyroidism 242 (6.3) 102 (4.9) 140 (7.9) <0.001 64 (26.4)
Rheumatoid arthritis 209 (5.4) 79 (3.8) 130 (7.3) <0.001 72 (34.4)
Osteogenesis imperfecta 24 (0.6) 5 (0.2) 19 (1.1) 0.001 18 (75.0)
Malabsorption 21 (0.5) 14 (0.7) 7 (0.4) 0.245 5 (23.8)
Chronic liver disease 17 (0.4) 7 (0.3) 10 (0.6) 0.285 6 (35.2)
Anorexia nervosa 15 (0.4) 10 (0.5) 5 (0.3) 0.327 4 (26.7)
a Low-energy fracture after age 40 years
bMore than one falls on 1 year where the falls arise without any external impact
c Dosage >5 mg more than 3 months
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oral glucocorticoids therapy, 30.8% in those with a low
BMI, 30.7% in patients with a history of falls, 27.3% in
those with conditions associated with secondary osteopo-
rosis, 25.7% in patients with a premature menopause,
23.4% in those with a history of parental hip fracture and
22.8% of those above 80 years.
Ten-year fracture risk and history of DXA
Table 3 shows the 10-year fracture risk as calculated from
FRAX in relation to the history of DXA. In women with a
10-year fracture risk below 15%, 8.7% had a history of
DXA. With increasing 10-year fracture risk more women
had a history of DXA scan; in women with a 10-year
fracture risk above 25%, 30.2% had a history of DXA. In
women above the age of 65 years 17.9% with 10-year
fracture risk below 15% had a history of DXA while this
was the case for 7.6% for women aged less than 65 years
(p<0.001).
Distance to DXA facility
Table 4 shows the distance from the women's home address
to nearest DXA facility in relation to history of DXA. In
women with less than 10 km to nearest scanner, 20.2% had
a history of DXA, while 11.5% of those with more than
40 km to the nearest scanner had a history of DXA.
Correspondingly, 35.5% of the women with a history of
DXA had less than 10 km to nearest scanner and 10.5% had
more than 40 km (Not shown). In the age-stratified
Table 2 Number of risk factors in 3,860 women aged 40–90 years according history of DXA
Number of risk factors Total History of DXA History of DXA History of DXA Z test for proportions (p value)
(n=3,860) All women
(n=3,860)
Women <65years
(n=2,087)
Women≥65years
(n=1,773)
(Between <65 and ≥65years)
(Column%) Yes (row%) Yes (row%) Yes (row%)
0 1,442 (37.4) 149 (10.3)a,b,c 69 (6.7)b,c 80 (19.2)a,b,c <0.001
1 1,315 (34.1) 202 (15.4)d,e 53 (7.4)d,e 149 (24.7)e <0.001
2 659 (17.1) 152 (23.1)f 38 (15.4)f 114 (27.6)f <0.001
≥3 444 (11.5) 161 (36.3) 33 (32.0) 128 (37.5) 0.155
Total 3,860 (100) 664 (17.2) 193 (9.2) 471 (26.6)
a Significant difference between 0 and 1 risk factors (5% level) within row
b Significant difference between 0 and 2 risk factors (5% level) within row
c Significant difference between 0 and 3 risk factors (5% level) within row
d Significant difference between 1 and 2 risk factors (5% level) within row
e Significant difference between 1 and 3 risk factors (5% level) within row
f Significant difference between 2 and 3 risk factors (5% level) within row
Table 3 10-year fracture risk in 3,636 women and history of DXA
10-year fracture risk Total History of DXA History of DXA History of DXA Z test for proportions (p value)
(n=3,860) All women
(n=3,860)
Women <65years
(n=2,087)
Women≥65years
(n=1,773)
(Between <65 and ≥65years)
(Column%) Yes (row%) Yes (row%) Yes (row%)
0–14.9% 1,999 (55.0) 173 (8.7)a,b,c 135 (7.6)a,b,c 38 (17.9)a,b,c <0.001
15–19.9% 511 (14.1) 119 (23.3)e 37 (18.1)e 82 (26.7) 0.012
20–24.9% 258 (7.1) 63 (24.4)f 6 (23.1) 57 (24.6) 0.433
25–100% 868 (23.9) 262 (30.2) 10 (45.5) 252 (29.8) 0.114
Total 3,636 (100) 617 (17.0) 188 (9.2) 429 (26.9)
a Significant difference between 0–14.9 and 15–19.9% fracture risk (5% level) within row
b Significant difference between 0–14.9 and 20–24.9% fracture risk (5% level) within row
c Significant difference between 0–14.9 and 25–100% fracture risk (5% level) within row
d Significant difference between 15–19.9 and 20–24.9% fracture risk (5% level) within row
e Significant difference between 15–19.9 and 25–100% fracture risk (5% level) within row
f Significant difference between 20–24.9 and 25–100% fracture risk (5% level) within row
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analysis, there is a significant difference (p<0.001) at all
distances in women less than 65 years compared with
women above 65 years, where distance seem to have a
higher influence on history of DXA at the women above
65 years. This finding was not explained by differences in
fracture incidence, pattern of risk factors or age distribu-
tion between the women living near or far from a DXA
clinic (data not shown). The absolute differences between
<10 km versus >40 km is much higher for above 65 years
reflecting the higher absolute use of DXA for above
65 years but the relative rates (<10 km versus>40 km)
appeared quite similar for those over age 65 (31.7%/
17.1%~1.8) versus those below the age of 65 years
(10.2%/5.9%~1.7).
Logistic regression
As seen in Table 5; the logistic regression analysis for all
variables shows that distance to DXA clinics, use of oral
glucocorticoids, 10-years fracture risk, age (65–79 years),
low BMI, history of falls, conditions associated with
secondary osteoporosis, history low-energy fracture, living
with a spouse, and income per year (150,000–249,999 Dkk.
per year) were significantly associated with positive history
of DXA. Only the variable current smoker significantly
decreased the odds-ratio of having a history of DXA. The
Hosmer–Lemeshow goodness-of-fit test indicated good
overall fit to the data (1.4, p=0.99).
Discussion
Our study showed that 10.3% of the women without risk
factors, 21% of the women with one or more risk factors,
and only 36% of the women with three or more risk
factors had a history of DXA scan (Table 2). According
to the Danish guidelines, women with one or more risk
factors are eligible for referral to DXA if the result could
influence clinical management [16]. We found that
likelihood of a history of DXAwas higher with increasing
10-year fracture risk; i.e. 8.7% and 30.2% in patients with
a 10-year fracture risk of 0–14.9% and 25–100%,
respectively. Nevertheless, the relatively high use of
DXA in low-risk women and the relatively low coverage
in women with multiple risk factors suggest that the
current strategy is ineffective and support the findings of
Vestergaard et al. that osteoporosis is under-diagnosed in
Denmark [17]. The USPSTF [5] and NOF [6] recommend
DXA in all women aged 65+ regardless of clinical risk
factors. However, no randomized controlled trials on
screening for osteoporosis with fracture as outcome
have been performed [23] to support this approach [8,
17, 24]. Several studies suggest that osteoporosis risk
assessment tools may be useful as part of case-finding
strategies [8, 23]. Thus, the NOS has recently updated
their guidelines and included FRAX as a tool for case-
finding [11]. Our data support the idea that more precise
risk profiling using FRAX [10] or similar instruments
could result in better resource utilization.
Our study further determined the prevalence of risk
factors in a Danish population. The prevalence of
smokers in our series was relative high (21%) compared
with other Scandinavian countries such as Sweden where
smoking is less prevalent, i.e., 15% of the women above
15 years [25]. We found that only 15.3% of the smokers
had a history of DXA. This is remarkable low since the
Danish Bone Society recommends [16] that smokers
should be referred to a DXA scan and meta-analysis has
Table 4 Distance from the 3,860 women's home address to nearest DXA facility in relation to history of DXA
Distance from the women's
home address to nearest
DXA facility
Total History of DXA History of DXA History of DXA Z test for proportions (p value)
(n=3,860) All women
(n=3,860)
Women <65years
(n=2,087)
Women≥65years
(n=1,773)
(Between <65 and ≥65years)
(Column%) Yes (row%) Yes (row%) Yes (row%)
<10 km 1,169 (30.3) 236 (20.2)a,b 64 (10.2)b 172 (31.7)a,b <0.001
10–29 km 1,500 (38.9) 272 (18.1)d 82 (9.7)d 190 (28.9)c,d <0.001
30–39 km 582 (15.1) 86 (14.8) 29 (9.2) 57 (21.3) <0.001
≥40 km 609 (15.8) 70 (11.5) 18 (5.9) 52 (17.1) <0.001
Total 3,860 (100) 664 (17.2) 193 (9.2) 471 (26.6)
a Significant difference between <10 and 30–39 km (5% level) within row
b Significant difference between <10 and >40 km (5% level) within row
c Significant difference between 10–29 and 30–39 km (5% level) within row
d Significant difference between 10–29 and >40 km (5% level) within row
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shown that smoking are associated with increased fracture
risk [26]. The prevalence of glucocorticoids (4.5%) was
similar to that reported in other European studies [27].
Current and past use of glucocorticoids are important
predictors of fracture risk [27]. Thus, our finding that
52.2% of the women reporting a use of oral glucocorti-
coids had a history of DXA is encouraging. This even
included women, who had a history of glucocorticoids use
above the 5 mg threshold used in FRAX with past
exposure. While recent glucocorticoids exposure is a
stronger risk factor for fracture than past exposure [28]
our analysis used the same simple dichotomized risk
factor definition as in the FRAX algorithm. Accordingly,
one criticism of FRAX has been that it dichotomizes risk
factor status rather than allowing for a more complex dose
response relationship [29].
The second highest probability of having a history of
DXA is found in women with a history of low-energy
fracture (34.3%). Many studies indicate that history of
low-energy fracture is an important risk factor for further
fractures [30, 31]. Low BMI is also a well-recognized risk
factor for fractures [32], and the third highest probability
of having a DXA is seen in women with a low BMI
(30.8%).
We also found that the distance to the nearest DXA
facility influenced the use of DXA scans. Only 11.5% of
the women living more than 40 km away from the
nearest DXA facility had a history of DXA in contrast to
20.2% in those living less than 10 km away. This finding
is not explained by differences in fracture incidence nor
pattern of risk factors or difference in the age distribution
(data not shown). Age-stratified analysis showed that
distance was less of a barrier in women aged less than
65 years. Similarly, adjustment for potentially socio-
economic confounding factors did not alter the results. In
logistic regression analysis, higher income and living
with a spouse significantly increased the likelihood of
having a DXA scan. Our findings are in accord with a
U.S. study [33]. In general, distances in the US are much
larger than in Denmark as the majority of the Danish
Table 5 Results of logistic regression analysis for all variables: odds ratios and their 95% confidence interval (n=3,860 women)
Risk factors Variable (reference) History of DXA
OR 95% CI
Use of oral glucocorticoidsa Yes (No) 3.99 2.79; 5.66
Distance to DXA facility <10 km (≥40 km) 2.28 1.65; 3.14
10–29 km 2.01 1.47; 2.76
30–39 km 1.55 1.06; 2.26
Age 65–79 years (<65 years) 2.08 1.47; 2.94
≥80 years 1.13 0.71; 1.81
BMI ≤19 kg/m² (> 19 kg/m²) 2.04 1.36; 3.07
10-year fracture risk 15 to 19.9% (<15%) 1.88 1.37; 2.57
20 to 24.9% 1.63 1.08; 2.47
≥25% 1.80 1.19; 2.71
History of fallsb Yes (No) 1.82 1.32; 2.50
History of low-energy fracturec Yes (No) 1.72 1.30; 2.27
Conditions associated with osteoporosis Yes (No) 1.64 1.32; 2.03
Premature menopause <45 years (≥45 years) 1.39 1.06; 1.81
Spouse status Married/living with a spouse (living alone) 1.37 1.11; 1.70
Income per year 150,000–249,999 Dkk. (<150,000 Dkk.) 1.33 1.04; 1.70
≥250,000 Dkk. 1.21 0.88; 1.68
Ethnicity Danish (immigrant) 1.23 0.73; 2.07
Parental hip fracture Yes (No) 1.20 0.89; 1.60
Alcohol ≥3 units daily (<3 units daily) 1.12 0.60; 2.09
Current smoker Yes (No) 0.76 0.59; 0.98
Working status Working (not working) 0.67 0.47; 0.96
a Dosage >=5 mg more than 3 months
bMore than one falls one year where the falls arise without any external impact
c Low-energy fracture after age 40 years
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population live less than 30 km from a DXA clinic, but
even though does the distance also influence the Danish
women. This suggests that local clinics, mobile units, or
easy transportation are necessary especially for older
citizens. Several countries in Europe, including Denmark,
now use mobile units in mammography screening [34]
resulting in increased acceptance of the screening pro-
gram [34]. We are not aware of similar studies on
influence of travel distance and the use of DXA service
in Europe. Since our data demonstrated that even in a
small country as Denmark with good access to DXA
clinics, good infrastructure, and no copayment, the
distance to DXA clinics influenced the use of DXA,
distance be even more important in larger countries.
Following the introduction of risk assessment tools such
as FRAX, clinicians, and government policy makers may
come to view DXA as less critical in identifying and
managing patients at risk of fracture. Virtually all
randomized clinical trials demonstrating the efficacy of
currently used anti-osteoporosis drugs, however, used
BMD as inclusion criteria. Thus, evidence-based treat-
ment relies on access to DXA facilities until further
evidence are provided.
Our study had important strengths. First, it was population-
based and we are not aware of similar population-based
studies on use of DXA services. Second, we had a high
respondents rate (84%) and 77% of the invited popula-
tion were available for analysis. Third, data came from a
questionnaire validated in a large number of women
before its use. Finally, questionnaires were scanned
which could be shown to minimize errors during data
entry [12; manus submitted].
Our study also had some limitations. First, the data were
based on self-reported risk factors and thus potentially
prone to bias. Especially items regarding conditions
associated with secondary osteoporosis included some
ambiguity. Second, we had no data on the reason why or
when women had a DXA scan. GPs might have a reason
not reflected in the questionnaire to refer a woman.
Similarly, DXA scan could be performed in connection
with clinical research.
In conclusion, our study showed a relatively high use
of DXA in low-risk women and the relatively low
coverage in women with multiple risk factors. We further
found that distance to DXA clinics, age, and a number of
socio-economic factors influence the use of DXA. We
suggest that instruments such as FRAX may improve the
use of DXA resources. Moreover, local clinics, easy
transportation, or mobile units of DXA scan should be
considered.
Conflicts of interest None.
Appendix
References
1. World Health Organisation (2007) Assessment of osteoporosis at
primary health care level. World Health Organisation Scientific
Group Technical Report 2007
2. Mossey JM, Mutran E, Knott K, Craik R (1989) Determinants of
recovery 12 months after hip fracture: the importance of
psychosocial factors. Am J Public Health 79:279–286
3. Johnell O (1997) The socioeconomic burden of fractures: today
and in the 21st century. Am J Med 103:20S–25S
4. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D,
McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines
for the diagnosis and management of osteoporosis in postmeno-
pausal women and men from the age of 50 years in the UK.
Maturitas 62:105–108
5. U.S.Preventive Services Task Force (2009) The guide to clinical
preventive services, 2009, Recommendations of the U.S. Preven-
tive Services Task Force
6. National Osteoporosis Foundation (2008) Clinician´s guide to
prevention and treatment of osteoporosis
7. (2005) Sosial- og helsedirektoratet. Faglige retningslinjer for
forebygging og behandling av osteoporose og osteoporotiske
brudd
8. Kanis JA, Johnell O (2005) Requirements for DXA for the
management of osteoporosis in Europe. Osteoporos Int 16:229–
238
9. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J,
Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman
Table 6 Risk factors for osteoporosis according to the Danish Bone
society compared with the risk factors included in this study
Risk factors according to
the Danish Bone Society
Risk factors according to this study
Parent-diagnosed osteoporosis Parental hip fracture
Age above 80 years +
BMI <19 kg/m2 +
Low-energy fracture Low-energy fracture after the age of
40 years
Early menopause (<45 years) +
Use of oral glucocorticoids Use of oral glucocorticoids; 5 mg or
more for at least 3 months
Smoking Current smoker
Massive alcohol intake Three or more units daily
Older with increased risk of
fracture due to falls tendency
Have you been falling more than
ones a year where the falls arise
without external impact?
Conditions associated with
osteoporosis
- Anorexia Nervosa
- Rheumatoid arthritis
- Osteogenesis imperfecta
- Untreated hyperthyroidism
- Hypogonadism
- Malabsorption
- Chronic liver disease
Osteoporos Int
JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La
CA, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J,
Sanders K, Schott AM, Silman A, Torgerson D, van ST, Watts
NB, Yoshimura N (2007) The use of clinical risk factors enhances
the performance of BMD in the prediction of hip and osteoporotic
fractures in men and women. Osteoporos Int 18:1033–1046
10. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008)
FRAX and the assessment of fracture probability in men and
women from the UK. Osteoporos Int 19:385–397
11. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F,
Oden A (2008) Case finding for the management of osteoporosis
with FRAX–assessment and intervention thresholds for the UK.
Osteoporos Int 19:1395–1408
12. Rubin KH, Abrahamsen B, Hermann AP, Bech M, Gram J, Brixen
K (2010) Fracture risk as assessed by the Fracture Risk
Assessment Tool (FRAX®) in a random sample of women living
in Denmark compared with fracture risk derived from population
fracture rates and mortality rates. (In press)
13. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic
fracture in men and women in England and Wales: prospective
derivation and validation of QFractureScores. BMJ 339:b4229
14. Hyldstrup L, Brixen K, Eriksen EF, Gram J, Langdahl B,
Schwartz P, Sørensen HA (2000) Osteoporose. Klaringsrapport
fra Dansk Knoglemedicinsk Selskab
15. (2002) Dansk selskab for almen medicin. Osteoporose i almen
praksis med fokus på forebyggelse af frakturer hos ældre
16. (2009) Dansk Knoglemedicinsk Selskab. Vejledning til udredning
og behandling of Osteoporose
17. Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is
markedly underdiagnosed: a nationwide study from Denmark.
Osteoporos Int 16:134–141
18. Pedersen KM, Christiansen T, Bech M (2005) The Danish health
care system: evolution—not revolution—in a decentralized sys-
tem. Health Econ 14:S41–S57
19. Nationel Board of Health (2009) http://www.sst.dk/Indberetning%
20og%20statistik/Sundhedsdata/Download_sundhedsstatistik/
Behandling_ved_sygehuse/DSN.aspx
20. langtved data a s; www.langtved.dk. 2009
21. FRAX (2009); Fractures risk assessment tool; http://www.shef.ac.
uk/FRAX/tool.jsp?locationValue=5
22. Hosmer DW, Lemeshow S (2000) Applied logistic regression.
Wiley, New York
23. Lim LS, Hoeksema LJ, Sherin K (2009) Screening for osteopo-
rosis in the adult U.S. population: ACPM position statement on
preventive practice. Am J Prev Med 36:366–375
24. Gehlbach SH, Fournier M, Bigelow C (2002) Recognition of
osteoporosis by primary care physicians. Am J Public Health
92:271–273
25. Ministry of social development, 2009 the social report. www.
socialreport.msd.govt.nz/health/cigarette-smoking.html 2010
26. Kanis JA, Johnell O, Oden A, Johansson H, de LC, Eisman JA,
Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ,
Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and
fracture risk: a meta-analysis. Osteoporos Int 16:155–162
27. Kanis JA, Johansson H, Oden A, Johnell O, de LC, Melton LJ III,
Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA,
McCloskey EV, Mellstrom D (2004) A meta-analysis of prior
corticosteroid use and fracture risk. J Bone Miner Res 19:893–899
28. van Staa TP, Geusens P, Pols HA, de LC, Leufkens HG, Cooper C
(2005) A simple score for estimating the long-term risk of fracture
in patients using oral glucocorticoids. QJM 98:191–198
29. Lewiecki EM (2010) Bone: using FRAX wisely: lessons from
Switzerland and beyond. Nat Rev Endocrinol 6:126–128
30. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P,
Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV,
Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse
A (2004) A meta-analysis of previous fracture and subsequent
fracture risk. Bone 35:375–382
31. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger
M (2000) Patients with prior fractures have an increased risk of
future fractures: a summary of the literature and statistical
synthesis. J Bone Miner Res 15:721–739
32. de LC, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P,
Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV,
Mellstrom D, Melton LJ III, Meunier PJ, Pols HA, Reeve J,
Silman A, Tenenhouse A (2005) Body mass index as a predictor
of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338
33. Curtis JR, Laster A, Becker DJ, Carbone L, Gary LC, Kilgore
ML, Matthews RS, Morrisey MA, Saag KG, Tanner SB, Delzell E
(2009) The geographic availability and associated utilization of
dual-energy X-ray absorptiometry (DXA) testing among older
persons in the United States. Osteoporos Int 20:1553–1561
34. Bilde L, Rasmussen SR (2006) Europæiske erfaringer med
systematisk mammografiscreening
Osteoporos Int
 
  
 
 
Rubin KH, Abrahamsen B, Holmberg TF, Hjelmborg JVB, Bech M, Hermann AP, Barkmann R, Glüer 
CC, Brixen K.  
Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to 
identify women with increased risk of fracture. A population-based prospective study. 
Published: Bone. 2013 May 10;56(1):16-22 
  
Paper III 
  
 
 
Original Full Length Article
Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS,
SCORE and age alone) to identify women with increased risk
of fracture. A population-based prospective study☆
Katrine Hass Rubin a,b,⁎, Bo Abrahamsen a,c, Teresa Friis-Holmberg d, Jacob V.B. Hjelmborg e, Mickael Bech f,
Anne Pernille Hermann b, Reinhard Barkmann g, Claus C. Glüer g, Kim Brixen a,b
a Institute of Clinical Research, University of Southern Denmark, Denmark
b Department of Medical Endocrinology, Odense University Hospital, Denmark
c Department of Medicine F, Copenhagen University Hospital Gentofte, Denmark
d National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
e Department of Biostatistics, Institute of Public Health, University of Southern Denmark, Odense, Denmark
f COHERE, Department of Business and Economics, University of Southern Denmark, Denmark
g Section Biomedical Imaging, Department of Diagnostic Radiology, University Hospital Schleswig-Holstein, Kiel, Germany
a b s t r a c ta r t i c l e i n f o
Article history:
Received 15 January 2013
Revised 16 April 2013
Accepted 3 May 2013
Available online 10 May 2013
Edited by: Robert Recker
Keywords:
Epidemiology
Risk factors
Screening tools
Prediction
Fracture
Purpose: To compare the power of FRAX® without bone mineral density (BMD) and simpler screening tools
(OST, ORAI, OSIRIS, SCORE and age alone) in predicting fractures.
Methods: This study was a prospective, population-based study performed in Denmark comprising 3614
women aged 40–90 years, who returned a questionnaire concerning items on risk factors for osteoporosis.
Fracture risk was calculated using the different screening tools (FRAX®, OST, ORAI, OSIRIS and SCORE) for
each woman. The women were followed using the Danish National Register registering new major osteopo-
rotic fractures during 3 years, counting only the ﬁrst fracture per person. Area under the receiver operating
characteristic curve (ROC) and statistics and Harrell's index were calculated. Agreement between the tools
was calculated by kappa statistics.
Results: A total of 4% of the women experienced a new major osteoporotic fracture during the follow-up pe-
riod. There were no differences in the area under the curve (AUC) values between FRAX® and the simpler
tools; AUC values between 0.703 and 0.722 (p = 0.86). Also, Harrell's C values were very similar between
the tools. Agreement between the tools was modest.
Conclusion: During 3 years follow-up FRAX® did not perform better in the fracture risk prediction compared
with simpler tools such as OST, ORAI, OSIRIS, SCORE or age alone in a screening scenario where BMD was not
measured. These ﬁndings suggest that simpler models based on fewer risk factors, which would be easier to
use in clinical practice by the GP or the patient herself, could just as well as FRAX® be used to identify women
with increased risk of fracture.
Summary: Comparison of FRAX® and simpler screening tools (OST, ORAI, OSIRIS, SCORE) in predicting frac-
tures indicate that FRAX® did not perform better in fracture risk prediction compared with the simpler
tools or even age alone in a screening scenario without bone mineral density assessment.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.
Introduction
Fragility fractures associated with osteoporosis are common [1]
and impose considerable burdens on the individual [2], increased
mortality [3] and add signiﬁcant costs to the society [4]. Approxi-
mately 50% of postmenopausal women and 20% of men older than
50 years will experience a fragility fracture in their remaining lifetime
[5]. At present, the majority of men and women at high risk of
fracture are not diagnosed or treated [6] and several studies have
suggested that the case-ﬁnding strategies endorsed in many coun-
tries perform less than well [7]. Several tools have been developed
to integrate risk factors such as age, low body weight, history of frac-
tures and use of glucocorticoids into a single estimate of fracture risk
for an individual. These tools are either aimed at identifying individ-
uals with an increased risk of fractures (with the option to include a
BMD result in the risk scoring) or identifying individuals at increased
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risk of having low BMD. However, because the effect of BMD on frac-
ture risk is in itself inﬂuenced by the presence of clinical risk factors,
fracture risk tools have also been used to guide physicians in whether
to refer patients to a BMD measurement or not [8].
Fracture Risk Assessment Tool (FRAX®) uses 10 clinical risk fac-
tors and can be used with or without bone mineral density (BMD)
to predict the 10-year probability of hip fractures or major osteopo-
rotic fractures in patients (clinical spine, forearm, hip or shoulder
fracture) [9,10]. The recently updated National Osteoporosis Founda-
tion (NOF) guidelines recommend treatment of individuals with an
increased risk of fracture based on the FRAX® [11]. This involved
postmenopausal women and men aged 50 years and older with low
bone mass (T-score between−1.0 and−2.5, osteopenia) at the fem-
oral neck or spine and a 10-year hip fracture probability ≥ 3% or a
10-year major osteoporotic fracture probability ≥ 20% as calculated
by the FRAX® tool [11]. FRAX® has been validated in 11 independent
cohorts [9], and country speciﬁc adaptations are available to a large
number of countries, including Denmark [9]. Simpler approaches
have also been suggested. Age is strongly associated with fracture
risk [1] and the U.S. Preventive Services Task Force (USPSTF) recom-
mends screening with DXA in all women aged 65 years and older and
in women below 65 years with increased risk of fracture (whose
10-year fracture risk is equal to or greater than that of 65-year-old
whitewomenwithout additional risk factors; 9.3% based on FRAX® cal-
culation); diagnosis and treatment are determined from DXA result
[12]. NOF also recommends DXA testing in women above 65 years
and women aged 50–65 years with high risk factor proﬁle [11].
BMD has also a strong association with fracture risk where indi-
viduals with low BMD have progressively higher risk of fracture
[13]. Several tools based on fewer clinical risk factors are available
to predict low BMD. As discussed above, the justiﬁcation for such
tools is primarily to identify women who are more likely to have
low BMD and then could undergo BMD measurement for a deﬁnitive
assessment. The simplest tool is the Osteoporosis Self-assessment
Tool (OST), which is based on age and body weight alone [14],
while others include more risk factors in addition to age and weight:
the Osteoporosis Risk Assessment Instrument (ORAI) [15], the OSteo-
porosis Index of RISk (OSIRIS) [16], and the Simple Calculated Osteo-
porosis Risk Estimation (SCORE) [17]. All these tools have been
developed in women, validated in independent cohorts and the per-
formance of the tools was similar to that seen in the development
cohorts [15,18–20]. OST has been validated in both men [21] and
women [20,22]; validation studies of the other tools included only
women.
Since the release of FRAX® in 2008, a number of studies have com-
pared the performance of FRAX® with other online risk algorithms
with an outcome of 5 or 10-year probability of fractures and several
other parsimonious models including age. Most of these studies con-
clude that simpler models perform as well as FRAX® in predicting
fractures. Kanis et al. [23] have criticized the conclusions of these
studies in part because of the comparison of FRAX® with what
Kanis et al. called “home grown” models. Such bespoke models in-
cluded age or BMI alone, age plus BMI, age plus previous fracture.
OST, ORAI, OSIRIS and SCORE include some of the same risk factors
and they are also simpler than FRAX. However, tools will always per-
form well within the derivation cohort and the test of their perfor-
mance lies in veriﬁcation within other cohorts.
To date none has tested the performance of FRAX® compared with
the simple well validated osteoporosis risk assessment tools (ORAI,
OSIRIS, OST and SCORE) and it is uncertain whether FRAX® performs
better that these simpler tools. Therefore the aim of the present study
was to compare the power of FRAX® (without BMD) and simpler
screening tools (OST, ORAI, OSIRIS, SCORE and age alone) in
predicting fractures. We hypothesized that the more complex
FRAX® (without BMD) tool predicts fracture better than OST, ORAI,
OSIRIS, SCORE and age alone.
Methods
Design
This study was a prospective, population-based study performed in
the Region of Southern Denmark. Study design and baseline data have
been reported previously [24]. In brief, data on self-reported risk factors
were collected in a random sample of the population in spring 2009.
Data regarding fractures (type and date) during follow-up were
extracted from theDanish National Patient Register (NPR) and informa-
tion on death and emigration were extracted from the Danish National
Civil Registration System (NCR) after three years of follow up.
Study population
From the NCR we randomly selected 5000 women living in the Re-
gion of Southern Denmark, aged 40–90 years, stratiﬁed by decades.
During the period from March to May 2009, a self-administered ques-
tionnaire concerning risk factors for osteoporosis was issued to the
study population together with a pre-paid return envelope. Reminders
were mailed to non-respondents twice. All women returning a ques-
tionnaire were included in the analysis, with the exception of those di-
agnosed with and treated for osteoporosis. Signed and returned
questionnaires were considered as informed consent to be included in
the analysis. All participants were anonymized and the study was ap-
proved by the Local Ethical Committee.
Questionnaire
The questionnaire was designed to enable calculation of fracture
risk based on each tool at an individual level. It therefore comprised
items on weight, height, ethnicity, history of osteoporosis, personal
and family history of fracture, smoking habits, consumption of alco-
hol, use of oral glucocorticoids, use of oestrogen, and diseases associ-
ated with secondary osteoporosis (e.g. rheumatoid arthritis, type 1
diabetes, osteogenesis imperfecta, untreated long-standing hyperthy-
roidism, hypogonadism or premature menopause (b45 years),
chronic malnutrition, or malabsorption and chronic liver disease).
The questions were constructed to allow answering by simple “yes”,
“no” or “don't know”, however, body height and weight could be en-
tered as digits. The questionnaire was validated and the reliability
tested as previously reported [24]. The questionnaire was read by op-
tical character recognition (OCR); the accuracy of this setup was pre-
viously tested without any difference in data registration [24].
Fracture risk prediction tools
Self-reported baseline data were used to calculate the 10-year
probability of fracture by FRAX® and to calculate the risk estimate
using the simpler tools, ORAI, OSIRIS, OST and SCORE in each
woman. Further, age alone was used in the analysis, where the age
of the women is used as a simple continuous variable. The number
of risk factors used in each tool varies from two in OST to 10 in
FRAX®. Table 1 shows the clinical risk factors included in each tool.
Since the detailed algorithm for FRAX® is still not in the public do-
main, the 10-year probability of fracture was calculated by individual
risk scoring using the Danish version of FRAX® [25] using a call of the
FRAX® website (version 3.4) [26]. ORAI, OSIRIS, OST and SCORE are
instruments designed to predict low BMD. The scoring system for
ORAI [15] is as follows: +2 points for non-current usage of estrogen;
+9 points for a body weight of less than 60 kg or +3 points for a
body weight between 60 and 70 kg and 0 points for weight above
70 kg; and +15 points for ages 75 years or more, +9 points for
ages between 65 and 74 years, +5 points for ages between 55 and
64, and 0 points for ages between 45 and 54. To calculate the OST
score [14], age was subtracted from weight, the result multiplied by
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0.2 and truncated to yield an integer. The OSIRIS score [16] was
calculated by adding the index valueweighted for each variable:weight
(kg) × 2 and remove last digit; age (year) × −2 and remove last digit;
+2 if a current HRT user, and −2 if the women have a history of low
impact fracture. The SCORE index [17] was calculated as: +5 points
for a race other thanblack;+4points for rheumatoid arthritis sufferers;
+4 points for non-traumatic fractures (wrist, hip and rib) over the age
of 45 years; up to a total of 12 points;+1 if the patient never used HRT,
3 times the ﬁrst digit of the patient's age, and−1 times body weight in
pounds divided by ten and truncated to an integer.
In the analyses, we primarily used the nominal score from each
tool. In analyses with tools divided into high and low risk of fractures
the following dichotomous cut-offs were used: b2 for OST, ≥6 for
SCORE, ≥9 for ORAI, ≤1 for OSIRIS, and ≥20% for FRAX® (probability
of major osteoporotic fractures). These cut-offs are based on the sug-
gestion of their developers and from validation studies of the tools in
Caucasian populations [11,15,19,22,27].
Follow-up
Incident fracture outcomes for this analysis included “major oste-
oporotic fractures” (FRAX®-deﬁned major osteoporotic fracture; hip,
clinical vertebral, wrist or humerus fracture) (ICD-10 codes: S120,
S121, S122, S220, S221, S320, T08, S422, S423, S720, S721, S722,
S525, S526), and any “osteoporotic fractures” (all fractures except
fractures of ﬁngers, toes, skull or face) (ICD-10 codes: S12, S22, S32,
S42, S52, S72, S82, T08) during the follow up period. Fracture infor-
mation on the 5000 women was collected from NPR in April 2012.
This register covers all in- and out-patient records in Danish hospitals.
Since all persons in Denmark are assigned with a unique personal
identiﬁcation number at birth, it is possible to link data from all public
registers at an individual level [28]. Records are available for any
given International Classiﬁcation of Diseases code and surgical proce-
dure [29]. The register has a high validity also regarding the diagnosis
of fractures [30,31]. Fractures during the follow-up were counted
conservatively as the ﬁrst fracture (in each category) in each person
to avoid overestimating rates due to readmissions. Hip fracture en-
tries with no appropriate surgical code associated were excluded
[32]. Follow-up information on death and emigration was also col-
lected in April 2012.
Statistical analysis
Data are shown as mean ± SD or median (range) as appropriate.
Frequency tables are used to present the prevalence of each risk fac-
tor. Chi-square test (2-sided) for categorical variables and t-test for
continued variables were applied to test the difference in baseline
characteristics of women with and without fractures during follow
up. p-values below 0.05 were considered statistically signiﬁcant.
Kaplan–Meier curves of cumulative incidence of major osteopo-
rotic fractures are shown for three years of follow-up divided in
high and low risk of fractures in the different tools and age alone.
Competing risk regressions as alternative to the Kaplan–Meier curves
were conducted with incident fractures and death as failure. This
analysis was compared to the Kaplan–Meier results to assess the in-
ﬂuence of censorings not independent of occurrence of fractures.
We used receiver operating characteristic (ROC) curve analyses to
assess the ability of each tool to discriminate between womenwith or
without incident fractures. The AUC of each risk assessor for fracture
at follow-up was modeled by univariate logistic regression on the risk
assessor as only explanatory variable. In order to adjust for censored
women and take time to event (fracture) into consideration, we esti-
mated the Harrell's C index by Cox regression modeling. Harrell's C is
analog to AUC in a survival setting. Standard errors robust for cross
validation were achieved by the Jack knife-method. Tool assessors
with AUC statistics of 0.50 do not perform better than chance alone,
while tools with higher AUC statistics perform better than chance.
We compared AUC statistics between FRAX® and simpler tools
using the “roccomp” procedure in STATA. Finally, the population
was divided into quartiles based on fracture risk as predicted by
each tool and compared the observed fracture rates across the quar-
tiles. Agreement as to how well each tool assigned the women to
risk quartiles was tested using weighted kappa statistic. All analyses
were conducted using STATA 12.
Results
As previously reported [24], the respondent rate to the question-
naire was 84%. A total of 334 questionnaires were blank or had several
missing items and were excluded leaving 3860 complete question-
naires. We further excluded, 246 women diagnosed with and treated
for osteoporosis, leaving 3614 women for analysis. The follow-up peri-
od ranged from March 2009 to April 2012. Mean follow up time in the
total cohort was 36 months (range 30 to 37 months) and the total
follow-up comprised 10,385 person-years. During follow-up, 156 (4%)
women suffered “major osteoporotic fractures”, 225 (6%) women
sustained an “osteoporotic fracture”, 174 women died and 6 were lost
to follow-up.
The Kaplan–Meier plots of cumulative incidence of major osteopo-
rotic fracture are shown in Fig. 1. The3 year cumulative “major osteopo-
rosis fracture” estimates for all the toolswere similar and ranged at high
risk of fracture from 8% in the FRAX® curve to approximate 6% for the
SCORE tool. Nearly identical curves were seen in competing-risks re-
gression (data not shown).
Baseline characteristics of the study population overall and strati-
ﬁed according to incident fractures are shown in Table 2. The mean
age of the women was 64 ± 13 years and mean BMI was 26 ±
5 kg/m2. Women with incident fractures were older (mean age
73 ± 11 versus 63 ± 13 years, p = 0.001), had more frequent his-
tory of fractures (22% versus 9%, p b 0.001) and history of falls dur-
ing the previous 12 months (14% versus 6%, p b 0.001), had diseases
more often related to secondary osteoporosis (26% versus 18%, p =
0.011), and had less frequently used estrogen currently (3% versus
11%, p = 0.001).
ROC curve analysis was used to assess the discrimination between
the tools. AUC values were very similar (0.703 to 0.722) with no sig-
niﬁcant differences (p = 0.86) in the AUC values between FRAX®
and the more simple tools (Table 3). Also, Harrell's C values were
very similar between the tools and identical to the AUC values of
the different tools.
Restricting the analysis to women aged 50+ years or 65+ did not
change the nonsigniﬁcant differences in the AUC values between the
tools, only the AUC values were lower; about 0.66 and 0.59, respec-
tively (data not shown).
Table 1
Clinical risk factors included in each tool.
FRAX SCORE OSIRIS ORAI OST
Age X X X X X
Weight X X X X X
Previous low energy fractures X X X
Estrogen therapy X X X
Rheumatoid arthritis X X
Height X
Parental hip fractures X
Smoking X
Alcohol X
Glucocorticoid therapy X
Secondary osteoporosis X
Sex X
Ethnicity X
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The observed incidence of fractures in women was plotted against
quartiles of predicted risk of fractures from each tool. The tools and
age alone performed similarly (Fig. 2). The percentages of women in
the highest risk quartile who had a major osteoporotic fracture
were approximately 8% for all tools.
Agreement between the tools when assessed using weighted
kappa statistic was modest for quartiles of predicted risk of fractures
and women with incident fracture. The weighted kappa was best for
FRAX® versus age alone (0.73). It was good for FRAX® versus ORAI
(0.65) and for FRAX® versus SCORE (0.64), moderate for FRAX® ver-
sus OSIRIS (0.53) and for FRAX® versus OST (0.48).
Regarding major osteoporotic fractures, the proportion of women
in the highest risk quartile of FRAX®, who also were in the highest
quartile for other tools, was 88% for SCORE, 83% for age alone, 79%
for ORAI, and 78% for both OST and OSIRIS. Restricting the analysis
to women aged 50+ years did not change the results (data not
shown).
Discussion
In this study we found that FRAX® and simpler screening tools
such as OST, ORAI, OSIRIS, SCORE and even age alone performed sim-
ilarly in predicting fractures in a screening scenario without BMD as-
sessment. The comparison between tools was based on the AUC and
the Harrell's C index by Cox regression modeling and the results
were virtually identical for all the tools.
Our results are comparable with the results of several other stud-
ies comparing FRAX® both with simple tools and more elaborate
tools [33–38]. Most of these studies have included age in the con-
struction of new models. Ensrud et al. [35] included models based
on age and BMD or fracture history in comparison with FRAX® in a
cohort study of 6652 women with 10-years of follow-up. They con-
cluded that the simple models based on age and BMD or age and frac-
ture history alone predicted the 10-year probability of fractures as
well as the more complex FRAX® model. These ﬁndings were based
on older women (mean age 71 years) and the simple model has not
yet been validated in independent populations. Bolland et al. [33]
compared age, the Garvan calculator and FRAX® in using data from
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Fig. 1. The Kaplan–Meier plots of cumulative incidence of major osteoporotic fractures divided in high and low risk of fracture for the different tools and for age alone. *3 year frac-
ture estimates. #Division into high and low risks depends of the chosen cut-off for each tool. High risk corresponds to: FRAX® ≥ 20%, age ≥ 65 years, OSIRIS ≤ 1, OST b 2,
ORAI ≥ 9, and SCORE ≥ 6.
Table 2
Baseline characteristics of the 3614 women stratiﬁed according to incident major oste-
oporotic fractures.
Variable All women
N = 3614
N (%)
Fracture
N = 156
N (%)
No fracture
N = 3458
N (%)
p-value⁎
Age year, mean (SD) 64 ± 13 73 ± 11 63 ± 13 0.001
40–50 694 (19) 3 (2) 691 (20) p b 0.001
51–60 826 (23) 17 (11) 809 (23)
61–70 859 (24) 40 (26) 819 (24)
71–80 680 (19) 41 (26) 639 (19)
81–90 555 (15) 55 (35) 500 (15)
BMI kg/m2, mean (SD) 26 ± 5 25 ± 4 26 ± 5 0.07
b19 kg/m2 116 (3) 5 (3) 111 (3) 0.62
≥19 kg/m2 3498 (97) 151 (97) 3347 (97)
History of parental hip fracture 374 (10) 16 (10) 358 (10) 0.55
History of low energy fracture 337 (9) 35 (22) 302(9) p b 0.001
Smoking 742 (21) 38 (24) 704 (20) 0.14
Alcohol use, >2 drinks/day 69 (2) 2 (1) 67 (2) 0.42
Rheumatoid arthritis 175 (5) 9 (6) 166 (5) 0.34
Glucocorticoid therapy 131 (4) 7 (5) 124 (4) 0.34
Secondary osteoporosis 655 (18) 40 (26) 615 (18) 0.01
Current estrogen therapy 370 (10) 5 (3) 365 (11) 0.001
Non-black race 3604 (99.7) 156 (100) 3448 (99.7) 0.64
History of falls 218 (6) 22 (14) 196 (6) p b 0.001
⁎ p value between the group with fractured and nonfractured women.
Table 3
Area under the curve for receiver operating characteristic curves for each tool and for
age alone.
3614 women Major osteoporotic fractures (N = 156) All fractures (N = 225)
AUC (95% CI) AUC (95% CI)
FRAX 0.722 (0.686, 0.758) 0.701 (0.668, 0.735)
Age alone 0.720 (0.685, 0.755) 0.694 (0.660, 0.727)
ORAI 0.713 (0.677, 0.749) 0.690 (0.658, 0.723)
SCORE 0.712 (0.675, 0.750) 0.691 (0.657, 0.725)
OST 0.704 (0.663, 0.745) 0.682 (0.646, 0.717)
OSIRIS 0.703 (0.664, 0.742) 0.681 (0.646, 0.716)
# No signiﬁcant differences in AUC values were seen between algorithms (p = 0.86 for
major osteoporotic fractures and p = 0.56 for all fractures).
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a RCT regarding calcium supplementation in New Zealand comprising
1422 women aged 55+ years with a follow-up period of 8.8 years.
They concluded that FRAX® and the Garvan calculator had moderate
discriminative ability for fractures and did not have greater discrimi-
nation than simpler models based on age and BMD. This study was
also based on older women (mean age 74 years). Incident fractures
were recorded by telephone interview and only 57 hip fractures oc-
curred over the 8.8 years of follow-up.
Our results are based on data without BMD using an approach
similar to that of the GLOW study [36], which comprised an interna-
tional cohort with 19,586 women aged 60+ years who had consulted
their physician in the past 24 months. They found that a simple
model consisting of age and prior fractures performed as well as
FRAX® and the Garvan calculator when BMD was unknown. As in
our study, they based assessment on self-reported clinical risk fac-
tors; however, they used self-reported incident fractures during
2 years of follow-up while we collected fracture data from national
registers. We invited participants from a random selection in the gen-
eral population and had a high responder rate (84%). In contrast, the
GLOW study group acknowledged that their sample was prone to
bias due to the selection of physicians and due to the sampling and
recruitment of patients [36]. Also, their model (with age and prior
fracture) was not validated in independent populations. Several
other studies have also compared FRAX® with other more elaborate
tools such as the QFracture algorithm [34] and the Garvan calculator
[33,37] arriving to the same conclusions as the studies mentioned
above.
In our study, agreement between the tools with regard to catego-
rizing women into quartiles of risk for major osteoporotic fracture
was moderate. However, agreement between the tools in identifying
women at the highest quartile of risk for major osteoporotic fracture
was high. Approximately 80% of the women classiﬁed in the highest
risk quartiles by FRAX® were also categorized as highest risk by all
the other tools. Sambrook et al. [36] came to a similar conclusion in
the GLOW study and our research supports that if women were se-
lected for treatment based on being in the highest quartile of risk, vir-
tually the same women would meet the threshold for treatment
regardless of the tool used.
FRAX® is the most complex tool in this study and incorporate 11
risk factors in the algorithm (and may in addition include BMD),
whereas the simpler tools only incorporated between 2 and 6 risk fac-
tors (Table 1). All the tools included age and BMI. Additional variables
did not appear to improve the performance of the tools. Both age and
BMI are associated with fracture risk, however, age is the strongest
risk factor [1]. Our study also showed that even age alone performed
as well as the FRAX® tool without BMD.
Kanis et al. [23] recently discussed potential pitfalls in external
validation of FRAX®. Several studies [33,35,38–40] compared the
AUC of ROC curves across studies. In the present study we compared
the AUC of the different predeﬁned toolswithin the same well deﬁned
study population. There are limitations to the ability of ROC analysis
to discriminate accurately between the performance of predictive
models and it is argued that addition of additional variables in models
may improve decision-making without materially increasing the AUC,
which reﬂects the diagnostic performance of the models across the
range and not just around the point at which critical decisions are
made regarding treatment [23]. Because of this, we also undertook
analyses where models were compared at relevant clinical interven-
tion threshold (Fig. 1). Kanis et al. [23] also criticized comparison of
“home grown” models with the FRAX® tool using the population
from which the “home grown” model was derived. This is a relevant
concern as the best model to ﬁt a dataset will invariably be a model
developed from that particular dataset even if the diagnostic perfor-
mance may not at all translate to other populations. In our study,
we compared the performance of FRAX® and other models to that
of age alone. This is a simple epidemiological tabulation of fracture in-
cidence as a function of age and does not constitute a bespoke model
to ﬁt the data. Furthermore, OST, ORAI, OSIRIS and SCORE are already
well validated simpler tools derived from other cohorts [15,18–20].
Another limitation accurately identiﬁed by Kanis et al. [23] is the
comparison between predicted and observed outcomes. Since we do
not have 10 years of follow-up we look at the observed fractures
and compared it with the FRAX® probability of being in risk of frac-
ture. Moreover, we took time-to-event into account by estimating
the Harrell's C which did not inﬂuence the results. Same results
were seen in the GLOW study [36]; these results also showed that
AUC values and Harrell's C values were similar for major osteoporotic
fractures. Finally, FRAX® adjusts for risk of death while the other
tools do not. Our ﬁndings, however, were robust to competing-risks
regression with both incident fractures and death as failure as alter-
native to Kaplan–Meier analysis.
In the analyses with each tool dividing participants into those with
high versus low risk of fracture we chose to use the cut-off suggested
by the developers from validation studies of tools in Caucasian popu-
lations. Different cut-offs have been also recommended even among
Caucasian populations from studies validating the tools but there
was no clear agreement regarding cut-off values for the different
tools [41–44]. One study by Rud et al. [41] investigated the perfor-
mance of SCORE, OST and ORAI in a Danish population. The sensitivity
of SCORE, OST and ORAI was 69%, 90% and 50%, respectively, when
applied as described by the developers. The authors also tried differ-
ent cut-offs with higher sensitivities, but since the study only includ-
ed peri- and early postmenopausal women (mean age 50.5 years)
and there are no other studies on Danish women conﬁrming the sug-
gested cut-off from Rud et al. [41] we found it most reasonable to use
the cut-offs from the developer of the tools in this study.
The aim of the different tools, i.e. FRAX®with OST, ORAI, OSIRIS or
SCORE, differs. FRAX® predicts the probability of fractures while
ORAI, OSIRIS, OST and SCORE are designed to predict low BMD. How-
ever, since BMD predicts fracture [45] and low BMD are strongly asso-
ciated with risk of fractures [13] the output of the simpler tools may
be perceived as a proxy for probability of fractures. Furthermore,
SCORE, OST and ORAI have once each in three different studies been
validated with fracture outcome [46–48]. The overall conclusions
from these studies were that tools to predict low BMD modestly cor-
relate with clinical fractures.
Other tools such as the Garvan calculator and the QFracture algo-
rithm have similar aim as FRAX®, but we were unable to calculate the
fracture risk of these tools since we have no data on the number of
falls but only data on whether participants have been falling more
*** P<0.001 in-between quartiles for each tool
Fig. 2. Observed prevalence of major osteoporotic fractures plotted according to quar-
tiles of predicted fracture risk based as estimated by FRAX®, ORAI, OSIRIS, OST, SCORE
tool and age alone. ***p b 0.001 in-between quartiles for each tool.
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than once the last year. In our study population prior falls were signif-
icantly more frequent in fracture cases than in non-fracture cases
(14% versus 6%, p b 0,001).
Our study had a number of important strengths. First, it was a
large prospective population-based and including a wide age range
(40–90 years). Thus, the results may be applicable to the wider pop-
ulation of women. Second, we had a high response rate and 77% of the
invited population were available for analyses. Third, the question-
naire was validated in a large number of women prior to the current
study and had a high reliability [24]. Finally, the outcome data relied
on data from highly valid Danish national registers and ensured near-
ly complete follow-up [30,31]. Speciﬁcally, the diagnosis of fractures
in the NPR has previously been shown to be highly accurate [49].
Our study also has some potential limitations. Follow-up was only
three years. However, we took time-to-event into account in our
analyses and studies with longer follow-up have showed similar re-
sults [33,35,39]. We did not measure BMD in our study. This preclud-
ed the possibility to investigate the performance of FRAX® with BMD
in comparison with the simpler tools. While we cannot exclude the
possibility that FRAX® with BMD would perform better than the sim-
pler tools due to the lack of such data, other studies comparing
FRAX® with simpler models including BMD showed that FRAX®
with BMD had only a slightly higher AUC than FRAX® without BMD
and the simpler models [33,35,38,39]. A further limitation could be
that the data on clinical risk factors were self-reported and thus po-
tentially prone to bias. One study demonstrated that a cohort of post-
menopausal women over-reported their height by a mean of 2.8 cm
and underreported their weight by a mean of 2.1 kg [50]. In our
study, the use of self-reported height and weight could result in an
over-estimation of the 10-year fracture risk because the BMI might
be lower than the real BMI. Also, we cannot completely exclude the pos-
sibility that women at high risk of fractureweremoremotivated to par-
ticipate in this study. Comparison of respondents and non-respondents
revealed some differences as previously reported [24]. Finally, only
women participated in the study, thus the results are not generalizable
to men.
In conclusion our data indicate that – during medium-term
follow-up (3 years) and using self-reported clinical risk factors –
more complex tools as FRAX® did not perform better in the fracture
risk prediction compared with simpler tools such as OST, ORAI,
OSIRIS and SCORE or even age alone in a screening scenario where
BMD was not measured. These ﬁndings suggest that simpler tools
based on fewer risk factors, which would be easier to use in clinical
practice by the GP or the patient herself, could just as well as
FRAX® be used to identify women with increased risk of fracture
and therefore should be referred to a DXA scan.
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ABSTRACT
A huge number of risk assessment tools have been developed. Far from all have been validated in external studies, more of them have
absence of methodological and transparent evidence, and few are integrated in national guidelines. Therefore, we performed a
systematic review to provide an overview of existing valid and reliable risk assessment tools for prediction of osteoporotic fractures.
Additionally, we aimed to determine if the performance of each tool was sufﬁcient for practical use, and last, to examine whether the
complexity of the tools inﬂuenced their discriminative power. We searched PubMed, Embase, and Cochrane databases for papers and
evaluated these with respect to methodological quality using the Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS)
checklist. A total of 48 tools were identiﬁed; 20 had been externally validated, however, only six tools had been testedmore than once in a
population‐based setting with acceptable methodological quality. None of the tools performed consistently better than the others and
simple tools (i.e., the Osteoporosis Self‐assessment Tool [OST], Osteoporosis Risk Assessment Instrument [ORAI], and Garvan Fracture Risk
Calculator [Garvan]) often did as well or better than more complex tools (i.e., Simple Calculated Risk Estimation Score [SCORE], WHO
Fracture Risk Assessment Tool [FRAX], and Qfracture). No studies determined the effectiveness of tools in selecting patients for therapy
and thus improving fracture outcomes. High‐quality studies in randomized design with population‐based cohorts with different case
mixes are needed. © 2013 American Society for Bone and Mineral Research.
KEY WORDS: RISK ASSESSMENT TOOLS; SYSTEMATIC REVIEW; SCREENING; WOMEN; OSTEOPOROTIC FRACTURE
Introduction
Osteoporosis is deﬁned as a systemic skeletal diseasecharacterized by decreased bone strength leading to
increased risk of fracture.(1) The disease can cause signiﬁcant
physical disability(2) and is associated with increased mortality.(3)
Osteoporotic fractures are a major and increasing cause of
morbidity and pose a considerable burden to health services.(3)
The number of fractures in the elderly and the associated
economic burden will continue to rise due to the aging of the
world’s population.(4)
Osteoporosis is asymptomatic until fracture occurs but may be
diagnosed using dual‐energy X‐ray absorptiometry (DXA). Most
countries, including Denmark, have adopted a case‐ﬁnding
strategy whereby persons with one or more risk factors for
osteoporosis may be referred for a DXA scan. This strategy,
however, does not perform well, because osteoporosis remains
underdiagnosed and undertreated in Denmark and else-
where.(5,6) Danish studies have shown that many resources are
used to examine women with low risk of fracture, whereas only a
few high‐risk patients are referred(6); thus, 10% of women above
the age of 40 years without risk factors and only 36% of women
with three or more risk factors had received a DXA scan.(6)
Population screening could remedy this and, for instance,
the U.S. Preventive Services Task Force (USPSTF) and the National
Osteoporosis Foundation (NOF) are recommending that women
aged 65 years and older be routinely screened for osteoporosis.(7)
We are unaware of studies investigating the performance of this
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strategy. At present, there is no universally accepted policy for
population screening in Europe to identify patients with
osteoporosis or those at high risk of fracture.
Numerous risk factors for osteoporosis and fractures have
been identiﬁed and several tools have been developed to
integrate risk factors into a single estimate of fracture risk for
individuals.(8) Recently developed prediction tools, such as the
WHO Fracture Risk Assessment Tool (FRAX) algorithm,(9)
Qfracture algorithm,(10) and Garvan Fracture Risk Calculator
(Garvan),(11,12) are aimed at assisting clinicians in the manage-
ment of their patients through the calculation of the patient’s 5‐
year or 10‐year risk of fracture based on a combination of known
risk factors. Many other tools exist and differ according to the
type and number of risk factors included. Common to all these
tools is the ability to identify women at increased risk of
osteoporotic fracture and to stratify them into risk categories for
osteoporosis or fracture. Several studies(13–17) have compared
various tools for their ability to identify women at highest risk of
fracture. Most of these studies reached the conclusions that the
simpler tools perform as well as the more complex tools.
Targeting individuals with increased risk of osteoporotic
fracture is an important challenge in the ﬁeld of osteoporosis.
Risk assessment tools may contribute to health care decision‐
making by identifying which patients would beneﬁt most from
DXA scanning or treatment.
Except for the FRAX algorithm,whichhas been incorporated into
several national guidelines, these tools have not yet found broad
acceptance; however, it is unknown why some prediction tools in
common use whereas others are not.(18) Recent reviews of clinical
prediction models in other areas such as cancer,(19,20) diabetes,(21)
and traumatic brain injury(22) have consistently highlighted design
problems, methodological weaknesses, and deﬁciencies in
reporting as reasons for the lack of uptake. These same reasons
could apply to the osteoporosis risk assessment tools.
Therefore, the aim of this systematic review was to provide an
overview of existing valid and reliable risk assessment tools for
prediction of osteoporotic fracture. We investigated which tools
had been validated in a population‐based setting in studies with
properly documented methodology. We have also aimed to
determine if the performance was sufﬁcient for practical use, and
last, to examine whether the complexity of the tools inﬂuenced
their discriminative power.
We hypothesized that complex tools would have a better
predictive accuracy than simple tools to identify women at
increased risk of osteoporotic fracture.
Methods
We followed the current analytical methods and standards
established by the Preferred Reporting Items for Systematic
Reviews and Meta‐Analyses (PRISMA) group for systematic
reviews and meta‐analyses.(23)
Study selection
We included studies of externally validated tools that were
developed to identify women with an increased risk of
osteoporotic fracture. The studies should have reported perfor-
mance characteristics of risk assessment tools that had fracture
or bone mineral density (BMD) measured by DXA as the
outcome. Moreover, studies had to provide a description of
participant recruitment and the methods used for selecting the
variables included in the tool.
Inclusion criteria
The Population, Intervention, Comparison, and Outcome (PICO)
format was used to deﬁne the inclusion criteria.(23) The
population was deﬁned as women aged 40 years and over.
The “intervention” was a risk assessment tool for the identiﬁca-
tion of women with increased risk of osteoporotic fracture. The
comparison component was fracture risk and the main outcome
should be osteoporotic fracture or BMD (measured by DXA).
Risk assessment tools were included if they were derived from
an initial population and then validated in a separate population
in a new or different setting from the initial one.
Studies were excluded if they focused on secondary
osteoporosis or targeted speciﬁc patient groups being treated
for osteoporosis or related conditions.
Literature search
We searched for relevant papers in the PubMed, Embase, and
Cochrane databases. The following search terms were used:
osteoporosis, osteoporotic fractures, risk assessment, risk factors,
comparison, prediction, screening, and tools. Synonyms were
searched for the keyword “tool”; ie, algorithm(s), model(s),
instrument(s) and questionnaire(s).
The search string used in PubMed was as follows: ((((tool OR
tools OR algorithm OR algorithms OR questionnaire OR
questionnaires OR models OR instruments OR instrument))
AND (mass screening OR screening OR comparison OR
comparisons OR prediction OR predictions OR predictive))
AND (risk factors OR risk assessment)) AND (Osteoporosis,
Postmenopausal OR Osteoporotic Fractures) AND (Humans
[Mesh] AND English[lang] AND Female[MeSH Terms]).
The ﬁnal electronic searchwas undertaken on August 18, 2012.
All citations were exported to Reference Manager 12. Titles and
abstracts were ﬁrst screened based on the inclusion criteria. If it
was uncertain whether or not a study fulﬁlled the inclusion
criteria, it was included in the second reviewing of full‐text
versions. Articles were limited to English language, full‐text, and
published in a peer‐reviewed journal. Reviews were excluded.
Full‐text papers were retrieved and reviewed for quality and
relevance. We then used the papers already found to make a
further search in Web of Science (ﬁnal search was undertaken on
October 26, 2012). We assumed that validation studies on an
existing risk assessment tools would cite the primary study.
Data extraction, analysis, and reporting
Two independent reviewers (KHR and TFH) screened the full‐text
articles for inclusion in the ﬁnal review. The level of agreement
between the two reviewers was 98% (184/188 full‐text articles).
In the four cases of disagreement, studies were included in the
review.
For each paper, details on study design, site and setting,
baseline BMD, risk factors, statistical methods, data collection,
number of participants, inclusion and exclusion criteria,
outcome, follow‐up period, and results were recorded.
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To assess themethodological quality of the studies we applied
the Quality Assessment Tool for Diagnostic Accuracy Studies
(QUADAS) checklist(24) as recommended by the Cochrane
Handbook for Systematic Reviews of Diagnostic Test Accura-
cy.(25) Some modiﬁcation of the checklist was necessary,
including the addition of new items speciﬁc to this review topic
as suggested by the developers of QUADAS.(26) The modiﬁed
QUADAS checklists are provided online (Supporting Table S3 for
tools to predict low BMD and Supporting Table S4 for tools to
predict fractures). In papers reporting both a development and a
validation cohort in the same paper, the methodological quality
was only assessed on the development cohort. Any discrep-
ancies between the reviewers’ assessments were resolved
through discussion.
We evaluated the ability of the tools to differentiate between
individuals with low and normal BMD or their ability to predict
fracture by comparing the area under the receiver operating
characteristic (ROC) curve (AUC).
Finally, we evaluated tools validated more than once in a
population‐based setting and with a methodologically quality
above 60% (as assessed by QUADAS) to estimate if performance
was sufﬁcient for clinical use.
Results
A total of 991 papers were identiﬁed after removing duplicates.
The screening of title and abstract excluded 803 papers, leaving
188 potentially relevant papers for full‐text screening. We further
excluded 100 papers due to irrelevant intervention (n¼ 62),
irrelevant outcome (n¼ 34), irrelevant population (n¼ 3), or
inability to retrieve full text(27) (n¼ 1). A hand search (n¼ 7) and a
search in Web of Science (n¼ 9) identiﬁed 16 additional papers
that meet the inclusion criteria. A further 28 papers were then
excluded because the tool in the studies was developed for a
single study and was either internally validated or not validated
at all. Thus, 76 papers were included in the initial review (Fig. 1).
Detailed descriptions of the 76 included papers are provided
in Supporting Tables S1 and S2. In all, 20 tools were externally
validated; of these, eight tools (counting Osteoporosis Self‐
Assessment Tool [OST] and Osteoporosis Screening Tool for
Asians [OSTA] together) were developed to predict low BMD
(Table 1) and 12 tools to predict fractures (Table 2). Five of the
tools (Age Body Size No Estrogen [ABONE], BodyWeight Criterion
[BWC], OST, Osteoporosis Risk Assessment Instrument [ORAI],
and Simple Calculated Risk Estimation Score [SCORE]) developed
to predict low BMD were also validated regarding their ability to
predict fractures.(28–30)
Risk assessment tools predicting BMD
Eight tools predicting low BMD were externally validated in a
total of 31 studies (Table 1). There were large variations in how
many times each tool had been validated; e.g., the Osteoporosis
Prescreening Risk Assessment (OPERA) tool was externally
validated once, whereas the ORAI, SCORE, and OST/OSTA tools
were externally validated in 16, 19, and 19 studies, respectively.
A number of tools were validated in studies comparing several
tools. All tools were developed between 1996 and 2005; BWC
and SCORE were the ﬁrst and OPERA the most recent.
Fig. 1. Flowchart of included papers.
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The deﬁnition of low BMD in the nine tools varied slightly:
SCORE andORAI used T‐scores2.0 as the cutoff whereas OST/
OSTA, BWC, Osteoporosis Index of Risk (OSIRIS), OPERA, National
Osteoporosis Foundation (NOF), and ABONE used T‐score-
s2.5. The tools were primarily developed and validated for
postmenopausal white/Caucasian women, except for six studies
that validated the OSTA tool for Asian women and one study that
validated OST, SCORE, ORAI, ABONE, and BWC for African‐
American women.
The age of women included in the 31 studies was 40 to
98 years with a mean age between 51 and 73 years. The
women were youngest in the validation studies of OSIRIS
and OST.
In total 78,588 women (mean, 2535; range, 117–32,513) were
enrolled in the 31 studies. The OST, SCORE, and ORAI tools were
validated on the highest numbers of subjects. The tools included
between one and six clinical risk factors in their algorithms
(Tables 1 and 3). The simplest were BWC (including weight) and
OST/OSTA (including age and weight). The study design was
cross‐sectional except in one retrospective cohort study.(30) Most
of the studies used regression analysis and reported sensitivity,
speciﬁcity and ROC analyses. The reported AUC estimates ranged
from 0.13 to 0.87, with most between 0.60 and 0.80. Some tools
had higher AUC estimated in selected studies, but none
demonstrated high estimates in several studies and none
performed consistently better than others.
Most studies (29/31) reported sensitivity and speciﬁcity at the
cutoffs suggested by the developers. Sensitivity ranged
from 50% to 100%, with most between 80% and 90%.
Speciﬁcity ranged from 10% to 88%, with most around 50%.
Several studies reported analyses with other cutoffs ﬁnding
better results.
All primary papers stated the final algorithm
OPERA and OSIRIS were validated in selected populations
whereas the other tools were validated in at least one general
population setting.
Five tools developed to predict low BMD were validated in
studies with fracture outcome.(28–30) In the study by Morin and
colleagues,(30) OST and BWC only had AUC values of about 0.55 in
predicting fractures. Wei and Jackson(29) concluded that ABONE,
ORAI, and BWC onlymoderately correlated with clinical fractures.
The SCORE tool had the highest age‐adjusted fracture rates
compared with two other screening strategies in the study by
LaCroix and colleagues.(28)
Methodological quality of the studies describing tools to
predict low BMD
According to our assessment, the 39 studies developing
or validating tools to predict low BMD complied with a mean
of 11.6 items (range, 6–14) out of the possible 19 QUADAS items
(our QUADAS scoring of the individual studies is reported in
Supporting Table S3).
Only eight studies could be considered population‐based
(i.e., included unselected women from the general population)
(Fig. 2). Only two studies accounted for uninterpretable test
results and presented results for all subjects who were described
as having been entered into the study. Furthermore, only seven
studies accounted for the whole study population using, e.g.,
ﬂowcharts. Most of the studies (n¼ 23) were relatively small, with
study samples below 1000 subjects, but 16 studies had more
than 100 events (women with low BMD). Data on the risk factors
included in the tools were reported in 16 studies based on
interview and not only from self‐reported data through
Table 1. Externally Validated Risk Assessment Tools to Predict Low BMD
Tool
(reference)
Validation studies n
(references) Risk factors in the tool
Enrolled women
total n (mean); rangea
Age (years)
mean (range)a
AUC
(range)a
ABONE(84) 4(29,68,72,78,80) Age, weight, estrogen use 4346 (1086); 135–2365 63.6 (59.4–68.4) 0.67–0.72
BWC(85) 8(68,70,72,73,76,78,80,86) Weight 5088 (636); 135–2365 61 (54.2–66.4) 0.13–0.79
NOF(87) 3(73,77,80) Age, weight, previous fracture,
parental fracture, smoking
3241 (1080); 351–2365 63.9 (57.3–68) 0.60–0.70
OPERA(88) 1(88) Age, weight, previous fracture,
glucocorticoid use, early
menopause
1522 63.1 0.81
ORAI(89) 16(68–81,86,90) Age, weight, current estrogen
use
57,625 (3602); 135–32,513 60.8 (50.5–68.4) 0.32–0.84
OSIRIS(91) 7(70,71,76,90,92–94) Age, weight, previous fracture,
current estrogen use
6840 (977); 207–4035 59.8 (54.2–62.7) 0.63–0.80
OST(90) 13(30,68–71,73–76,78,79,86,90) Age, weight 62,825 (4833); 207–32,513 58.5 (50.5–62.4) 0.32–0.82
OSTA(95) 7(68,72,96–100) Age, weight 5937 (848); 135–1597 61.5 (59.1–68.4) 0.65–0.85
SCORE(101) 19(69,71,72,74–81,90,102–108) Age, weight, previous fracture,
estrogen use, RA, race
61,314 (3227); 117–32,513 62.2 (50.5–72.5) 0.65–0.87
BMD¼bonemineral density; AUC¼ area under the curve in receiver operating characteristics curve; ABONE¼Age Body Size No Estrogen; BWC¼ Body
Weight Criterion; NOF¼National Osteoporosis Foundation; OPERA¼Osteoporosis Prescreening Risk Assessment; ORAI¼Osteoporosis Risk Assessment
Instrument; OSIRIS¼Osteoporosis Index of Risk; OST¼Osteoporosis Self‐Assessment Tool; OSTA¼Osteoporosis Screening Tool for Asians;
SCORE¼ Simple Calculated Risk Estimation Score; RA¼ rheumatoid arthritis.
aIn validation studies.
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questionnaires. Missing data were accounted for in 19 studies.
The remainder of the studies either applied the tools without
knowledge about some of the information or the procedure
regarding missing values was unclear. Although no study was
explicit about blinding, we scored ﬁve studies with “yes” because
the data on risk factors was obtained from the general
practitioner or medical reports before the patient was DXA
scanned or else the questionnaire was sent to the subject before
the DXA scan. For 14 studies, we scored “yes” to the item of
whether the DXA scan was analyzed blind to the tool results,
because the study population was referred to a DXA scan before
entering the study. In 31 studies, the DXA was described in
sufﬁcient detail to permit its replication.
Risk assessment tools predicting fractures
Twelve tools and an updated version of Qfracture developed
to predict fractures had been subject to external validation in
33 studies with fracture as an outcome (Table 2).
Six tools to predict fractures had been externally validated
once, three tools (Study of Osteoporotic Fractures [SOF],
Women’s Health Initiative [WHI], and Fracture and Immobiliza-
tion Score [FRISC]) twice, Qfracture three times, Garvan four
times, and FRAX 18 times. Most of the tools were validated in
studies in which the authors compared several tools or
compared a tool with simpler models or a single risk factor.
The tools were developed between 1995 (SOF) and 2010
(FRISC) and were primarily developed and validated for
postmenopausal white/Caucasian women. However, the FRISC
was both derived(31) and validated(14) for Asian women, and
FRAX was externally validated twice in an Asian population.(32,33)
Only one study(29) had a population with a high proportion of
African‐American women (38%).
The age of the women included in the 33 studies ranged from
30 to 100 years (mean, 48–81 years). The women were youngest
in the validation study of the updated Qfracture (mean, 50 years)
and oldest in the study of the FRACTURE index (mean, 81 years).
A total of 3,105,136 women (mean, 94,095; range, 200–
1,117,982) were enrolled in the 33 studies. Studies on Qfracture
(plus updated version) and FRAX were validated on the most
women (n¼ 1,760,719 for Qfracture; n¼ 804,563 for Qfracture
plus updated version; and n¼ 391,334 for FRAX). The tools
included between one and 31 risk factors in their algorithms
(Tables 2 and 3). The most complex were FRAX (n¼ 11 risk
factors), WHI (n¼ 14), SOF (n¼ 14), Qfracture (n¼ 18), and
Qfracture updated version (n¼ 31). The tools for predicting
fractures generally included more risk factors (mean, 8.4 risk
factors) than the tools for predicting low BMD. All the fracture‐
predicting tools included age; thereafter, the four most
frequently included risk factors in the ﬁnal models were weight,
prior fracture, BMD, and maternal/parental history of fracture.
All of the algorithms were available in the literature except for
the FRAX tool, which is the only algorithm still not in the public
domain.
Incident fracture rates in the validation studies varied from 1%
to 21%. Most studies used a prospective design, whereas ﬁve
studies were retrospective.(15,17,34–36) Themean follow‐up period
varied between 1.7 and 13.4 years.
Most of the studies used ROC, regression (mostly Cox
regression), and survival analysis. The reported AUC estimates
ranged from 0.54 to 0.84 for major osteoporotic fractures and
0.64 to 0.89 for hip fractures, withmost between 0.60 and 0.80. As
with the tools predicting BMD, some fracture‐predicting tools
had a higher AUC in selected studies, but none demonstrated
high estimates in several studies and none performed consis-
tently better than the others.
Fig. 2. Methodological quality (according to a modiﬁed QUADAS checklist) of the 39 included studies of tools predicting low BMD. QUADAS¼Quality
Assessment Tool for Diagnostic Accuracy Studies; BMD¼bone mineral density.
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The Osteoporosis Canada (OC),(37) WHI,(38) and the tool
developed by Ettinger and colleagues(39) were validated in
subgroups of the population. The other tools were validated at
least once in a general population setting.
Methodological quality of the studies describing tools to
predict fractures
According to our assessment, the 37 studies of tools predicting
fractures complied with a mean of eight items (range, 4–11) out
of the possible 13 QUADAS items (our QUADAS scoring of the
individual studies is reported in Supporting Table S4).
About one‐half of the studies included subjects from the
general population (Fig. 3). Only seven studies included a
ﬂowchart or a description of the whole study population and
none of the studies clearly reported intermediate or uninterpret-
able test results or accounted for all subjects who were
potentially included in the study.
In approximately one‐half of the studies, the data on risk
factors were obtained from interview, and only six studies
accounted for missing data in the calculation of the tools.
Most of the studies included over 1000 subjects and had over
100 major osteoporotic fractures during follow‐up. In 29 studies,
fractureswere veriﬁedby radiographic reports ormedical records;
in eight of these 29 studies, fractures were self‐reported but then
conﬁrmed by radiographic reports or medical records afterward.
Only 15 studies used a follow‐up time corresponding to the
period for which the tool had been intended (5 or 10 years for all
subjects included in the study, depending on the outcome
period of the tools).
In one case, the tool did not have a ﬁnal model(9) and for an
other tool the ﬁnal model was not clear in the papers, but the
ﬁnal model could be found on a website.(10,40) One study was not
clear about which version of FRAX was used.(14) The rest of the
developmental studies described the ﬁnal model for the tool,
and the validation studies described the included tool/tools in
details.
Predictive performance
We found that 26 studies were carried out in population‐based
settings with an acceptable methodological quality. In these
studies, only six tools—ORAI, SCORE, OST, FRAX, Garvan, and
Qfracture—were validated more than once with an acceptable
sample size for events (“yes” to item 19 in QUADAS; 5, 4, 4, 4, 2,
and 2 times, respectively in 14 studies). The total number of
women in these validation studies was; 14,124 for ORAI, 12,653
for SCORE, 18,637 for OST, 18,452 for FRAX, 5322 for Garvan, and
1,760,135 for Qfracture (Table 4). Figures 4 and 5 show the ability
of these tools to predict low BMD or fractures (i.e., AUC values) in
relation to the number of risk factors included in the tool and the
sample size of the validation studies.
AUC estimates ranged from 0.64 to 0.80 and from 0.62 to 0.82
in the validation studies of tools to predict low BMD and tools to
predict fractures, respectively. The simplest of these tools were
OST, ORAI, and Garvan, with 2, 3, and 5 risk factors included in the
algorithm, respectively.
Of these six tools, only ORAI, Garvan, and Qfracture were also
developed in studies with a population‐based setting and
applying proper methodology.
Comparative studies
A total of 13 tools were compared and validated against each
other in 31 studies (Table 5). Thus, 12 studies compared different
tools with fracture outcome, 16 studies compared different tools
with low BMD as outcome, and three studies compared tools
with BMD outcome against fracture. The overall ﬁnding
conclusion of in these comparative studies was that simple
tools with fewer risk factors or simplermodels often did as well or
better than more complex tools with more risk factors.
Risk‐assessment tools in clinical practice
We identiﬁed three studies evaluating the use of risk assessment
tools in clinical practice in a randomized design.(28,41,42)
Fig. 3. Methodological quality (according to a modiﬁed QUADAS checklist) of the 37 included studies of tools predicting fractures. QUADAS¼Quality
Assessment Tool for Diagnostic Accuracy Studies.
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Table 4.Discriminative Power (AUC) of the Six Tools That Were Validated at Least Once in Population‐Based Settings With an Acceptable
Methodological Quality
Author (reference) Tool Women (n) AUC (low BMD) AUC (MOP fracture)
Machado and Da Silva(68) OST 588 0.65
Gourlay and colleagues(69) OST 7779 0.72
Rud and colleagues(75) OST 2016 0.68
Morin and colleagues(30) OST 8254 0.77
OST, total 18,637
Machado and Da Silva(68) ORAI 588 0.67
Gourlay and colleagues(69) ORAI 7779 0.70
Rud and colleagues(75) ORAI 2016 0.64
Cadarette and colleagues(80) ORAI 2365 0.79
Cadarette and colleagues(89) ORAI 1376 0.79
ORAI, total 14,124
Gourlay and colleagues(69) SCORE 7779 0.71
Rud and colleagues(75) SCORE 2016 0.68
Cadarette and colleagues(80) SCORE 2365 0.80
Cadarette and colleagues(104) SCORE 493 0.71
SCORE, total 12,653
Langsetmo and colleagues(51) Garvan 4152 0.69
Bolland and colleagues(16) Garvan 1170 0.63
Garvan, total 5322
Bolland and colleagues(16) FRAX 1170 0.62
Hillier and colleagues(65) FRAX 6252 0.62
Fraser and colleagues(112) FRAX 4778 0.69
Ensrud and colleagues(49) FRAX 6252 0.67
FRAX, total 18,452
Collins and colleagues(64) Qfracture 1,117,982 0.82
Hippisley‐Cox and Coupland(10) Qfracture 642,153 0.79
Qfracture, total 1,760,135
AUC¼ area under the receiver operating characteristics curve; BMD¼bone mineral density; MOP¼major osteoporotic fractures; OST¼Osteoporosis
Self‐Assessment Tool; ORAI¼Osteoporosis Risk Assessment Instrument; SCORE¼ Simple Calculated Risk Estimation Score; Garvan¼Garvan Fracture Risk
Calculator; FRAX¼WHO Fracture Risk Assessment Tool.
Fig. 4. Ability of the OST, ORAI, and SCORE tools to predict low BMD (AUC
values) in relation to thenumber of included risk factors and the sample size
in each population‐based validation study. The size of the circles reﬂects
the number of women included in the study. OST¼Osteoporosis Self‐
assessment Tool; ORAI¼Osteoporosis Risk Assessment Instrument; SCORE-
¼ Simple Calculated Risk Estimation Score; AUC¼ area under the receiver
operating characteristic curve; BMD¼bone mineral density.
Fig. 5. Ability of the Garvan, FRAX, and Qfracture tools to predict
fracture (AUC values) in relation to the number of included risk factors
and the sample size in each population‐based validation study. The size
of the circles reﬂects the number of women included in the study.
Garvan¼Garvan Fracture Risk Calculator; FRAX¼WHO Fracture Risk
Assessment Tool; AUC¼ area under the receiver operating characteristic
curve.
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LaCroix and colleagues(28) evaluated three screening strate-
gies involving either BMD testing alone or evaluation by risk
assessment tools followed by BMD testing if the tool indicated
high risk. Of the 9268 women invited, 3167 participated. They
were allocated to (1) DXA scan, (2) SCORE followed by DXA if
SCOREwas7, or (3) SOF followed byDXA for5 hip fracture risk
factors. After 33months of follow‐up, the screening programwas
shown to have inﬂuenced total fracture rates, but there were no
intergroup differences in osteoporosis treatment rates.
Dargent‐Molina and colleagues(41) (EPIDOS study) compared
four different screening strategies among 5910 of the 7575
invited women: (1) DXA alone, (2) quantitative ultrasound (QUS)
alone, (3) QUS followed by DXA among subjects with medium‐
lowQUS, and (4) DXA among subjects<59 kg followed by clinical
evaluation. After 3.7 0.8 years of follow‐up, strategy 3 and 4 had
the same discriminant value as strategy 1, but resulted in less
than 50% BMD examinations. A combination of strategy 3 and 4
would allow an increased number of women to be identiﬁed as
being at high risk.
Barr and colleagues(42) used a combination of known risk
factors for fractures and a QUS heel scan. Of the 5306 women
invited, 2515 participated and were randomly assigned to
screening or control groups. After 1 to 3 years of follow‐up, the
risk of fracture was reduced in the screening group.
Discussion
Main findings
In the last decades many different risk assessment tools have
been developed, but only 20 of 48 identiﬁed risk assessment
tools for prediction of osteoporotic fractures were externally
validated; eight tools were developed to identify individuals at
risk of low BMD and 12 tools were developed to identify
individuals with an increased risk of fractures. Only six tools (OST,
ORAI, SCORE, Garvan, FRAX, and Qfracture) were externally
validated in a population‐based setting with proper methodo-
logical quality. None of the tools performed consistently better
than others when tested in external validation studies, and
simple tools with fewer risk factors often did as well or better
(i.e., OST, ORAI, Garvan) than more complex tools with more risk
factors (i.e., SCORE, FRAX, Qfracture).
We did not identify studies that prospectively tested tools in a
population‐based setting with a randomized design or deter-
mined its effectiveness in selecting patients for therapy. On the
other hand, three studies evaluated the use of risk assessment
tools in clinical practice in a randomized design but none of the
studies demonstrated improved fracture outcome when using
risk‐assessment tools in clinical practice to identify individuals for
screening for osteoporosis or treatment.
Methodological quality
Scoring the methodology by the QUADAS checklist, we found
that most of the included studies had several shortcomings.
Similar results were reported in previous reviews of clinical
prediction tools regarding osteoporosis,(7,43,44) but also can-
cer,(19,20) diabetes,(21) and traumatic brain injury.(22) Nevertheless,
all studies in this review had participant selection criteria
described; the tools were well described and the ﬁnal model/
algorithm was presented with few exceptions. The clinical risk
factors included in the tools were possible to collect in clinical
practice and in most studies the participants were adequately
described. However, these attributes were overshadowed by
issues such as poor study design, inappropriate study samples,
and incomplete reporting, especially of subject withdrawals, data
collection methods (self‐report or assisted interview), treatment
of missing data, and uninterpretable test results.
In many cases, inadequate reporting made it difﬁcult for us to
judge the quality of the studies, thus resulting in several items
Table 5. An Overview of 13 Tools Validated and Compared Against Each Other
Qfracture SOF FRAX Garvan FRISC Risk factora ABONE ORAI BWC NOF OSIRIS OST OSTA SCORE
Qfracture X
SOF X
FRAX X X X X
Garvan X X
FRISC X
Risk factora X X X
ABONE X X X X X X X X
ORAI X X X X X X X
BWC X X X X X X X
NOF X X X X X
OSIRIS X X X X X
OST X X X X X X X
OSTA X X X X X
SCORE X X X X X X X X
aRisk factors such as: BMD, age, prior fracture, body mass index (BMI), weight, and femoral neck T‐score.
SOF¼ Study of Osteoporotic Fractures; FRAX¼WHO Fracture Risk Assessment Tool; Garvan¼Garvan Fracture Risk Calculator; FRISC¼ Fracture and
Immobilization Score; ABONE¼Age Body Size No Estrogen; ORAI¼Osteoporosis Risk Assessment Instrument; BWC¼ Body Weight Criterion;
NOF¼National Osteoporosis Foundation; OSIRIS¼Osteoporosis Index of Risk; OST¼Osteoporosis Self‐Assessment Tool; OSTA¼Osteoporosis Screening
Tool for Asians; SCORE¼ Simple Calculated Risk Estimation Score; BMD¼bone mineral density; BMI¼body mass index.
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classiﬁed as unclear. Other authors reported similar experiences
and noted their disappointment that many risk assessment tools
have been developed and used without greater consideration of
methodological shortcomings.(18,43)
The development, validation, and performance assessment of
prognostic tools are complex processes, and rely on a good
understanding of statistical methods and their appropriate
application.(19) The lack of transparency, inadequate reporting,
and inappropriate methodological choices may partly explain
why so few risk assessment tools are used in clinical practice.(18,19)
A single tool, i.e., FRAX, has been incorporated into several
national guidelines; however, FRAX was scored low against
QUADAS.(9) Other authors have raised similar criticism regarding
both the original development and validation cohorts(18) and
the insufﬁcient information available for objective evaluation of
FRAX.(44)
Population‐based sampling
Item 1 in the QUADAS checklist (concerning the representative-
ness of the sample) opens up thequestion of generalizability.Most
validation studies of tools to predict low BMD were evaluated in
selected populations rather than the general population. Even
among the 26 studies evaluating tools to predict fractures that we
characterized as population‐based, few resulted in truly general-
izable ﬁndings because of the high proportion of subject
withdrawals and nonrespondents.(45) In one of the reviewed
studies, for instance, only 18% of the subjects from the afﬁliates of
a large insurance company participated, even though they were
randomly selected.(46) Nonresponse at random is rare(47) and
participants and nonparticipants often differ,(48) thus limiting
external validity studies.(45) Some authors(11,12,16,49–52) com-
mented, for example, that the participants were healthier, had
lower mortality rates, and were older than the general population.
Thus, results can hardly be generalized from the studies with very
low participation rates,(9,11,28,46,51) because the extent to which a
cohort sample is representative of the total reference population
depends on the completeness of the population frame available
to the investigator.
Furthermore, the omission of uninterpretable test results and
subject withdrawals from the analysis usually leads to an
overestimation of the accuracy/differentiation of the tool.(53)
Missing items
Data collection and quality of data were also issues in several
studies because it was uncertain whether the data were self‐
reported or collected with assistance, and whether the
participants answered all questions or if there were some
missing items. Few studies had complete data on the entire study
population. Some of the authors handled missing data by
multiple imputations, but most did not account for the missing
data. Thus, the possibility of inaccurate and biased estimates of
performance in the studies that did not account for missing data.(18)
Sample size
Sample sizes were generally—and appropriately—higher in
studies validating tools to predict fractures than in studies of
tools to predict low BMD. Thus 30 of 37 studies of tools to predict
fractures had a sample size of at least 1000 women, compared to
16 of 39 studies of tools to predict low BMD. No ﬁrm guidelines
exist on sample size requirements for development or validation
studies.(18,54)
In terms of whether the studies could be underpowered, it is
worth emphasizing that the effective sample size is not driven by
the number of subjects in the cohort, but the number of events
(i.e., fractures or low BMD). Empirical simulations have found that
at least 100 events are required to validate a prediction tool.(54)
Thus, 10 of the reviewed studies of tools to predict low BMD
and eight of the studies of tools to predict fractures were
underpowered.
Assessing performance of a predictive tool
It is important that osteoporosis risk assessment tools are accurate
and effective in determining those at risk of disease.(55–57)
Ideally, they should include an appropriate number and range
of risk factors and these should be easy to record in clinical
practice.
In nearly all the studies, performance of the tools was
evaluated using ROC analysis. The AUC estimates mostly ranged
between 0.6 and 0.8, indicating that the tools are modest
predictors of low BMD or fractures. In general, an AUC of at least
0.80 is considered necessary for a diagnostic test to be
effective.(58) None of the tools produced AUC estimates above
0.80 in more than one validation study.
Kanis and colleagues(59) criticized the use of ROC analysis in
this context. First, ROC analysis may lack sensitivity to additional
variables. Second, it may be inappropriate to compare AUCs
across studies. Third, ROC analysis is unable to determine the use
of a clinical tool to identify risk categories for intervention.
Although nearly all the tools assessed performance through ROC
analysis, we are aware of the limitations in the use of ROC analysis
and especially of the danger in comparing AUC between studies.
Our conclusions, however, are mostly based on the number of
external validation studies on the tool and the studies’
methodological quality.
Further, it is argued that calibration of the tool is also
important for prediction models to be able to compare the
accuracy of tools.(21,60) Despite the importance of calibration of
the tools, we and other systematic reviews have all found that
calibration is frequently not done.(19,21)
Strengths and limitations
A major strength of this review is that we performed a
comprehensive systematic search of the literature retrieved
from several databases. We followed the analytical methods and
standards established by the PRISMA group for systematic
reviews and we assessed the methodological quality of the
included studies. Two reviewers independently reviewed the
papers in proportion to the inclusion/exclusion criteria and
assessed the methodological quality.
In our experience, the use of the QUADAS checklist caused
some problems, as reported by others.(26,43) First, it is challenging
to adapt the generic items used to assess the quality of diagnostic
accuracy to ﬁt the context in the reviewwhen assessing the quality
of risk assessment tools. Second, it was difﬁcult to score some of
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the items, especially items concerning uninterpretable test results
and withdrawal, but also in relation to poor standard of reporting.
These difﬁculties will also tend to reduce the strength of some
dimensions of methodological quality.
A limitation of our study is that we only included studies
published in the English language and that we did not include
“gray literature” (i.e., abstracts and unpublished data) or clinical
trials databases. A second potential limitation could be that we
only included women. However, osteoporosis is most prevalent
in women and screening programs are likely to be implemented
only in women.
We assessed the performance of the tools in the general
population and the conclusions rely on their performance in this
setting. We are aware of the possibility that some risk factors
could be of particular relevance in other settings, for example
corticosteroid use and rheumatoid arthritis in a rheumatology
practice, or aromatase inhibitors or androgen deprivation
therapy in an oncology practice. Ultimately, the need to include
such risk factors depends both on their effect size and on their
prevalence in the population. We recommend that such tools be
developed and validated in a setting that is representative of the
population in which the tool will ultimately be applied; hence,
the greatest societal impact will generally be provided by a tool
that can be used successfully in the general population.
Risk factors for osteoporosis
Most tools included the same risk factors but the number of risk
factors varied greatly. All but one of the 20 tools included age in
the algorithm. Age is also strongly associated with fracture risk(1)
and has the strongest known association with BMD.(61) The next
most frequently included variables were body weight, prior
fracture, and maternal history of fractures (Table 3). These three
risk factors are also consistently associated with increased
fracture risk.(1,62,63) Tools to predict fractures generally included
more risk factors than did tools to predict low BMD.
Complex versus simple
The simplest tools included one or two risk factors, whereas the
most complex tool included 31 risk factors. OST was one of the
simplest tools to predict low BMD and Garvan the simplest to
predict fractures.
The most complex tool is the updated Qfracture, with 31
clinical risk factors included in the algorithm.
As noted by other authors,(57) the usefulness of a tool not only
depends on its diagnostic accuracy but also on its ease of use.(9)
Risk factors should be unambiguous and easily determined—
ideally through patient self‐report. Although the developers of
Qfracture expected that the included risk factors would be either
known to the patient or could be collected in routine clinical
practice,(64) we question the applicability of such a complex tool.
Patients will not always be able to reliably report past use of
glucocorticoids or estrogen, for example. Tools that would bemore
amenable for self‐report include OST, BWC, NOF, and Garvan.
Comparing the simple versus complex tools
Several of the studies compared tools against each other with
respect to their ability to identify individuals at increased risk of
osteoporotic fracture or low BMD, especially as to whether the
more complex tools perform better in this regard than simpler
tools.(13–17,28,32,33,46,49,65–81) Most of these studies reached the
conclusions that simpler models or tools perform as well as the
more complex (typically FRAX) in predicting fractures. Kanis and
colleagues(59) recently raised criticisms of numerous studies in
the ﬁeld and concluded that most of the studies had used
inappropriate methodologies with overreliance on AUC and
comparisonswithmodels derived from the validation population
itself. Thus, in the examination and evaluation of the tools
included in this systematic review we only included externally
validated tools and not “homegrown” models.
We found no difference in the predictive performance (in
terms of AUC) of the simple and complex tools. Simpler tools with
fewer risk factors would be easier to use in clinical practice by the
doctor or the patient herself, and thus may be sufﬁcient to
identify womenwith increased risk of osteoporotic fractures who
should be referred for a DXA scan.
It remains to be seen whether well‐designed population‐
based studies in which participants are randomly allocated to a
screening group with a risk assessment tool and a control group
to evaluate the cost‐effectiveness of screening for osteoporosis
would lead to the same conclusions.
We are aware of two ongoing population‐based, randomized
studies in progress, in which patients are selected for DXA using
FRAX and with fractures as the primary outcome. The English
study (SCOOP)(82) included approximately 12,000 women aged
70 to 85 years. Participants were randomly allocated via primary
care to receive either questionnaire‐based screening (with BMD
measured by DXA in selected participants), or standard care.
The Danish study (ROSE) (Holmberg and colleagues, “The Risk‐
Stratiﬁed Osteoporosis Strategy Evaluation Study [ROSE]”;
manuscript in preparation) currently includes 35,000 women
aged 65 to 80 years randomly allocated to a screening group and
a control group. Both group received a questionnaire about risk
factors for osteoporosis and those with a major osteoporotic
fracture at 15% or more in the screening group were provided a
DXA scan.
Ultimately, these studies may provide data on the effective-
ness of FRAX in improving fracture outcome and cost‐
effectiveness in screening. Further, a U.S. study (POROS)(83) is
ongoing to determine the clinical utility of a three‐step fracture
risk screening program in a population of younger women (aged
50–65 years). Approximately 3000 women received a question-
naire and those with one or more risk factors for fractures (from a
modiﬁcation of the FRACTURE index and additional risk factors
from FRAX) were randomized with a 4:1 allocation to either the
intervention or nonintervention group. As in the ROSE study,
results are not yet available.
We suggest that future research should also focus on
validating the simpler tools such as OST, ORAI, and Garvan in
similar settings to those described in the above paragraphs.
Conclusion
Many different risk assessment tools have been developed but
only 20 tools were externally validated and only six tools (OST,
ORAI, SCORE, Garvan, FRAX, and Qfracture) were validated in a
Journal of Bone and Mineral Research A SYSTEMATIC REVIEW OF OSTEOPOROSIS RISK ASSESSMENT TOOLS 1713
population‐based setting with a proper methodological quality.
No tool performed consistently better than others and simple
tools with fewer risk factors often did as well or better (i.e., OST,
ORAI, and Garvan) than more complex tools with more risk
factors (i.e., SCORE, FRAX, and Qfracture). No studies determined
the effectiveness of tools in selecting patients for therapy and
thus improving fracture outcomes.
High‐quality studies of randomized design with population‐
based samples or cohorts with different case mixes are needed.
We suggest that future research also focus on validating the
simpler tools (for example Garvan) in the ﬁeld of using risk
assessment tools in targeting individuals at increased risk of
osteoporotic fractures.
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 Appendix 1 
 
 
 
 
 
  
Questionnaire 
 
  
 
  CPR-nr. «V_PNR»  
     
1 
 
   
 
 
Spørgeskema 
 
  Knogleskørhed/Osteoporose 
 
 
Sådan udfylder du spørgeskemaet. 
 
Spørgsmålene bedes besvaret af den person, hvis CPR-nr. er anført på dette spørgeskema. 
 
Er der spørgsmål, du finder svære at besvare, må du gerne få hjælp fra pårørende eller venner 
til at besvare spørgeskemaet. 
 
Hvis der er spørgsmål, hvor dit svar ikke helt passer til svarmulighederne, skal du sætte kryds 
ved det svar, der passer bedst til din situation.  
 
Det er vigtigt for undersøgelsen, at alle spørgsmålene besvares. 
 
Der er spørgsmål på begge sider af siderne, så husk at vende siden. 
 
 
Svarene bliver skannet ind på en maskine, så tal og kryds skal være nemme at tolke, som vist i 
nedenstående eksempler. 
 
Eksempler på angivelser af afkrydsning, tal og 
tekst 
RIGTIGT FORKERT 
Sæt tydeligt kryds indenfor for feltet. 
 
Kryds eller tal må ikke ramme kanten rundt om 
feltet 
   
Hvis et felt er udfyldt forkert, skal HELE feltet 
skraveres, og krydset sættes i det rigtige felt. 
  
Tal skrives ét tal i hvert felt   
Tal skrives så det sidste ciffer i tallet står længst 
til højre 
  
 
  
  
 X 
X X 
5 3 3
5 
X 
3 3  3 3  
 5
5 
CPR-nr. «V_PNR» 
  
 
  CPR-nr. «V_PNR»  
     
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1) Hvad er din nuværende højde?  
    cm. (Skal skrives i cm, f.eks. 167 cm) 
2) Hvad er din nuværende vægt? 
    kg. (Skriv hele tal, f.eks. 65 kg) 
3) Hvad er din etniske oprindelse? 
Europæisk (f.eks. dansk)   
Mellemøstlig   
Afrikansk   
Asiatisk   
Latinamerikansk   
Andet   
4) Har du fået konstateret knogleskørhed af din læge? 
Ja   
Nej   
Ved ikke   
Indledningsvis handler spørgsmålene om din højde, vægt og etniske 
oprindelse 
Følgende spørgsmål handler om knogleskørhed 
 
  
 
  CPR-nr. «V_PNR»  
     
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5) Får du aktuelt receptpligtigt medicin mod knogleskørhed? 
Ja   
Nej   
Ved ikke   
6) Har du fået foretaget en skanning af ryg og/eller hofte (såkaldt DEXA-skanning) 
for at undersøge, om du har knogleskørhed? 
Ja   
Nej   
Ved ikke   
7) Er du faldet mere end én gang i løbet af de sidste 12 måneder, hvor faldene 
opstod uden ydre påvirkning, som f.eks. sammenstød eller skub fra omgivelserne?  
Ja   
Nej   
Ved ikke   
Følgende spørgsmål handler om fald og knoglebrud hos dig selv 
 
  
 
  CPR-nr. «V_PNR»  
     
4 
 
 
8) Har du haft knoglebrud efter, at du er fyldt 40 år? 
Ja   
Nej    Gå venligst direkte til spm. 9 
Ved ikke    Gå venligst direkte til spm. 9 
 
Hvis ja, udfyld venligst nedenstående 
 
Sæt venligst et kryds ved både alder, knogle og årsag til knoglebrud for hvert brud 
efter, at du er fyldt 40 år. 
      
Alder ved knoglebrud 1. brud 2. brud 3. brud 4. brud 5.brud 
40-44 år            
45-49 år            
Over 50 år            
Hvilken knogle 1. brud 2. brud 3. brud 4. brud 5. brud 
Hofte            
Ryg (inkl. sammenfald i ryg)            
Håndled            
Ribben            
Andre brud            
Årsag til knoglebrud 1. brud 2. brud 3. brud 4. brud 5. brud 
Fald på samme niveau (f.eks. 
fald over tæppe), snuble el. lign. 
           
Trafikuheld, fald fra højde (f.eks. 
trappe, stige) el. lign. 
           
Løft af lettere ting, bukken 
forover, hoste, nyse el. lign. 
           
Andet            
  
 
  CPR-nr. «V_PNR»  
     
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9) Har din mor eller far haft hoftebrud? 
Ja   
Nej   
Ved ikke   
10) Har nogle i din nærmeste familie (far, mor eller søskende) haft håndledsbrud, 
hoftebrud eller brud i ryggen efter, at de var fyldt 50 år? 
Ja   
Nej   
Ved ikke   
11) Ryger du? 
Ja, dagligt  
Ja, mindst én gang om ugen  
Ja, sjældnere end én gang om måneden  
Nej, jeg er holdt op  
Nej, jeg har aldrig røget  
Følgende spørgsmål handler om livsstilsfaktorer 
 
Følgende spørgsmål handler om knoglebrud hos nærmeste 
familiemedlemmer 
 
  
 
  CPR-nr. «V_PNR»  
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12) Indtager du alkohol i løbet af ugen? 
Ja  
Nej  
 
Hvis ja, hvor mange genstande drikker du på hver af dagene i en typisk uge? 
Start med mandag og tag én dag ad gangen. 
Antal genstande skrives i HELE tal f.eks. rundes 1,5 genstand op til 2. 
Mandag  
Tirsdag   
Onsdag  
Torsdag   
Fredag   
Lørdag  
Søndag  
Genstand: 
1 Øl = 1 genstand,                 1 glas vin = 1 genstand,                1 glas hedvin = 1 genstand,       
1 stærk øl = 1,5 genstand,    1 flaske vin = 6 genstande,       4 cl spiritus = 1,5 genstand 
  
 
  CPR-nr. «V_PNR»  
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13) Har du været i behandling med binyrebarkhormon?  
F.eks. Prednisolon, prednison, hydrokortison, medrol. 
Ja  
Nej    Gå venligst direkte til spm. 14 
Ved ikke    Gå venligst direkte til spm. 14 
Hvis ja, udfyld venligst nedenstående 
Fik du behandling med binyrebarkhormon gennem? 
Tabletter  
Andet    Gå venligst direkte til spm. 14 
 
Hvis tablet behandling, udfyld venligst nedenstående 
Har dosis på tabletbehandling været 5 mg eller derover? 
Ja   
Nej    Gå venligst direkte til spm. 14 
Ved ikke   Gå venligst direkte til spm.  14 
 
Hvis ja, hvor længe (mdr./år) har den længste tabletbehandling været? 
Antal måneder (skrives i hele tal f.eks. 5 mdr.)  mdr. 
Eller: 
Antal år (skrives i hele tal f.eks. 1 år)  År 
Følgende spørgsmål handler om medicinforbrug 
 
  
 
  CPR-nr. «V_PNR»  
     
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14) Har du passeret overgangsalderen (er dine menstruationer ophørt)? 
Ja  
Nej    Gå venligst direkte til spm. 18 
Ved ikke    Gå venligst direkte til spm. 18 
16) Hvad var årsagen til, at du gik i overgangsalderen? 
Naturlig årsag  
Livmoder fjernet  
Æggestok(ke) fjernet  
Ukendt årsag/ved ikke  
15) Hvor gammel var du cirka, da du havde din sidste menstruation? 
Under 45 år  
45 år eller derover  
17) Har du været i behandling med kvindeligt kønshormon (inkl. p-piller) efter, at 
du har passeret overgangsalderen? 
Ja  
Nej  
Ved ikke  
Følgende spørgsmål handler om kvinders cyklus 
 
  
 
  CPR-nr. «V_PNR»  
     
9 
Følgende spørgsmål omhandler faktorer/sygdomme, der kan være en 
medvirkende årsag til udvikling af knogleskørhed 
 
 
 
 
 
 
 
 
 
 
 
 
18) Er du aktuelt i behandling med kvindeligt kønshormon (inkl. p-piller)? 
Ja  
Nej  
Ved ikke  
19) Har du nogensinde af en læge fået konstateret, at du har: 
 (sæt venligst ét kryds i hver linje) 
 Ja Nej Ved ikke 
Slidgigt    
Leddegigt (f.eks. ægte gigt, rheumatoid arthritis)    
Kronisk leversygdom    
Type 1 diabetes (ungdoms diabetes)    
Sygdommen osteogenesis imperfecta (OI)    
Spiseforstyrrelsen anoreksi (anorexia nervosa)    
Problemer med at optage næringsstoffer fra kosten 
(f.eks. cøliaki eller malabsorption)    
Tarmsygdomme, som medfører nedsat optagelse 
af føden/kosten (f.eks. Crohns sygdom eller colitis 
ulcerosa) 
   
Forhøjet stofskifte  
(f.eks. thyrotoksikose eller hyperthyroidisme)    
  
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Underskrift: _______________________________________________________________ 
 
 
 
MANGE TAK FOR HJÆLPEN 
 
Spørgeskemaet bedes sendt retur i vedlagte frankerede svarkuvert. 
20) Har du nogensinde været sengeliggende i mere end 1 måned? 
Ja  
Nej  
Ved ikke  
Hvis ja, hvor gammel var du? 
 Hvis du har været det flere gange, bedes du anføre alderen ved de sidste 2 tilfælde. 
Alder   år Alder   År 
21) Er du immobil i en sådan grad at du: Ja Nej 
Ikke kan gå udenfor dit hjem   
Ikke kan udføre almindeligt husarbejde   
 
22) Må vi senere hen kontakte dig, hvis vi laver en opfølgende undersøgelse på et 
senere tidspunkt?  
Ja  
Nej  
Telefon-nummer  
 Dag  Måned  År 
Skemaet udfyldt den  -  - 2009 
 Appendix 2 
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S1: Description of all 39 included papers with tools to predict low bone mineral density (BMD). 
 
  
Appendix S1 
 
S1: Description of all 39 included papers with tools to predict low bone mineral density (BMD).
Author            
year
Studie 
purpose 
Compare (C) 
Development (D) 
Validation (V)
Study site 
and ethnicity
Setting                            Age range
Number of 
eligible 
participants
Number of  
included 
participants
Mean BMD 
or T-score 
details  
(baseline)
Tool  Risk factors
Ben                        
2001
V Belgium        
100% white 
women
Postmenopausal 
women from an 
outpatient OP center 
in Liege.
45-96 yrs. 
Mean 
61.5±8.8 
yrs.
NS 4,035 NS SCORE As in SCORE
Brenneman            
2003
C Seattle, USA  
Caucasian: 
93.5%
women selected 
from managed care 
(group health) 
enrollment.
60-79 yrs   
Mean: 
69.3±5.5 
yrs.
847 416 NS,                      
30.3% had OP
SCORE, SOF-
based 
algorithm
As in: SCORE, SOF-based 
algorithm
Cadarette            
1999
V Canada   
White: 87%  
black: 2.3% 
Asian: 8.3%
Postmenopausal 
women from CAMOS 
study (Toronto site) 
Invited through 
telephone contact.
≥ 45 yrs  
Mean: 
64.5±8.7 
yrs.
NS 493 NS SCORE As in: SCORE
Cadarette            
2004
C Toronto, USA             
NS, primary 
white women 
Women from two 
family practices of 
three University 
affiliated hospitals. 
45-90 yrs  
Average: 
62.4 yrs.
NS 190 women 
evaluated 
prospective-ly 
and 552 
women 
retrospec-
tively.
NS,                     
16.5% had OP
ORAI, OST, 
BWC
As in: ORAI, OST, BWC
Exclusion criteria
Outcome 
(Fracture 
or BMD)
Follow-up
Definition 
of outcome 
Results  Events 
Low 
BMD/Fracture 
Results AUC
Study design   
prospect (P)    
retrospect (RET)                     
Cross sectional 
(CR)                   
statistical 
methods
Score of the 
QUADAS tool
NS BMD NR NR 380+ Using the cut-point ≥ 6;  AUC 0.70, 
Sens 91.5%, Spec 26.5%, PPV 52.8% 
NPV 77.7%.                                      More 
values at other cut-off and t-score.                                                     
CR Sens/spec 
and ROC 
analysis.
Yes: 3, 5, 6, 8, 9, 
11, 12, 15, 16, 
17, 18, 19, 20.                      
No: 1, 13, 14.      
Unclear: 2, 4, 10
Diagnosis of OP. BMD NR NR 124 AUC/ Sens/Spec for T-score ≤-2.5: 
SCORE 0.73/93.7%/23.8%               SOF 
0.54/32.6%/76%.
CR Sens/spec 
and ROC 
analysis
Yes: 2, 3, 4, 5, 6, 
8, 12, 14, 16, 
17, 19, 20.                 
No: 9, 18     
Unclear: 1, 10, 
11, 13, 15.
if the data required to calculate the 
SCORE were missing
BMD NR NR 100+ At the recommended threshold of 6; 
AUC: 0.71, Sens: 90%, Spec: 32%, PPV: 
64% 
CR Sens/spec 
and ROC 
analysis.
Yes: 1, 2, 3, 5, 6, 
8, 12, 15, 16, 
17, 19, 20.                          
No: 9, 13, 14, 
18.             
Unclear: 4, 10, 
11.
Bone sparing drug other than HRT, 
prior fragility fx, secondary cause for 
OP or missing DXA.
BMD NR NR 106 AUC/Sens/Spec for T-score ≤ -2.5: 
ORAI: 0.802/92.5%/38.7%             
BWC: 0.733/93.4%/34.6%                
OST: chart 0.818/91.5%/45.7%         
OST: equation 0.822/95.3%/39.6%. 
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 4, 5, 6, 
8, 11, 16, 19, 
20.                  
No: 1, 9, 13, 14, 
17, 18           
Unclear: 10, 15.
Cadarette          
2000
D Canada  
Caucasian: 
95%          
Asian: 3%
CaMOS: women, all 
cognitively normal.
≥ 45 yrs 
Mean: 
62.8±9 / 
63.5±10 
yrs in 
dev/val.
1.930 1376 women 
Dev: 926,           
Val: 450 
BMD FN: 
0.74,              
BMD LS: 0.97 
in both dev 
and val 
cohort.
ORAI Age, Weight, Current 
estrogen use
Cadarette         
2001
C Canada  
write:97%  
Asian: 2%
Menopausal women 
from the CaMos.
≥ 45 yrs  
Mean: 
66.4±8.8 
yrs.
3,288 2,365 NS,                        
10% had OP,  
NOF, SCORE, 
ORAI, ABONE 
and BWC
As in: NOF, SCORE , 
ORAI, ABONE and BWC
Cass               
2006
C US          
White: 29% 
African-
American: 
44%   
Hispanic: 28%
Postmenopausal 
women were 
recruited from a 
university-based 
family medicine 
clinic.
≥ 45 yrs  
Mean: 
60.2±9.6 
yrs.
399 203 NS,                   
11% had OP
ORAI, SCORE As in: ORAI, SCORE
Chan              
2006
C Singapore     
Asian 
(Chinese 
women)
Postmenopausal 
women were 
recruited in the 
eastern part of 
Singapore.
≥ 55 yrs 
Mean: 
68.4±5.5 
yrs.
135 135 T-score FN:         
-1.7 (1.01)         
T-score LS:           
-1.58 (1.28)
SCORE, ORAI, 
ABONE, BWC 
AND OSTA
As In: SCORE, ORAI, 
ABONE, BWC AND OSTA
Diagnosed OP or taking bone active 
dedications other than ovarian 
hormones.
BMD NR NR 101 Development cohort: 
AUC/Sens/Spec/PPV for low BMD ar 
recommended cut-off: 
0.79/90%/45.1%/32.5%.     Validation 
cohort: 0.77/93.3%/46.4%/34.6%
CR Logistic 
regression 
and ROC 
analysis 
Yes: 1, 2, 3, 5, 6, 
7, 8, 12, 14, 15, 
16, 17, 19, 20.                          
No: 13, 18.     
Unclear: 4, 10, 
11.
Physician-diagnosed bone disease, use 
of bone sparing medication other than 
ovarian hormones, missing data for any 
of the risk factors required by tools or 
NOF guidelines.
BMD NR NR 236 AUC/Sens/Spec for T-score ≤-2.5: NOF 
0.70/96.2%/17.8%                  SCORE 
0.80/99.6%/17.9%            ORAI 
0.79/97.5%/27.8%           ABONE 
0.72/83.3%/47.7%           BWC 
0.79/87%/47.6%
CR Sens/spec 
and ROC 
analysis.
Yes: 1, 2, 3, 5, 6, 
8, 9, 12,15,  16, 
17, 18, 19, 20.                                   
No: 13.     
Unclear: 4, 10, 
11, 14.
Prior diagnosis of OP or those taking 
bone active medications. Women with 
other bone diseases.
BMD NR NR 22 AUC/sens/spec/PPV/NPV:        ORAI: 
0.74/68%/66%/20%/94%   SCORE: 
0.67/54%/72%/19%/93%. Also values 
for the tools stratified by race/ethnic. 
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 4, 5, 6, 
8, 9, 10, 12, 14, 
16, 18, 20.   No: 
1, 15, 19.    
Unclear: 11, 17.
NS BMD NR NR 33 AUC/Sens/Spec for T-score ≤ -2.5 at 
recommended cut-offs of the tools:                                                 
SCORE 0.80/100%/30.4%                  
ORAI 0.76/100%/9,8%                ABONE 
0.70/100%/16.7%            BWC 
0.78/97%/18.6%                  OSTA 
0.82/97%/43.1%.        Conclude OSTA 
most effective.
CR Sens/spec 
and ROC 
analysis.
Yes: 3, 4, 5, 6, 8, 
12, 15, 16, 17, 
20.                  
No: 9, 13, 14, 
18, 19.                
Unclear: 1, 2, 
10, 11.
Cook                   
2005
C UK                    
NS, primary 
white
Postmenopausal 
women recruited 
with consent from a 
DXA scanning clinics. 
All subject attended 
the clinic with 
presence of on or 
more clinical risk 
factor for OP.
29-87 yrs 
Average: 
59.7 yrs
NS 208 NS,                    
21.6% had OP 
at LS or hip.
OST, SCORE, 
ORAI, OSIRIS, 
SOFSORF, BWC 
and QUS 
(ultrasound).
As in: OST, SCORE, ORAI, 
OSIRIS, SOFSORF, BWC.
D'Amelio      
2005
C Italy  
Caucasian
Postmenopausal 
Caucasian women. 
From a DXA clinic.
NS,  Mean 
normal/OP
: 57.3±6.6 
/ 62.2±6.7 
yrs. 
NS 525 NS,                    
47.4% had OP
NOF, OST, 
BWC, ORAI and 
AMMEB 
decision rulle 
As in: NOF, OST, BWC, 
ORAI and AMMEB 
decision rulle (age yrs 
after menopausa, age at 
menarche and BMI).
Falasca                
2003
V UK    
Caucasian: 
83%     
African-
American: 
8.7%
Women from Cooper 
Medical center. All 
person referred for 
DXA. 
≥ 45 yrs  
Mean: 
64±10 yrs.
912 912 T-score FN:         
-1.42±1.08,              
T-score tot 
hip:                               
-0.99±1.13
SCORE As in: SCORE
Geater                 
2004
V Thailand       
Asian (Thai 
women)
Women attending 
the postmenopausal 
clinic or internal 
medicine out-patient 
department of 
Songklanagarind 
hospital.
43-91 yrs  
Mean: 
60.5±10 
yrs.
NS 388 NS,                    
11.8% and 
30.8% had OP 
at FN and LS 
respectively.
OSTA As in: OSTA
No exclusion critiria. BMD NR NR 45 AUC for T-score ≤ -2.5: OSIRIS 0.747, 
SCORE 0.720, SOFSURF 0.717, OST 
0.716, ORAI 0.664 and BWC 0.665.                                                     
Also AUC value for the QUS 
measurement. Compared Sens/Spec 
for various cut-off points for the tools.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 4, 5, 6, 
8, 9, 12, 11, 20.                  
No: 1, 13, 14, 
16, 18, 19.        
Unclear: 10, 15, 
17.
Premenopausal women BMD NR NR 249 AUC for T-score ≤ -2.5: NOF 0.60, OST 
0.33, ORAI 0.32, BWC 0.13 and 
AMMEB 0.71.                             
CR ANOVA and 
ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
11, 12, 16, 19, 
20.                    
No: 1, 9, 13, 14, 
18.               
Unclear: 4, 10, 
15, 17.
NS BMD NR NR over 160 AUC/Sens/Spec for FN (using a 
threshold of 6 points): 0.80/0.97/0.36                                     
For total hip: 0.77/0.95/0.30. 
CR Sens/spec 
and ROC 
analysis
Yes: 3, 4, 5, 6, 8, 
9, 11, 12, 16, 
19, 20.                       
No: 1, 2, 13, 14, 
18.                       
Unclear: 10, 15, 
17.
Treatment for OP and if they had 
disease of the thyroid, parathyroid, 
liver and kidney, AIDS, Cushing 
syndrome or exposure to 
corticosteroid, eostrogen, thyroid 
hormones, biphosphonate, calcitonin 
and vitamin D).
BMD NR NR 46-119 No AUC, Performance of OSTA for 
identifying women with  T ≤ -2.5 at 
FN: Sens 93% and Spec 61%.            At 
LS: Sens 80% and Spec 70%.        To 
improve the sensitivity of detection of 
OP of the LS, the cut-point of ≤ 0 may 
be more appropriate.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 16, 
17, 20.                      
No: 1, 13, 14, 
18.                   
Unclear: 4, 10, 
15, 19.
Geusens              
2002
C Netherland  
NS, primary 
white women
Postmenopausal 
women from 4 
samples: U.S. clinics , 
from Rotterdam 
study, women 
screened for study of 
alendronate and 
women from general 
practice.
45-87 yrs  
Mean: 61 
yrs.
NS 32,513 T-score FN:            
-1.36
OST, ORAI, 
SCORE, 
SOFSURF
As in: OST, ORAI, SCORE, 
SOFSURF
Gourlay          
2008
C US          
White
Postmenopausal 
women recruited 
from population-
based listings at four 
US sites. From SOF.
≥ 67 yrs 9,704 7,779 NS,                  
20.5% had OP
OST, ORAI and 
SCORE
As in: OST, ORAI and 
SCORE
Gourlay        
2005
C Belgium        
100% white
Postmenopausal 
women from an 
outpatient OP center 
at Liege.
45-96 yrs 
Mean 
61.5±9 yrs.
NS 4,035 eligible 
women. 2,539 
aged 45-64 yrs 
and 1,496 
aged ≥65 yrs.
BMD FN:         
45-64 yrs:     
0.30 (0.118)  
≥65 yrs:             
0.657 (0.107)
OST, ORAI and 
SCORE.
As in: OST, ORAI and 
SCORE.
Harrison            
2006
C UK  Caucasian White Caucasian 
women who were 
referred to DXA.
55-70 yrs 
Mean 
61±4 yrs.
NS 207. 70 
osteoporotic 
and 137 non-
osteoporotic 
women.
BMD:                
OP women: 
0.369 (-1.64) 
NON-OP:   
0.463 (-0.46) 
ORAI, OSIRIS, 
SCORE, OST 
and 
combination of 
OSIRIS and 
QUS.
As in: ORAI, OSIRIS, 
SCORE, OST.
Any medical problems that precluded 3 
yrs of participation, severe 
malabsorption, BP > 210 mm HG 
systolic or 105 mmHG diasolic, 
myocardial infarction, unstable angine, 
hypothyroidism, hyperparathyroidism, 
significant renal or hepatic dysfunction, 
history of major GI mucosal erosive 
disease, ulcer disease, esophageal 
/gastric varicies, or dyspepsia requiring 
daily medication.
BMD NR NR 500+ No AUC,                                                      
Spec for identifying BMD T-scores of -
2.5 or less ranges from 37% to 58% 
when Sensitivity was approximately 
90%.                           OST is the easiest 
to calculate and therefore may be 
most useful in clinical practice.
CR Sens/spec 
and 
likelihood 
analysis.
Yes: 3, 5, 6, 8, 9, 
11, 12, 15, 16, 
17, 18, 19, 20.                    
No: 2, 13, 14.      
Unclear: 1, 4, 
10.
Bilateral hip replacement. BMD NR NR 1,562 AUC for T-score ≤ -2.5: OST 0.72, ORAI 
0.70 and SCORE 0.71, age 0.58.                                                       
Various Sens/Spec values at different 
cut-offs, but none for OST at the cut-
off recommended from developer.
CR Sens/spec 
and ROC 
analysis.
Yes: 1, 2, 3, 5, 6, 
8, 9, 12, 14, 16, 
18, 19, 20.                    
No: 13, 17.     
Unclear: 4, 10, 
11, 15.
Premenopausal women and those with 
Paget´s or advance OA.
BMD NR NR 380 AUC for T-score ≤ -2.5 women aged 
45-64 yrs: OST 0.768, ORAI 0.750 and 
SCORE 0.757.                              AUC for 
T-score ≤ -2.5 women aged ≥65 yrs: 
OST 0.762, ORAI 0.747 and SCORE 
0.745.                               Various 
Sens/Spec values at different cut-offs.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 18, 
19, 20.                   
No: 1, 13, 14, 
16.                  
Unclear: 4, 10, 
15, 17.
Reasons for referral included suggested 
osteopenia on radiograph, low trauma 
fx, estrogen deficiency, secondary 
causes of OP, glucocorticoid excess or 
therapy, monitoring of therapy or 
other reason (family history). No 
esclusion criteria.
BMD NR NR 70 AUC: SCORE 0.67, ORAI 0.70, OSIRIS 
0.69, OST 0.78.                                    
More values for tools in combination 
of QUS.
CR Logistic 
regression 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 12, 15, 20.        
No: 1, 13, 14, 
16, 18, 19.         
Unclear: 4, 10, 
11, 17
Horner             
2007
V Greece, 
Belgium, 
Sweden and 
UK                  
NS, primary 
white
Women from 4 
centers attending for 
routine or 
emergency dental 
care and women 
working in the 
localities of the 
Universities involved.
45-70 yrs 671 653 NS,                
21.6% had OP
OSIRIS OSIRIS
Karkucak               
2008
V Turkey    
Caucasian: 
100%
Postmenopausal 
women from the 
Karadenic university 
medical faculty with 
suspected OP. 
≥ 45 yrs  
Mean: 
59.4±9.9 
yrs.
117 117 NS,                        
BMD ≤2 SD 
below the 
young adult 
mean at the 
FN: 51.4%
SCORE As in: SCORE
Koh                        
2001
D (and V) Asia         
Asian 
(Japanese 
women)
Community-dwelling 
participants were 
recruited conse-
cutively from 21 
clinics in Asia. 
Validation cohort: 
Existing popula-tion-
based sample of 
postmenopausal 
women.
45-88 yrs. 
Mean 62 
yrs.
NS Dev: 860,                
Val: 1123
NS,                     
14% had OP
OSTA Age and weight
Pregnant women BMD NR NR 141 At recommende threshold at +1 for 
OSIRIS:                                                     
AUC: 0.752 (0.704-0.800)              
Sensitivity: 71%                               
Specitivity: 80%.                                
Also results for MCI
CR Sens/spec 
and ROC 
analysis
Yes: 2, 3, 5, 6, 8, 
9, 12, 15, 19, 
20.                             
No: 10, 13, 14, 
16, 18.                 
Unclear: 1, 4, 
11, 17.
Metabolic bone disease (apart from 
OP), cancer with metastasis to bone, 
renal function defect, bilateral hip 
prothesis, receiving thyroid hormone 
treatment or active thyrotoxicosis or 
receiving antiresorptive drugs or 
vitamin D apart from HRT.
BMD NR NR 60- 68 AUC/Sens/Spec/PPV/NPV for SCORE 
at cut-off 6: 
0.64/86.7%/59.1%/63%/82.5%
CR Sens/spec 
and ROC 
analysis
Yes: 2, 5, 6, 8, 
11, 12, 15,  16, 
20.                     
No: 1, 9, 13, 14 
18, 19.         
Unclear: 3, 4, 
10, 17.
Caucasion women, history or 
evidencen of metabolic bone disease, 
presence of cancer with known 
metastasis to bone, evidence of 
significant renal impariment, ≥ 1 ovary 
removed, both hips previously fx or 
replaced, and prior use of any bisphos-
phonate, fluoride or calcitonin.
BMD NR NR 120 AUC: 0.79, Sens: 91%, Spec: 45% with 
an index cutoff of -1. Validation 
cohort:                          Sens: 98%, 
Spec: 29%.                       Also divided 
the women in three categories of the 
index value: < -4, -1 to -4 and >-1
CR Multiple 
variable 
regression 
and ROC 
analysis
Yes: 2, 3, 5, 6, 8, 
9, 12, 16, 19, 
20.                                                   
No: 1, 13, 14, 
15, 18.                
Unclear: 4, 10, 
11, 17.
Kung                    
2003
V China      
Asian 
(Chinese 
women)
Postmenopausal 
women from 
Southern Chinese 
recruited from the 
community when 
they passed by public 
road, health fair or 
health talk on OP.
43-81 yrs  
Mean: 
62±8 yrs.
767 722 T-score FN:         
-1.6 (1.9)           
T-score LS:              
-1.8 (1.2)
OSTA and QUS As in: OSTA
Lacroix                 
2005
C US             
Most 
caucasian (90-
93%)
Postmenopausal 
women OPRA 
randomized trial.
60-80 yrs 
Average: 
69.1 to 
70.3 yrs in 
the 3 
groups.
9,268 3,167 (415 
universal, 576 
SCORE and 
2176 in SOF 
based group
NS SCORE, SOF As in: SCORE, SOF
Li-Yu              
2005
V Philippines   
Asian 
(Filipino)
Adults who had their 
BMD measuremens 
done at a tertiary 
referral hospital in 
Manila.
40-89 yrs 
Mean 
women: 
60±10 yrs
NS 1,465 women 
and 132 men
BMD FN: 
Women: 
0.7674 
(0.1397)  
11.26% of the 
women had 
OP.
OSTA As in: OSTA
Lydick                  
1998
D US,              
White: 89%, 
Black: 6%
Perimenopausal and 
postmeno-pausal 
women who were 
seen for routine 
check-up or follow-
up of any medical 
condition at one of 
the 106 physician 
practices that 
participated.
≥ 45 yrs 
Mean: 
61.5±9.6 / 
63.1±9.5 
in dev/val 
cohort
1,600 Dev: 1.424 
(1.279 post-
menopausal)V
al: 259 (208 
postmeno-
pausal)
NS,                     
38% and 44% 
had OP in dev 
and val 
cohort 
respectively.
SCORE Race, RA, History of fx, 
age, estrogen, and 
weight.
History or evidencen of metabolic bone 
disease, presence of cancer with 
known metastasis to bone, menopause 
before the age of 40 yrs,  evidence of 
significant renal impariment, ≥ 1 ovary 
removed, history of fx or replacement 
of both hips, or history of 
bisphosphonate, fluoride or calcitonin 
and women with abnormal 
biochemistry. 
BMD NR NR 272 AUC/Sens/Spec for T-score ≤ -2.5: 
OSTA: 0.78/88%/54%                    QUS: 
0.78/81%/65%.            Conclude that 
The OSTA is a free and effective 
method to identifying subjects at 
increased risk of OP. 
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 4, 5, 6, 
8, 9, 12, 15, 16, 
17, 19, 20.                   
No: 13, 14, 18.    
Unclear: 1, 10, 
11.
HRT or OP medication for the previous 
12 months.
Fracture 
(and 
BMD) 
33 
months
Self-
reported in 
question-
naire.
SCORE group: 
116 fx, SOF-
based group: 
93 fx and 
Universal 
group: 89 fx
No AUC,                                                  
OP treatment rates did not differ 
among all women contacted, but 
were slightly higher among universal 
and SCORE group and SOF group.
P Logistic 
regression.
Yes: 2, 3, 4, 8, 9, 
10, 12, 14, 16, 
18, 19, 20.    No: 
5, 6, 13.  
Unclear: 1, 11, 
15, 17.
Chronic corticosteroid intake, 
hyperthyroidism, chronic renal disease, 
inflammatory arthropathy, i.e.; RA, 
ankylosing spondyloarthropathy, 
fragility fx, taking antiresorptive agents 
and/or HRT within the recent 6 
months.
BMD NR NR 165 Performance of OSTA for identifying 
women with  T ≤ -2.5: Sens 98%, Spec 
59%, PPV 23 %, NPV 98% AUC 0.8506.                    
Also values for T ≤ -2.0.            Similar 
results for men.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 16, 
18, 19, 20.              
No: 1, 13, 14.     
Unclear: 4, 10, 
15, 17.
Scoliosis, trauma, or sequelae of 
orthopadic procedures prohibiting 
BMD measurement, metabolic bone 
disease (other than OP, cancer with 
matastasis to bone, renal impairment 
or perimenopausal.
BMD NR NR 500+ No AUC;                                           
Development cohort:                    Sens: 
89%, Spec: 50%.              Validation 
cohort:                         Sens: 91%, Spec: 
40%.               Threshold value of 6. 
The likelyhood ratio at this threshold 
were 1.78
CR Logistic 
regression 
models and 
ROC
Yes: 2, 5, 6, 8, 9, 
12, 16, 18, 19, 
20.                                     
No: 1, 13, 14, 
15.           
Unclear: 3, 4, 
10, 11, 17.
Machado         
2008
C Portugal       
NS, primary 
white 
(portuguese 
women)
Postmenopausal 
women from 
Coimbra in Portugal. 
Participants were 
invited by mail.
42-87 yrs 
Mean: 
60.2±8.6 
yrs
6,000 588 T-score LS:               
-1.57 (1.25)         
T-score FN:            
-1.28 (1.02)
ORAI, ABONE, 
BWC, OSTA, 
OST
As in: ORAI, ABONE, 
BWC, OSTA, OST
Martinez-Aguila              
2007
C Spain             
NS, primary 
white 
(Spanish 
women)
Postmenopausal 
women referred by 
gynecologist for BMD 
testing.
≥ 40 yrs  
Mean: 
54.2±5.4 
yrs
1,059 665 T-score FN:         
-0.90 (0.99)          
T-score LS:              
-1.19 (1.38). 
17.6% had OP
ORAI, OST, 
OSIRIS, BWC
As in: ORAI, OST, OSIRIS, 
BWC
Mauck                 
2005
C UK                
NS, primary 
white
Postmenopausal 
women aged 45 yrs 
and older enrolled on 
the Rochester 
Epidemiology 
project.
≥ 45 yrs 
Mean 
68±13 yrs
812 351. Only 202 
were 
postmeno-
pausal
NS,                            
34% and 7% 
had OP at FN 
and LS 
respectively.
SCORE, ORAI 
and NOF 
guidelines
As in: SCORE, ORAI and 
NOF guidelines
Michaelsson         
1996
D Sweden     NS, 
primary white 
women
Women selected 
from the population 
register.
28-74 yrs  
Mean: 
50.8±12.9 
yrs.
175 175 BMD FN:       
0.90 (0.16) 
BMD tot 
body:       1.12 
(0.10)  BMD 
LS:       1.12 
(0.19).
BWC Weight
Minnock          
2008
V UK   
Caucasian
Postmenopausal 
women referred to 
DXA scanning clinics 
at Great Western 
hospital. 
NS, Mean 
age 59.7 
yrs
NS 274 NS,                    
23.8% had OP 
OSIRIS and 
QUS
As in: OSIRIS and QUS
No exclusion critiria. BMD NR NR 156 AUC/Sens/Spec/PPV/NPV for T-score 
≤ -2.5:                                     ORAI: 
0.669/81/53/38/88,        ABONE 
0.674/71/64/41/86,         BWC 
0.611/78/45/34/85,             OSTA 
0.668/76/58/39/87               OST 
0.652/81/50/37/88.                Also age 
ranged results.
CR Sens/spec 
and ROC 
analysis.
Yes: 1, 2, 3, 5, 6, 
8, 9, 12, 14, 16, 
19, 20.           
No: 13, 17, 18.           
Unclear: 4, 10, 
11, 15.
Age < 40 or >69 and missing data. BMD NR NR 117 AUC/Sens/Spec/PPV/NPV for T-score 
≤ -2.5:                                      ORAI: 
0.615/64.1/58.9/25/88.5    OST: 
0.640/69.2/58.8/26.4/89.9 OSIRIS: 
0.630/58.1/67.9/27.9/88.4 BWC: 
0.586/83.8/33.4/21.2/90.6. Other cut-
off suggestion and measure in age 
different age range.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 13, 
14, 16, 17, 19, 
20.                       
No: 1, 4, 10, 15, 
18.  
NS BMD NR NR 69 AUC/Sens/Spec/PPV/NPV:      SCORE 
0.87/100%/25%/41%/100% ORAI 
0.84/99%/36%/44%/98%   NOF 
0.70/100%/10%/37%/100%. Also age 
adjusted results.
CR Sens/spec 
and ROC 
analysis.
Yes: 1, 2, 3, 4, 5, 
6, 8, 9, 10, 12, 
15, 16, 20.            
No: 13, 17, 18, 
19.                 
Unclear: 11, 14.
No exclusion critiria. BMD NR NR 42-64 No AUC,                                                
Test specifics of a weight under 70 kg 
for OP: Sens: 94%, Spec: 35%, PPV: 
21%, NPV: 97%.
CR Multiple 
linear 
regression 
models. 
Sens, spec, 
PPV and 
NPV.
Yes: 1, 2, 3, 4, 5, 
6, 8, 9, 12, 15, 
16, 17, 20.     
No: 13, 14, 18, 
19.                
Unclear: 10, 11.
Disease known to cause secondary OP. BMD NR NR 56 AUC for OSIRIS: 0.80. CR Regression 
and ROC 
analysis.
Yes: 3, 5, 6, 11, 
12, 16, 17.                 
No: 1, 13, 14, 
18, 19.         
Unclear: 2, 4, 8, 
9, 10, 15, 20.
Morin             
2009
C Canada        
NS, Primary 
white
Women from a 
health care database 
in Manitoba who 
underwent clinical 
BMD testing.
40-59 yrs  
Mean 52.7 
yrs.
8,254 8,254 T-score FN:          
-1.1 (0.9)            
T-score LS:             
-0.8 (1.4).
OST, weight, 
BMI
As in: OST, weight, BMI
Park                       
2003
V Korea        
Asian (Korean 
women)
Postmenopausal 
women from a 
menopause clinic in 
Korea who were not 
currently using HRT.
48-87 yrs 
Mean 
59.1±7.7 
yrs.  
NS 1,101 NS,                   
11% had OP
OSTA As in: OSTA
Pongchaiyakul2
005
V Thailand       
Asian (Thai 
women)
Women from the 
Khon Kaen province 
with the majority of 
them bieng farmers 
and house workers.
45-84 yrs  
Mean 
60±10 yrs
322 322 BMD FN:      
0.77 (0.15)  
BMD LS:       
0.96 (0.19)
OSTA As In: OSTA
Reginster             
2004
V France         
NS, primary 
white (French 
women)
Postmenopausal 
women from 
rheumatology clinics
≥ 45 yrs  
Mean: 
62.7±8 yrs.
889 798 NS;                   
21.8% had OP
OSIRIS As in: OSIRIS
Richy                   
2004
V and C Belgium        
100% white 
women
Postmenopausal 
women from an 
outpatient OP center 
in Liege.
45-96 yrs  
Mean: 
61.5±8.8 
yrs.
NS 4,035 NS,                   
32% had OP
OST As in: OST, SCORE, ORAI, 
OSIRIS
NS BMD and 
fracture
Mean 3.3 
yrs. 
27,256 
person yrs
Found in 
the health 
service 
records.
MOP fx: 225 AUC for FN T-score: OST 0.77, BMI 
0.72, Weiht 0.76.                               
AUC for incident fx: OST 0.56, BMI 
0.55 and weight 0.55.                     
More AUC value for subanalysis with 
startification on age and prior history 
of fx or corticosteroids.
RET Cox 
proportional 
hazard 
models
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 16, 
17, 18, 19, 20.           
No: 1, 4, 13, 14.          
Unclear: 10, 15.
Both hips fractured or replaced or if 
they had used fluoride, 
bisphosphonates, or calcitonin.
BMD NR NR 119 No AUC, At recommended cut-off 
point of -1: Sens 87%, Spec 67%, PPV 
24 %, NPV 98% for T ≤ -2.5. Also 
values for T ≤ -2.0.                                        
Similar results as derivation cohort.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 16, 
17, 18, 19, 20.                      
No: 1, 13, 14.                   
Unclear: 4, 10, 
15.
History of metabolic bone disorders, 
presence of cancer with known 
metastasis to bone, menopause before 
the age of 40 yrs, at least on ovary 
removed, history of taking medications 
affecting calcium and bone 
metabolism.
BMD NR NR 106 Performance of OSTA for identifying 
women with  T ≤ -2.5 with cut-off at -
1: Sens 81.9%, Spec 64.2%, PPV 53.1% 
false positive 35.8% and AUC 0.81. 
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 4, 5, 6, 
8, 9, 12, 13, 15, 
16, 17, 19, 20.                                 
No: 1, 18.       
Unclear: 10,11, 
14.
Previous corticosteroid or thyroid 
hormone intake for more than 3 
months.
BMD NR NR 275 No AUC,                                                   
At recomended cut-off point of +1: 
Sensitivity: 85%.                            
Prevalence of OP in those OSIRIS 
score >+1 was 16.8%
CR Multiple 
variable 
regression 
and 
Sens/spec 
analysis.         
Yes: 2, 3, 4, 5, 6, 
8, 9, 10, 12, 15, 
16,  17, 19, 20.                               
No: 1, 10, 13, 
14, 18.          
Paget´s disease and advanced 
osteoarthritis
BMD NR NR 1,290 AUC/Sens/Spec/PPV/NPV for T ≤ -2.5:                                                          
OST 0.726/86%/40%/41%/86% 
SCORE: 0.708/86%/40%/41%/86% 
ORAI: 0.670/76%/48%/41%/80% 
OSIRIS: 0.730/64%/69%/50%/80%.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 8, 
9, 11, 12, 16, 
18, 19, 20.                      
No: 1, 13, 14.                   
Unclear: 4, 10, 
15, 17.
Rud                  
2005
C Denmark  
White
Women recruited for 
DOPS. DOPS is a 
prospective, 
multicenter trial 
investigating the 
effect of HRT on 
prevention of OP fx
45-58 yrs  
Median: 
50.5 yrs
NS 2,016 BMD FN:     
0.797 (0.114) 
BMD LS:     
1.027 (0.139) 
BMD TH:     
0.917 (0.118)
SCORE, ORAI , 
OST 
As in: SCORE, ORAI , OST 
vs. Case finding based on 
(CFMRF). CFMRF: Age at 
menopause < 45 yrs, 
secondary amenorr-hea 
>1 yrs, hip FX in mother, 
BMI<19, fragility fx >45 
yrs, RA, CORD, 
immobilization >1 month 
after age 45 yrs.
Salaffi                     
2005
D Italy             
NS, primary 
white (italian 
women) 
Postmenopausal 
women>age 50, who 
underwent DXA 
(outpatient OP 
center).
≥ 50 yrs   
Mean: 
63.1±8.3 
yrs.
1,522 1,522 BMD FN: 
0.701±0.125, 
BMD LS: 
0.889±0.146
OPERA Age >= 65 yrs, Weight < 
57 kg, History of minimal 
trauma fx after age 45, 
Early memopause, 
Steroid use > 6 months 
(> 5 mg/day).
Sedrine              
2002
D Belgium 
Caucasian
Postmenopausale 
women from 
outpatient clinic.
60-80 yrs  
Mean: 
67.1±5.2 
yrs.
1,303 1,303 BMD FN:     
0.850 (0.10) 
BMD Spine: 
1,210 (0.15) 
BMD TH:     
0.890 (0.10)
OSIRIS Age, weight, current HRT 
and prior low impact fx
Von                     
1999
V California, 
USA 
Caucasian
Women from the 
community of 
Rancho Bernardo, 
participated in a 
study of OP.
44-98 yrs  
Mean: 
72.5 yrs.
NS 1,013 NS SCORE As in: SCORE
Metabolic bone disease including OP, 
current estrogen or past 3 months, 
current glucocorticoid use, current or 
past malignancy, thromboembolic 
disease, newly diagnosed or 
uncontrolled ckronic disease or alcohol 
or drug dependency.
BMD NR NR 92 AUC/Sens/Spec/PPV/NPV for T-score 
≤ -2.5 at recommended cut-off:                                                    
SCORE 0.68/69%/66%/9%/98%   OST 
0.68/92%/71%/2%/100%     ORAI 
0.64/50%/75%/23%/91%            AUC 
for CFMRF: 0.52.              Various other 
values af other cut-offs.
CR Sens/spec 
and ROC 
analysis.
Yes: 1, 2, 3, 4, 5, 
6, 8, 9, 10, 12, 
16, 17, 18, 20.                    
No: 13, 15, 19.    
Unclear: 11, 14.
Taking bone-active medications 
(ovarian hormones, calcitonin, 
bisphosphonates, or fluoride).
BMD NR NR 336 AUC for T-score<-2.5 in LS: 0.866. AUC 
for T-score<-2.5 in FN: 0.814 for the 
optimal cutoff point (2)
CR ROC. Yes: 2, 3, 4, 5, 6, 
8, 9, 12, 18, 19, 
20.                    
No: 1, 13, 14, 
16.                 
Unclear: 10, 11 
15, 17.
Absence of previous or currewnt 
pharmacological management of OP, 
except HRT, calcium or vitamin D.
BMD NR NR 455 AUC: 0.71, Sens: 78.5%, Spec: 51.4%, 
PPV:46.4% and NPV: 81.6 % at an 
OSIRIS value of +1.                   Three 
calegoris were arbitrarily created 
using OSIRIS value > +1, +1 to -3 and < 
-3
CR Regression 
models both 
uni-variate 
and 
multivariate; 
and ROC 
analysis.
Yes: 2, 3, 5, 6, 9, 
12, 16, 18, 19, 
20.                  
No: 1, 13, 14, 
15.         
Unclear: 4, 10, 
11, 17.
NS BMD NR NR 670+ Using the cut-point ≥ 6:                 AUC 
0.696, Sens 98%, Spec 12.5%, PPV 
69% and NPV 75%.               Better 
Sens/Spec at higher cut-offs.                                                   
SCORE has limited value as a method 
for appropriate refering older 
ambulatory women for DXA.
CR Sens/spec 
and ROC 
analysis.
Yes: 5, 6, 8, 9, 
12, 15, 16, 17, 
18, 19, 20.                  
No: 1, 2, 13, 14.                
Unclear: 3, 4, 
10, 11.
Wallace             
2004
C Texas, USA     
Africa-
American 
women
Postmenopausal 
women recruited 
from churches in east 
Texas.
35-80 yrs  
Mean: 
59.4±12.5 
yrs.
NS 174 NS,                     
14.9% had OP
ABONE, ORAI, 
OST, SCORE 
and BWC
As in: ABONE, ORAI, OST, 
SCORE and BWC
Weinstein        
2000
D US                   
NS, primary 
white
Menopausal women 
administered before 
they underwent a 
DXA for OP 
evaluation.
NS, Mean 
age 
62.3±10.4 
yrs
NS 1,610 NS,                       
35.3% had OP
ABONE Age, weight, never used 
estrogen
OP=osteoporosis, Fx= fracture, MOF=Major osteoporotic fractures, NS=Not Stated, Dev= Development cohort, Val= Validation cohort, BMD=Bone Mineral Density, 
yrs=years, NR=Not relevant, AUC=Area Under the Curve in receiver operating characteristics curve, ROC=Receiver Operating Characteristics Curve, Sens=sensitivity, 
Spec= Specificity, PPV=Positive Predictive Value, NPV=Negative Predictive Value
Renal disease, GI disorder affective 
digestion and absorption, long-term 
use of meds known to affect bone. 
BMD NR NR 26 AUC value NS but shown in at figure. 
Sens/Spec/PPV/NPV  for T-score ≤ -
2.0:                                 ABONE: 
73%/59.6%/80.9%/48.4% ORAI: 
65.6%/78.9%/87.9/49.4%  OST: 
75.4%/75%/87.6%/56.5% SCORE: 
83.6%/53.9%/81%/58.3% BWC: 
68,9%/69,2%/84%/48.7%.
CR Sens/spec 
analysis.
Yes: 2, 3, 4, 5, 6, 
8, 9, 12, 15, 16, 
17, 20.                   
No: 1, 13, 14, 
18, 19.             
Unclear: 10, 11.
NS BMD NR NR 568 No AUC; They determine that the 
strongest associations with OP occur 
with increasing age, decreasing 
weight and a history of never having 
used estrogen for a period of ≥ 6 
months.
CR Logistic 
regression
Yes: 4, 5, 6, 8, 
10, 12, 16, 18, 
19, 20.                        
No: 1, 2, 9, 13, 
14, 15.             
Unclear: 3, 11, 
17.
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Author     
year
Studie 
purpose 
Development (D) 
Validation (V) 
Compare (C) 
Study site 
and ethnicity
Setting                            Age range
Number of 
eligible 
participants
Number of  
included 
participants
Mean BMD 
or T-score 
details  
(baseline)
Tool  Risk factors
Ahmed        
2006
V Norway,     
NS, primary 
white
Women from the 
Tromso study - all 
residents of Tromso 
born 1969 or earlier 
and 5% random 
sample of women 
aged 75-84 yrs.
65-84 yrs. 
Mean: 
69.5±3.3 / 
70.4±3.4 
in women 
without / 
with hip 
fractures.
1,455 1,410 BMD 
Forearm: 
Without hip 
fx:                   
0.37 (SD 
0.06) With 
Hip fx:            
0.33 (SD 
0.06) 
SOF Weight loss, height, maternal 
history of hip fx, any fx, self-rated 
health, physically inactivity, 
benzodiazepine use, 
anticonvulsant drug use, pulse >80 
beats/min, caffeine, unable to rise 
from chair without help, pervious 
hyperthyroidism, age, BMD.
Albertsson        
2007
D Sweden        
NS primary 
white women
Women living in 3 
rural primary health 
recruited from the 
National Swedish 
Population Register.
70-100 yrs  
Mean: 
78.8±6.5 
yrs.
1,498 1,248 NS FRAMO age, weight, prior fragility fx, 
impaired rise-up ability.
Albertsson      
2010
V Sweden         
NS, primary 
white
Women involved in a 
fx prevention 
programme.
72-98 yrs 
Mean: 
79±5.3 yrs
390 285 NS FRAMO age, weight, prior fragility fx, 
impaired rise-up ability.
S2: Description of all 37 included papers with tools to predict fractures.
Exclusion criteria
Outcome 
(Fracture 
or BMD)
Follow-up
Definition of 
outcome 
Results  
Events 
Fracture 
Results AUC
Study design   
prospect (P)    
retrospect (RET)                     
Cross sectional 
(CR)                   
statistical 
methods
Score of the 
QUADAS tool
No prior hip fx Fracture Maximum 5 
yrs.
Fx registry is based 
on the radiographic 
archives at the 
University hospital in 
Tromsø.
Fx: 170                   
Hip fx: 49
No AUC,                                                
PPV was 11%. Cummings´ risk score 
do identify high-risk women aged 65+ 
well.
P Cox 
proportional 
hazard 
models and 
log rank 
statistic.
Yes: 1, 2, 8, 9, 
12, 14, 15, 16, 
18, 19, 20.                     
No: 17.      
unclear: 13. 
NS Fracture 
(hip)
2 yrs. FX were confirmed 
from registers.
Hip fx: 31 AUC for hip fx 0.72,               Sens/spec 
81%/64%               PPV/NPV 
5.4%/99.2%.
P Cox 
regression, 
kaplan Meier, 
ROC.
Yes: 1, 2, 8, 9, 
12, 16, 18, 20.                         
No: 13, 15, 
17.               
Unclear: 14, 
19.
NS Fracture 2 yrs. radiological reports Fragility fx: 14                        
Hip fx: 7 
No AUC,                                   
FRAMO index confirmed fx prediction 
with 6 fold increased risk of hip fx. 
FRAMO with heel BMD improve the fx 
prediction.
P Logistisk 
regression
Yes: 1, 8, 9, 
12, 14, 15, 16.                 
No: 13, 17, 
18, 19.             
Unclear: 2, 
14, 20.
Black                
2001
D and V USA and 
France      
Caucasian: 
99.7%
Development: SOF 
women. These 
women were 
recruited from lists 
such as health plan 
memberships and 
voter registration.     
Validation: EPIDOS 
women voter 
registration.
≥ 65 yrs  
Mean Dev: 
73.3 yrs. 
Mean val: 
80.5 yrs
Dev: 9,704,              
Val:       
7,575
Dev: 7,782, 
Val: 6,679
Overall BMD 
TH: 0,76.      
BMD hip: 
Incident hip 
fx: 0.76        
Without hip 
fx: 0.65 
FRACTURE 
INDEX (SOF)
Age, fx after age 50 yrs, maternal 
hip fx after age 50, weight, 
smoking, and use of arms to stand 
up from a chair, with or without 
BMD T-score.
Bolland          
2011
C New Zealand      
NS primary 
white women
Healty 
postmenopausal 
women who took 
part in a 5-yr 
randomized, placebo-
controlled trial of 
calcium 
supplements.
≥ 55 yrs  
Mean: 74 
yrs.
1,422 1,170 T-score FN:            
-1.3
FRAX, Garvan As in: FRAX with and without BMD, 
Garvan, Age, BMD, BMI, 
Age+BMD, Age+BMI, 
Age+BMD+BMI.
Cheung           
2012
C Hong Kong    
Asian 
(Chinese 
women)
Postmenopausal 
women from the 
Hong Kong OP study. 
Women were 
recruited from 
different districts of 
Hong Kong during 
health fairs and road 
shows on OP.
41-90 yrs 
Mean: 
62.1±8.5 
yrs
NS 2,266 BMD FN:    
0.629 (0.11)   
BMD LS:     
0.807 (0.148)
FRAX As in: FRAX with and without BMD, 
FN T-score, Age+FN T-score, Ethnic-
specific CRF+FN T-score, Age+FN T-
score+fx history, Age+BMI, Age+fx 
history.
previous hip fx or had 
undergone bilateral hip 
replacement.
Fracture 5 yrs. Every 4 months were 
the women 
contacted about 
possible fx. Copies of 
radiographic reports 
were obtained for all 
reported fx
Hip fx: 3% AUC for hip fx without BMD: 0.714; 
with BMD in the model 0.766. Sens: 
66%, Spec: 66.3%, PPV: 5.6% in the 
model without BMD (cutpoint of 4). 
Sens: 78.6%, Spec: 61.7% and 
PPV:5.8% in the model with BMD 
(cutpoint of 6).                  Also present 
5 yrs risk of vertebral and 
nonvertebral fx by quintile of 
FRACTURE score.
P Logistic 
regression 
and ROC
Yes: 1, 2, 8, 9, 
12, 16, 18, 19, 
20.                 
No: 13, 14.   
Unclear: 15, 
17.
women with major medical 
conditions,  and if they were 
taking treatment for OP 
(including HRT or vitamin D 
supplements in doses > 1000 
IU/day and had serum 
25(OH)D levels ≥25 nmol/L 
Fracture Mean 8.8 yrs 
(range 0.2-
11.4). 12,500 
patient-yrs.
End of study were 
the women 
contacted by phone 
and details of any fx 
were recorded.
FRAX defined 
MOP fx: 16%                   
Hip fx: 4% 
AUC for all fx: FRAX with BMD 0.62, 
FRAX without BMD 0.60, Garvan 0.63, 
age 0.55.                                 Many 
more AUC values for other simple 
models and for hip fx.     Low 
Sens/Spec/PPV for both tools. None 
of the tool had better discrimination 
than simple models.
P Sens/spec 
and ROC 
analysis
Yes: 1, 2, 8. 9, 
12, 15, 16, 17, 
18, 19.                 
No: 20.    
Unclear: 13, 
14.
Subjects already prescribed 
osteoporosis treatment
Fracture Mean 
4.5±2.8. 
10,010 
person-yrs.
By structured 
telephone interview. 
Report of Fx was 
subsequently 
confirmed by 
subject´ medical 
records.
MOP fx: 106         
Hip fx: 21 
AUC for MOP fx: FRAX 0.728, FRAX 
without BMD 0.706, Age+BMI 0.693, 
Age+fx history 0.708.       More AUC 
for other of the models. Also AUC for 
hip fx.                 Simpler models 
perform as good as FRAX.
P Cox 
regression , 
quartiles, 
sens/spec 
and ROC 
analysis.
Yes: 8, 9, 12, 
15, 16, 18, 19.                
No: 1, 13, 14, 
20.             
Unclear: 2, 17
Collins            
2011
V UK                
NS, Primary 
white women
Patients registered 
with records in the 
THIN database.
30-85 yrs 
Median: 
48 yrs
2,244,636 2,209,451 
(50.6% 
women).
NS Qfracture As in: Qfracture
Colon-Emeric           
2002
D and V US             
Iowa cohort: 
White: 45%  
Duke: 100%
Women and men 
from the EPESE 
study. Derivation 
cohort from Duke 
and validation cohort 
from Iowa.
≥ 65 yrs 
Mean: 
73.4±6.7 / 
74.5±6.6 
yrs in 
dev/val 
cohort
NS Dev: 4,149 
(65% 
women), Val: 
3,505 (60.6% 
women).
NS EPESE Gender (female), age, race, BMI, 
history of stroke, cognitive 
impairments, ADL impairments, 
one or more Rosow-Breslau 
impairments, anti-epileptic drug 
use.
Cummings        
1995
D UK                     
100% white 
women
Women recruited in 
7 states through 
mailings to women 
on lists such as voter-
registration lists.
≥ 65 yrs  
Mean: 
72±5 yrs.
9,516 7,786 BMD FN: 
0.65±0.11,      
BMD 
calcaneal: 
0.41±0.10
SOF Weight loss, height, maternal 
history of hip fx, any fx, self-rated 
health, physically inactivity, 
benzodiazepine use, 
anticonvulsant drug use, pulse >80 
beats/min, caffeine, unable to rise 
from chair without help, pervious 
hyperthyroidism, age, BMD.
Cummins       
2011
C UK and 
Ireland   
Caucasian
Postmenopausal 
women recruited as 
part of a multicenter 
study in Ireland and 
the UK.
50-85 yrs 
Mean fx: 
68±8      
Mean 
controls: 
66±7
NS 584 (246 
cases and 
338 
controls).
T-score FN: 
Cases:                  
-1.7 (0.9) 
Controls:               
-1.2 (1.1)
FRAX, 
Qfractures
As in: FRAX, Qfractures
Patients with a previous 
recorded fx, temporary 
residents, patients with 
interrupted periods of 
registration with the 
practice.
Fracture Median 
follow-up for 
OP fx 5,98 
yrs. 13 
million 
person yrs.
As recorded on the 
GP computer 
records.
OP fx: 25,208      
Hip fx: 12,188 
AUC for OP fx:                            Women 
0.82 and Men 0.74.                                            
AUC for hip fx:                            Women 
0.89 and Men 0.86.  
P Kaplan Meier, 
ROC D and R² 
statistic.
Yes: 1, 2, 8, 9, 
12, 14, 15, 16, 
18, 19.          
No: 17, 20.     
Unclear: 13.         
Subject who reported a 
history os skeletal fracture at 
baseline.
Fracture 6-10 yrs. Self-reported fx 
every yr with 
telephone contact 
and every 3 yrs with 
in-person interviews.
fx: 842 in 
both cohorts 
including 382 
hip fx
AUC presented for three models; 
Ranges from 0.640 to 0.640 for all fx 
and 0.755 to 0.789 for hip fx in the 
derivation cohort.                        In the 
validation cohort: 0.574 to 0.749 for 
hip fx
P Survival 
analysis, Cox 
proportional 
hazard, ROC.
Yes: 1, 2, 8, 
12, 16, 18, 19, 
20.                       
No: 9, 13, 14, 
15.                
Unclear: 17.
No prior hip fx or bilateral 
hip replacement or black 
race
Fracture 
(hip)
Mean 4.1 yrs. Contacted by 
postcards or 
telefone every 4 
months. Fx were 
confirmed by review 
of radiographic 
reports.
Hip fx: 192 No AUC,                                              
Women with 5+ risk factors are 
especially at high risk.
P Cox 
proportional 
hazard 
models.  
Yes: 1, 2, 8, 9, 
12, 15, 16, 17, 
18, 19.                   
No: 13, 14.              
Unclear: 20.
Women who were receiving 
treatment for OP, those on 
corticosteroids, and those 
with secondary cause of OP 
such as malabsorption, 
chronic liver disease, renal 
failure and malignant 
disease.
Fracture NS NS Low-trauma 
fx: 246
AUC/Sens/Spec for MOP fx: Qfracture  
0.668/16/95                FRAX 
0.665/37/77.             AUC/sens/spec 
for hip fx: Qfracture 0.637/3/99                    
FRAX 0.710/7/97.
RET Sens/spec 
and ROC 
analysis.
Yes: 2, 8, 12, 
19.                   
No: 13, 16, 
18.                 
Unclear: 1, 9, 
14, 15, 17, 20
Donaldson       
2009
C US                   
NS, primary 
white
Postmenopausal 
women from the 
placegroup of FIT 
intervention trial 
(Randomized 
placebo controlled 
trial of the effects of 
alendronate sodium 
on fx risk).
55-81 yrs   
Mean: 
68.2±6.1 
yrs
3,223 3,043 BMD FN:       
0.58 (0.06) 
FRAX As in: FRAX with and without BMD, 
age, Age +BMD, Age+prior fx, 
Age+prior fx+BMD, 
Age+BMD+baseline vertebral fx, 
FRAX+baseline vertebral fx
Ensrud            
2009
C US                   
NS, primary 
white
Women from SOF. 
Women were 
recruited from 
population-based 
listings in four areas 
of the United States.
 ≥ 65 yrs 
Average: 
71.3 yrs
9,704 6,252 BMD FN:       
0.65 (0.11)
FRAX As in: FRAX with and without BMD, 
Age + BMD, Age+previous fx.
Ettinger        
2005
D and V Northern 
California  
White: 70%  
Africa-
American: 8%               
Asian: 13.5%
Women from 
inpatient and 
outpatient of the 
KPMC, Northern 
California region. 
Validation: women 
from SOF and 
CaMOS.
45-79 yrs NS More the 
400,000 
women
NS Age, low body weight, current 
smoking, hip fx in mother or sister, 
personal fx history, BMD.
Fraser              
2011
V Canada        
NS, primary 
white
Women and men 
from the CaMOS 
study.
≥ 50 yrs 
Mean 
women: 
65.8±8.8 
yrs.
NS 4,778 
women and 
1,919 men.
T-score FN:       
Women:                
-1.5 (1.1)      
Men:                          
-0.5 (1.2) 
FRAX As in: FRAX
NS, has previous been 
described.
Fracture Mean 
3.8±0.8 yrs.
Vertebral fx 
detected by 
radiographs. MOP fx 
self-reported and 
confirmed by written 
reports of 
radiographs or other 
tests.
MOP fx: 7.8%  
Vertebral fx: 
7.3%
AUC for vertebral fx: FRAX with BMD 
0.71, FRAX without BMD 0.68, Age 
0.65, BMD 0.66, Age+BMD 0.71, 
Age+prior FX 0.68, Age+BMD+prior fx 
0.72, Age+BMD+baseline vertebral fx 
0.76, FRAX+baseline vertebral fx 0.75.                                              
Simpler models performed as well as 
the full index.
P Logistic 
regression, C-
statistic and 
ROC analysis.
Yes: 2, 8, 9, 
12, 16, 18, 19.                  
No: 1, 13, 17, 
20.               
Unclear: 14, 
15.
Black women and women 
unabled to walk witout 
assistance or had a history og 
bilateral hip replacement
fracture Average 8.7 
yrs for MOP 
fx and 9.2 yrs 
for hip fx.
Postcards or 
telefone every 4 
months. Fx were 
confir-med by 
review of 
radiographic reports.
MOP fx: 1,037                
Hip fx: 389 
AUC for major osteoporotic fx: FRAX 
without BMD 0.64, FRAX with BMD 
0.67, Age+prior fx 0.64, Age and BMD 
0.67.                                   Also results 
for hip and clinical fx. Conclude 
simpler models works as god as more 
complex models.
P ROC analysis Yes: 1,  8, 9, 
12, 15, 16, 18, 
19.                   
No: 13, 17       
Unclear: 2, 
14, 20.
Entire membership data 
used.
Fracture 5 yrs. NS Fx: 14,528 
Including 
3,412 hip fx
No AUC,                                                
The model predicted non-sine fx rates 
2-fold higher than SOF and 3-fol 
higher than CaMOS. Model predicted 
spine fx that were about 3-fold higher 
than CaMOS and similar to the rate in 
SOF.
P NS Yes: 2, 8, 12, 
18, 19, 20.     
No: 1, 13, 14, 
16.       
Unclear: 9, 
15, 17.
NS. Has been described 
elsewhere.
Fracture 10 yrs Self-reported fx 
were identified by 
yearly postal 
questionnaire. Fx 
were confirmed at 
the GP or hospital. 
MOP fx 
(women): 
12%                        
Hip fx 
(women): 
2.7%.
AUC for MOP fx: FRAX 0.69, FRAX 
without BMD 0.66.                           AUC 
for hip fx: FRAX 0.80 and FRAX 
without BMD 0.77.                        FRAX 
was found to be an accurate predictor 
of fx risk in both men and women.
P Kaplan-
Meier, 
competing 
risk, cox 
regresion and 
ROC analysis.
Yes: 1, 2, 8, 9, 
12, 15, 18, 19, 
20.                    
No: 13, 14, 
16.        
Unclear: 17.
Gonzales-
Macias              
2012
V Spain 
Caucasian
Women from the 
ECOSAP study 
recruited in 58 
primary care centers 
of National Health 
Service, regardless of 
the reason for 
consultation.
65-100 yrs 
Mean: 
72.3±5.3 
yrs.
5,201 4,453 NS FRAX As in: FRAX without BMD. 
Hillier           
2011
C US            
>99% white
Women from SOF. 
Women were 
recruited from 
population-based 
listings in four areas 
of the United States.
≥ 65 yrs 
Average: 
71 yrs
7,963 6,252 T-score FN 3 
categories: 
Normal:                     
-0.32 (0.66)           
Low:                      
-1.79 (0.41) 
Osteoporotic
:                          
-2.90 (0.33)
FRAX As in: FRAX with BMD and without 
BMD, Age+previous fx, Age+BMD, 
Age.
Paget´s disease, multiple 
myoloma, bone metastases, 
renal failure, hypercalcemia, 
immobilization for >3 
months in the preceding yr, 
anatomical anomalies of the 
right foot interfering with 
calcaneal ultrasound 
measurement, therapeutic 
doses of fluoride, a life 
expectancy of less than 3 yrs, 
or participation in any other 
study involving drugs. 
Missing FRAX items.
Fracture Median 36.1 
months. 
14,999 
person-yrs.
All fx were 
confirmed by the 
site investigator, 
who reviewed the 
original X-ray film or 
the radiological or 
surgical reports.
MOP fx: 201 
(3.1%)         
Hip fx: 50 
(0.96%)
AUC for MOP fx: 0.615                    AUC 
for hip fx: 0.640.                          The 
Spanish FRAX underestimate the risk 
of osteoporotic fx
P ROC analysis. Yes: 2, 8, 9, 
12, 16, 17, 18, 
19.                         
No: 1, 13, 20.          
Unclear: 14, 
15.
Women that were able to 
walk without assistance and 
those with bilateral hip 
replacements.
Fracture Mean 9.4 yrs 
(range 2.2-
10.0). 58,879 
person-yrs.
Contacted by 
postcards or 
telefone every 4 
months. Fx were 
confirmed by review 
of radiographic 
reports.
MOP fx: 1,011                 
Hip fx: 368
AUC for MOP fx (women with 
osteoponia (3,791 women)): FRAX 
with BMD 0.62, FRAX without BMD 
0.59, Age 0.57.                                
Many more AUC values for other 
simple models and for hip fx. 
Sens/Spec analysis showed large 
proportion af false-positive. Simpler 
models had similar AUC´s to FRAX.
P Sens/spec 
and ROC 
analysis
Yes: 1, 2, 8, 9, 
12, 14, 15, 16, 
17, 18, 19.                                 
Unclear: 13, 
20.      
Hippisley-Cox                  
2012
D and V UK               
95% white
Women and men 
from 627 practices in 
United Kingdom. 420 
GP were randomly 
assigned to 
development and 
207 GP to the 
validation.
30-100 yrs 
Mean in 
both dev 
and val:    
50 yrs
NS Dev: 
3,142,673 
(1,598,294 
women), Val: 
1,583,373 
(804,563 
women)
NS Updated 
Qfracture 2012
New factors added to updated 
algorithm: Ethnicity, history of 
prior fx, COPD, Epilepsy, dementia, 
parkinson, any cancer, systemic 
lupus erythematosus, chronic renal 
disease, type 1  diabetes, nursing 
or carehome residence, use of 
other antidepressants or 
anticonvulsants.
Hippisley-Cox              
2009
D and V England and 
Wales             
NS, primary 
white
535 practices in 
England and Wales. 
Men and women. 
357 practices were 
randomly assigned to 
the derivation 
dataset and 178 to 
the val dataset.
30-85 yrs 
Median 
women: 
48 yrs 
Median 
valid 
women: 
49 yrs
Dev 
women: 
1,204,222, 
Val women: 
653,789
Dev women: 
1,183,663, 
Val women: 
642,153
NS Qfracture Age, sex, BMI, smoking, alcohol, 
diabetes type 2, parental history of 
hip fx/OP, falls, atsthma, 
cardiovascular disease, chronic 
liver disease, RA, gastrointestinal 
malapsorption, use of tricyclic 
antidepressants, HRT or 
corticosteroids, endocrine 
problems, menopausal symptoms.
Hundrup         
2010
V Denmark     
Caucasian
Postmenopausal 
women  from the 
Danish Nurse Cohort
 ≥ 45 yrs 
Mean: 
61±7 yrs
15,648 13,353 NS WHI As in: WHI
Patients with a previous 
recorded fx.
Fracture Dev: 
23,608,337 
person yrs, 
Val: 
11,732,106 
person yrs. 
(7.4 yrs)
As recorded on the 
GP computer 
records.
OP fx (Dev): 
59,772 OP fx 
(Val): 28,685
AUC for OP fx: Women 0.790  and 
men 0.711.                                                
AUC for hip fx: Women 0.893 and 
men 0.875  
P Cox proportio-
nal hazards 
models and D 
and R² 
statistic.
Yes: 1, 2, 9, 
12, 15, 16, 18, 
19.       No: 13, 
14, 17, 20.          
Unclear: 8
Patients with a previous 
recorded fx, temporary 
residents, patients with 
interrupted periods of 
registration with the practice 
and patients who did not 
have a valid Townsend 
deprivation score.
Fracture Dev: 
7,898,208 
person yrs   
Val: 
4,401,261
As recorded on the 
GP computer 
records.
Dev women: 
OP fx: 24,350                     
Hip fx: 9,302  
val women: 
OP fx: 13,952                  
Hip fx: 5,424 
AUC osteoporotic fx: 0.79            AUC 
for hip fx: 0.89
P proportional 
hazards 
regression 
and ROC
Yes: 1, 2, 9, 
12, 15, 16, 18, 
19.       No: 13, 
14, 17, 20.          
Unclear: 8
If they had missing items in 
the questionnaire on 
smoking status, physical 
activity and self-reported 
health.
Fracture 
(hip)
5 yrs. Retrieved from The 
Danish Hospital 
Discharge  Register.
Hip fx: 122. Cut-off value for 5 yrs was set to 
0.5%; Sens 82%, Spec 61.4%, PPV 
1.9%, NPV 99.7% and AUC 0.82.
P Sens/spec 
and ROC 
analysis
Yes: 2, 8, 9, 
12, 14, 16, 18, 
19, 20.                 
No: 1 15, 17.        
Unclear: 13.
Kanis          
2007
D and V UK                    
NS, primary 
white
Individuals from 9 
population-based 
cohort for 
development and 11 
population-based 
cohorts for 
validation.
≥ 35 yrs  
Mean dev: 
65 yrs.   
Mean val: 
63 yrs
NS Dev: 46,340 
men and 
women (68% 
women), Val: 
230,486 
women
NS,                     
but available 
from 
published 
reports of 
each cohort
FRAX Age, BMI, family history of fx, 
glucocorticoids, prior fx, smoking, 
alcohol use, RA and FN BMD.
Langsetmo       
2011
V Canada        
NS, primary 
white
Women and men 
from the CaMOS 
study who had 
undergone 
measurement of 
BMD.
55-95 yrs  
Mean: 
68±8 yrs.
6,539 
women and 
2,884 men
4,152 
women and 
1,606 men.
T-score FN:        
Women:              
-1.43 (0.93)     
Men:                        
-1.00 (1.00) 
Garvan As in: Garvan
Leslie               
2011
V Canada        
NS, Primary 
white
Individuals from the 
Manitoba database. 
Randomly allocated 
to a dev and val 
subgroup.
≥ 50 yrs 
Mean: 
65.2±9.6 
yrs
NS 36,368 
(93.1% 
women). 
Dev:    18,153 
and val: 
18,215
T-score FN:                
-1.45 (SD 
0.98)                   
T-score LS:                  
-1.34 (SD 
1.54) 
FRAX As in: FRAX and Lumbar spine BMD
Leslie               
2011
V Canada        
NS, Primary 
white
Individuals from the 
Manitoba database. 
Randomly allocated 
to a dev and val 
subgroup. 
 ≥ 45 yrs 
Mean: 
63.6±10.4 
yrs
NS 37,032      
Dev: 18,447,      
Val: 18,585 
T-score FN:              
-1.4 (SD 1.0)           
T-score LS:                
-1.3(SD 1.5)
FRAX As in: FRAX and Lumbar spine BMD
Varied for each cohort Fracture approximate 
190,000 
person-yrs. 
An average 
between 3-8 
yrs.
NS, stated elsewhere OP fx dev: 
4,138 of 
which 850 
were the hip 
fx                     
OP fx Val: 
18,543 of 
which 3,360 
were hip fx
AUC for hip fx, BMD alone og age in a 
figure. Results further presented as 
gradient of risk
P Meta-analysis 
of individual 
person-levet 
data with 
regression to 
derive risk 
factors
Yes: 1, 9, 12, 
18, 19.             
No: 8, 13, 14, 
17, 20.    
Unclear: 2, 
15, 16.
NS. States elsewhere Fracture Mean 8.6 yrs 
for women 
and 8.6 yrs 
for men.
Self-reported mailed 
annually. Follow-up 
visit every 3 yrs. 
Obtained 
documented 
confirmation of 78% 
of the fx
MOP fx 
women: 583                       
MOP fx men: 
116.
AUC for MOP fx:                       Women: 
0.69                         Men: 0.70                                            
AUC for hip fx:                              
Women: 0.80                                  Men: 
0.85
P Cox 
proportion 
hazard, 
kaplan meier 
and Harrell C
Yes: 1, 2, 8, 
12, 14, 15, 16, 
17, 18, 19, 20.                     
Unclear: 9, 13
Statet elsewhere Fracture mean 5.5 yrs 
(range up to 
10 yrs).
Fx were assessed 
through a 
combination of 
hospital discharge 
abstracts and 
physician billing 
claims.
MOP fx: 2,321 
(1,160 in dev 
and 1,161 in 
val)
AUC ranged from 0.694 to 0.700 for 
all major osteoporotic fx.
RET Cox 
proportional 
hazards 
models, 
Kaplan Meier 
technique 
and ROC 
analysis.
Yes: 8, 9, 12, 
18, 19.           
No: 1, 13, 14, 
16, 17, 20.     
Unclear: 2, 
15.
Statet elsewhere Fracture Mean 5.6 yrs 
(range up to 
10 yrs).
Fx were assessed 
through a 
combination of 
hospital discharge 
abstracts and 
physician billing 
claims.
MOP fx: 1,748 
women 
(4.7%) 
AUC ranged from 0.671 to 0.750 RET Cox 
proportional 
hazards 
models and 
ROC analysis
Yes: 8, 9, 12, 
18, 19.           
No: 1, 13, 14, 
16, 17, 20.     
Unclear: 2, 
15.
Leslie            
2010
V Canada        
NS, Primary 
white
Men and women 
from the Manitoba 
bone density 
program database.
 ≥ 50 yrs 
Mean 
women: 
65.7±9.8 
yrs
NS 36,730 
women and 
2,873 men
T-score FN:        
Women:              
-1.5 (1.0)      
Men:                     
-1.2 (1.1) 
FRAX As in: FRAX
Leslie          
2009
V Canada        
NS, Primary 
white
Individuals from the 
Manitoba database. 
 ≥ 50 yrs  
Mean: 
65±9 yrs
NS 16,205 T-score FN:           
-1.5 (1.5)            
T-score LS:           
-1.3 (1.2)
OC Age, sex, DXA, Prior fx and 
systematic corticosteroid.
Nguyen         
2007
D Austratia   
Caucasian: 
98.6%   
Indigenous 
Aboriginal: 
1.4%
Women and men 
living in Dubbo were 
invited to participate 
in an epidemiological 
study (DOES).
≥ 60 yrs 2,095 
women and 
1,581 men
1,028 
women and 
740 men
BMD FN:              
-0.12 (HR 
2.62)          
BMD LS:                
-0.20 (HR 
2.37)
GARVAN hip Age, BMD, prior fx, falls, sex
Nguyen        
2008
D Austratia   
Caucasian: 
98.6%   
Indigenous 
Aboriginal: 
1.4%
Women and men 
living in Dubbo were 
invited to participate 
in an epidemiological 
study (DOES).
≥ 60 yrs 
Mean 
women: 
71±8 yrs.  
Mean 
men: 70±6 
yrs.
2,095 
women and 
1,581 men.
1,358 
women and 
858 men
BMD FN: 
Fractured:    
0.83±0.16     
Non-
fractured: 
0.93±0.15 
GARVAN Age, BMD, prior fx, falls, sex
NS Fracture 10 yrs. Health service 
records assessed for 
the presence of fx
MOP fx:  
2,380 women 
and 163 men.                       
Hip fx: 506 
women and 
43 men. 
AUC for MOP fx: FRAX 0.694 and FRAX 
without BMD 0.663.            AUC for hip 
fx: FRAX 0.830 and FRAX without BMD 
0.793.             The Canadian FRAX tool 
is considered suitable for clinical use 
in Canada.
P Kaplan-
Meier, cox 
proportional 
hazards 
models ROC 
analysis.
Yes: 8, 9, 12, 
18, 19.           
No: 1, 13, 14, 
16, 17.     
Unclear: 2, 
15, 20.
NS Fracture Mean 3.1 yrs. NS OP fx: 1.6%, 
3.8%, 8.4% in 
low-, 
moderate- 
and high-risk 
group
No AUC,                                                      
The system provides and assessment 
of fracture risk that is consistent with 
observed fx rates.
RET Cox  
proportional 
hazards 
models and 
kaplan meier 
curves
Yes: 8, 9, 12, 
16, 18, 19.      
No: 1, 13, 14, 
20.                
Unclear: 2, 
15, 17.
NS, Stated elsewhere Fracture 
(hip)
Median 13 
yrs. 10,523 
and 7,586 
person-yrs in 
women and 
men.
Fx were identified 
through 
radiologist´reports
Hip fx 
women: 96   
Hip fx men: 
31
AUC for women: 0.85                       
AUC for men: 0.85.
P Cox 
proportional 
hazards 
regression 
models and 
ROC analysis.
Yes: 1, 2, 8, 9, 
12, 18, 19, 20.              
No: 13, 16.   
Unclear: 14, 
15, 17.
NS, Stated elsewhere Fracture Median 13 
yrs. 14,443 
and 8,695 
person-yrs in 
women and 
men. 
Fx were identified 
through 
radiologist´reports
Fx women: 
426    Fx men: 
149 
AUC for women: 0.757                        
AUC for men: 0.754.
P Cox 
proportional 
hazards 
regression 
models and 
ROC analysis.
Yes: 1, 2, 8, 9, 
12. 15, 16, 18, 
19, 20.             
Unclear: 13, 
14, 17.
Robbins      
2007
D and V USA       
White: 83%, 
Black: 8%, 
Asian 3%
Postmenopausal 
women. From the 
observational 
component of WHI 
(dev) and from the 
clinical trial (for val).
50-79 yrs 
Mean val: 
62.7 yrs
NS Dev:   93,676,       
Val:           
68,132
NS,                 
BMD 
performed 
only on 
10,750 
women.
WHI Age, height, weight, self-reported 
health,  fx after age 55 yr, 
race/ethnicity, physical activity, 
current smoking, parental hip fx, 
corticisteroid use or hypoglycemic 
agent use,.
Sambrook         
2011
C 10 countries.  
NS, Primary 
white 
Postmenopausal 
women from the 
GLOW study where 
the practices of 723 
physicians were 
enrolled from 10 
countries. 
≥60 yrs 30,915 19,586 NS FRAX without 
BMD, Garvan
As in: FRAX, Garvan, and age+prior 
fx
Sandhu           
2010
C Austratia   
Caucasian
Women and men 
from medical records 
of patients attending 
fx and bone and 
calcium clinics in 
Sydney.
60-90 yrs 
Mean 
women 
fx/non-fx: 
73±8/68±8  
yrs  
330 200; Women 
144 (69 cases 
/ 75 control). 
Men 56 (31 
cases / 25 
controls).
T-score FN:     
Fx women:            
-2.2 (0.8)            
Non-
fractured:         
-1.7 (0.8)
FRAX, Garvan As in: FRAX, Garvan
If the women did not want to 
discontinue hormone 
therapy upon entry, or had a 
history of breast cancer; if 
they already followed a low-
fat diet or too frequently ate 
away from home, if they had 
a history of kidney stones or 
were unwilling to limit 
vitamin D intake.
Fracture 
(hip)
Observationa
l study, mean 
of 7.6 (1.7) 
yrs. Clinical 
trial, mean of 
8.0 (1.7) yrs.
Hip fx were self-
reported and then 
confirmed by x-ray 
and surgical reports.
Hip fx (obs 
study): 1,132.                   
Hip fx (Cli 
trial): 791.
Cutpoint for the WHI algorithm >21:                                                        
Deriv cohort AUC: 0.80 (0.77-0.82), 
Valid cohort: AUC 0.80 (0.77-0.83). In 
the 10,750 women who had BMD 
measured AUC 0.71 (0.66-0.76).
P Proportional
harzard 
models and 
ROC analysis
Yes: 2, 8, 9, 
12, 16, 18, 19, 
20.                
No: 1, 13, 15, 
17.        
Unclear: 14
Women receiving 
antiosteopotosis medication, 
women with incomplete 
data, and if they were unable 
to complete the study survey 
owing to cognitive 
impairment, language 
barriers, institutionalization, 
or illness.
Fracture 2 yrs (91% 
had 
complete 2-
yr follow-up.
Self-reported 
through question-
naire 1 and 2 yrs 
after baseline.
Hip fx: 69           
MOP fx FRAX 
defined: 468
AUC for MOP fx:  FRAX 0.60, Garvan 
0.64 and Age+prior fx 0.62.            AUC 
for hip fx: FRAX 0.65, Garvan 0.61 and 
Age+prior fx 0.75.   Neither algorithm 
was better the the model based on 
age+prior fx.
P Cox 
regression 
models, 
Kaplan Meier, 
Kappa 
statistics,  
Harrell´s C 
and ROC 
analysis.
Yes: 2, 8, 12, 
14, 16, 17, 18, 
19.                 
No: 1, 9, 15, 
20.         
Unclear: 13
If any prior MOP fx, any 
treatment with bone-specific 
agent for > 30 months, or 
presence of metabolic bone 
disorder (Paget´s, skeletal 
mets).
Fracture Average 1.7 
yrs in the fx 
group and 
3.7 yrs in the 
group 
without fx
Medical records FRAX defined 
MOP: 69 
women and 
31 men
AUC women: Garvan 0.84, FRAX-US 
0.77 and FRAX-UK 0.78.                    
Also values for men. 
RET ROC analysis Yes: 2, 8, 9, 
12, 15, 16, 17.                 
No: 1, 18, 19, 
20.       
Unclear: 13, 
14.    
Sornay-Rendu               
2010
C France        
NS, Primary 
white women
Women from the 
OFELY cohort. 
≥ 40 yrs  
Mean: 
58.8±10.3 
yrs.
NS 867 BMD FN: 
0.717±0.12
FRAX As in: FRAX with and without BMD, 
BMD, BMD+age
Tamaki          
2011
C Japan       
Asian 
(Japanese 
women)
Women from JPOS 
study. Women were 
randomly selected in 
three areas of the 
municipalities that 
where selected to 
the JPOS study.
40-74 yrs 
Mean: 
56.7±9.6 
yrs
1.040 815 BMD FN:    
0.706 (0.111)
FRAX As in: FRAX with and without BMD, 
BMD, Age+BMD, BW+BMD, 
Age+BW+BMD.
Tanaka              
2011
C Japan       
Asian 
(Japanese 
women)
Postmenopausal 
women recruited 
from a population of 
outpatient at a 
medical institute in 
Nagano Prefecture.
Mean: 
63.3 yrs
765 765 BMD LS: 
1.010±0.191.
FRAX, FRISC, 
BMD, 
Pentosidine+FR
ISC.
As in: FRAX, FRISC, BMD, 
Pentosidine+FRISC.
Tanaka           
2010
D and V Japan       
Asian 
(Japanese 
women)
Postmenapausal 
women from a 
hospital-based 
cohort in the dev 
cohort and a 
community-based 
cohort with women 
in the val cohort.
40-79 yrs 
Mean dev: 
63.4±11.1 
yrs        
Mean Val: 
59.5±11.3 
yrs
2,187 Dev: 1,787, 
Val: 400
T-score LS:         
Dev:                     
-1.55                    
Val:                     
-1.36  
FRISC Age, weight, BMD, menopausal, 
secondary OP, prior fx, back pain, 
dementia.
If the women had diseases or 
treatment known to affect 
bone metabolism. HRT use in 
the last 12 months.
Fracture 10 yrs. Fx were annual 
reported and 
confirmed by 
radiographs or by 
surgical reports.
MOP fx: 82 AUC for FRAX: 0.78                               
FRAX without BMD: 0.75                
BMD: 0.74                                             
BMD+age: 0.79.
P ROC analysis Yes: 1, 2, 8, 9, 
12, 16, 20.   
No: 13, 14, 
15, 18, 19.    
Unclear: 17.
Women without BMD 
measurements, women 
taking OP drugs or HRT at the 
baseline.
Fracture 10 yrs Self-reported at each 
follow-up (3 times).
MOP fx: 43           
Hip fx: 4
AUC for MOP fx: FRAX 0.69, FRAX 
without BMD 0.67, BMD 0.64, 
Age+BMD 0.69, BW+BMD 0.69, 
Age+BW+BMD 0.71.                         
Also AUC for hip fx . The predictive 
ability of FRAX was similar to simpler 
models.
P Logistic 
regression 
and ROC 
analysis.
Yes: 1, 8, 12 
14, 16, 20.    
No: 9, 18, 19.        
Unclear: 2, 
13, 15, 17.
Women receiving treatment 
for OP, and diseases releted 
to secondary OP.
Fracture 
(vertebral 
and long 
bone)
Mean 5.1 yrs. 
4561,2 
person-yrs.
Vertebral fx were 
evalua-ted by using 
radiographs taken at 
baseline and during 
the follow-up.
Clinical and 
morphome-
tric vertebral 
fx: 141 Long 
bone fx: 49
AUC for vertebral fx: FRAX 0.690, 
FRISC 0.702, BMD 0.613, 
Pentosidine+FRISC 0.732.            AUC 
for vertebral fx and long bone fx: 
FRAX 0.671, FRISC 0.685, BMD 0.598, 
Pentosidine+FRISC 0.711. 
P Cox 
regression 
models, ROC 
and Harrell C.
Yes: 2, 9, 12, 
15, 16.          
No: 1, 13, 17, 
18, 19, 20.   
Unclear: 8, 
14.
Metabolic bone disease and 
secondary OP.
Fracture 
and 
immobili-
zation
Median 5.3 
yrs. 
Annual reported 
incident fx
osteoporotic 
fx dev: 383  
Immobiliza-
tion: 83           
osteoporotic 
fx val: 60
AUC in the validation cohort: 0.727 P Multivariate 
regression 
and ROC 
analysis
Yes: 2, 8, 12, 
15, 16, 18, 19.              
No: 1, 13.        
Unclear: 9, 
14, 17, 20.
Tremollieres 
2010
C France       NS, 
primary white
Peri and early 
postmenopausal 
women from the 
MENOS cohort 
study.
NS, Mean: 
54±4 yrs
2,651 2,196 NS, 28.5% 
had OP in the 
women with 
incident fx.
FRAX As in: FRAX with BMD and BMD
Vaa Staa         
2006
D and V UK                
NS, primary 
white
Women from the 
THIN database. 
Validation study in 
the General Practice 
Research Database 
(GPRD).
≥ 50 yrs NS Dev: 
366,104,      
Val:     32,728
NS Age, FX history, Fall history, BMI, 
smoking, Chronic disease with or 
without recent GP 
visit/hospitalization, recent use of 
central nervous system 
medication, history of early 
menopause.
Wei             
2004
C US, 
Caucasian: 
53%, Africa-
American: 
38%
Postmenopausal 
women from a 
military primary care 
clinic.
≥ 40 yrs  
Mean: 
69±10 yrs
505 469 NS ORAI, ABONE, 
BWC
ORAI, ABONE, BWC
OP=osteoporosis, Fx= fracture, MOF=Major osteoporotic fractures, NS=Not Stated, Dev= Development cohort, Val= Validation cohort, BMD=Bone Mineral Density, 
yrs=years, AUC=Area Under the Curve in receiver operating characteristics curve, ROC=Receiver Operating Characteristics Curve, Sens=sensitivity, Spec= Specificity, 
PPV=Positive Predictive Value, NPV=Negative Predictive Value
Women with past/current 
OP treatment > 3 months 
(with the exception of PHT 
and calcium/vitamin D 
supplementation.
Fracture Mean 13.4 
(±1.4)
Self-reported fx and 
then confirmed by 
radiographs or 
medical/surgical 
reports.
MOP fx: 6.6%  AUC for major OP fx: FRAX 0.63, hip 
BMD 0.66.                                                 
In this population the FRAX tool had 
poor sens for fx prediction and did not 
significantly inprove the discriminant 
value of hip BMD alone. 
P Cox 
proportional 
hazard 
models. 
Sens/spec 
and ROC 
analysis.
Yes: 2, 8, 9, 
12, 15, 16, 18, 
19, 20.                    
No: 1, 13, 17.  
Unclear: 14.
Women with recent use of 
oral glucocorticoids.
Fracture Mean 5.8 yrs. 
(Validation 
mean 5.6 
yrs).
Fx during follow-up 
were determined in 
the database.
MOP fx: 
14,011 
Clinical 
vertebral fx: 
1,610                
Hip fx: 6,453
AUC for MOP fx: 0.60                      AUC 
for hip fx:  0.84                          AUC for 
clinical vertebral fx: 0.69               Fx 
rates in the validation were higher, 
not AUC presented from validation.
P Cox 
proportional 
hazard 
models and 
ROC analysis
Yes: 1, 2, 8, 9, 
12, 15, 16, 18, 
19, 20.                 
No: 13, 17.    
Unclear: 14.
Not menopausal Fracture % Self-reported in 
questionnaires.
Personal 
history of fx: 
15%
AUC/Sens/Spec:                               
ORAI: 0.65/83%/31%                        
ABONE: 0.63/74%/46%                        
BWC: 0.60/64%/56%.                  Tested 
in two racial groups, we found that it 
had best performance in caucasian 
women.
CR Sens/spec 
and ROC 
analysis.
Yes: 2, 8, 12, 
16,.              
No: 1, 9, 13, 
14, 15, 18, 19, 
20.  Unclear: 
17.
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S3: Modified version of QUADAS for risk assessment tools to predict low bone mineral density (BMD). 
 
S4: Modified version of QUADAS for risk assessment tools to predict fractures. 
  
QUADAS checklist 
 
S3: Modified version of QUADAS for risk assessment tools to predict low bone mineral density 
(BMD). 
 
This checklist was used to assess the study quality. All items were scored with “yes”, “no” or “unclear”. 
 
Item 7 of the standard QUADAS (shaded grey here) was excluded as it was not considered relevant in the 
current context – the result of the predictive tool is not incorporated in DXA measurement.   
 
We added 6 items to the checklist (items 15 to 20) as relevant for our review. 
 
Item Yes No Unclear 
1. Was the spectrum of patients representative of the patients who will receive the test in 
practice?  
(Unselected patients recruited from the general population?) 
( ) ( ) ( ) 
2. Were selection criteria clearly described? 
(Clear definition of the criteria used in- and exclusion criteria for entry into the study) 
( ) ( ) ( ) 
3. Is the reference standard likely to correctly classify the target condition?  
(Are DXA used as the reference test to measure BMD in femoral neck, total hip or lumbar 
spine and used T-score ≤ -2.5  to determine the presence or absence of osteoporosis?) 
( ) ( ) ( ) 
4. Is the time period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests? 
(Was the time period between DXA (BMD measurement) and calculation of the tools 
reasonable (less than 1 year)?) 
( ) ( ) ( ) 
5. Did the whole sample or a random selection of the sample, receive verification using a 
reference standard of diagnosis? 
(Did the whole sample or a random selection hereof have DXA (BMD measurement)?) 
( ) ( ) ( ) 
6. Did patients receive the same reference standard regardless of the index test result?  
(Did the patient receive DXA regardless of the score of the tools?) 
( ) ( ) ( ) 
7. Was the reference standard independent of the index test (i.e. the index test did not 
form part of the reference standard)? 
   
8. Was the execution of the index test described in sufficient detail to permit replication of 
the test? 
(Was the tool/tools described in sufficient detail to permit its replication (a final 
algorithm)?) 
( ) ( ) ( ) 
9. Was the execution of the reference standard described in sufficient detail to permit its 
replication?  
(Were DXA results described in sufficient detail to permit its replication (manufacturer, 
model etc.)? 
( ) ( ) ( ) 
10. Were the index test results interpreted without knowledge of the results of the 
reference standard? 
(Were the risk factors to calculate the risk assessment tool collected without knowledge to 
the DXA results or blinding explicitly stated?) 
( ) ( ) ( ) 
11. Were the reference standard results interpreted without knowledge of the results of 
the index test? 
(Were DXA performed and analyzed without knowledge of the tools results or blinding 
explicitly stated?) 
( ) ( ) ( ) 
12. Were the same clinical data available when test results were interpreted as would be 
available when the test is used in practice?  
(Is it possible to collected the risk factors included the tool in clinical practice?) 
( ) ( ) ( ) 
 Were uninterpretable/ intermediate test results reported?  ( ) ( ) ( ) 
13. (Were the any uninterpretable/ intermediate results and were the results reported for all 
patients who were described as having been entered into the study?) 
14. Were withdrawals from the study explained?  
(A patient flow diagram or results available for all patients who were reported to have 
been entered into the study) 
( ) ( ) ( ) 
15. Were the data on risk factors from interview (not only self-reported from 
questionnaires)? 
( ) ( ) ( ) 
16. Were the study participant adequately described (baseline characteristics)? 
(Age, BMD and risk factors for fracture included in the tool/tools used in the study?) 
( ) ( ) ( ) 
17. Were all data available on all subjects to calculate the score of the tool/tools?  
(No missing data on the risk factors included in the tool/tools?) 
( ) ( ) ( ) 
18. Size of the study? 
(Where the study sample of included subject over 1000?) 
( ) ( ) ( ) 
19. Size of the study (events)? 
(Where the number of events defined as subject with low BMD over 100?) 
( ) ( ) ( ) 
20. Was the cut-off of the tool/tools into high/low risk clearly described? ( ) ( ) ( ) 
 
 
 
 
 
S4: Modified version of QUADAS for risk assessment tools to predict fractures. 
The checklist was used to assess the study quality. All items were scored with “yes”, “no” or “unclear”. 
 
Items 3-7 and 10-11 (shaded grey here) were excluded as they were not considered relevant in the current 
context – DXA is the de facto reference standard. DXA scan is not a mandatory component of tools 
predicting fractures.  
 
We added 6 items to the checklist (items 15 to 20) as relevant for our review. 
Item Yes No Unclear 
1. Was the spectrum of patients representative of the patients who will receive the test in 
practice?  
(Unselected patients recruited from the general population?) 
( ) ( ) ( ) 
2. Were selection criteria clearly described? 
(Clear definition of the criteria used in- and exclusion criteria for entry into the study) 
( ) ( ) ( ) 
3. Is the reference standard likely to correctly classify the target condition?     
4. Is the time period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests? 
   
5. Did the whole sample or a random selection of the sample, receive verification using a 
reference standard of diagnosis? 
   
6. Did patients receive the same reference standard regardless of the index test result?     
7. Was the reference standard independent of the index test (i.e. the index test did not 
form part of the reference standard)? 
   
8. Was the execution of the index test described in sufficient detail to permit replication of 
the test? 
(Was the tool/tools described in sufficient detail to permit its replication (a final 
algorithm)?) 
( ) ( ) ( ) 
9. Was the execution of the reference standard described in sufficient detail to permit its 
replication?  
(Was the fracture collection verified and not only self-reported?) 
( ) ( ) ( ) 
10. Were the index test results interpreted without knowledge of the results of the 
reference standard? 
   
11. Were the reference standard results interpreted without knowledge of the results of 
the index test? 
   
12. Were the same clinical data available when test results were interpreted as would be 
available when the test is used in practice?  
(Is it possible to collected the risk factors included the tool in clinical practice?) 
( ) ( ) ( ) 
13. Were uninterpretable/ intermediate test results reported?  
(Were the any uninterpretable/ intermediate results and were the results reported for all 
patients who were described as having been entered into the study?) 
( ) ( ) ( ) 
14. Were withdrawals from the study explained?  
(A patient flow diagram or results available for all patients who were reported to have 
been entered into the study) 
( ) ( ) ( ) 
15. Were the data on risk factors from interview (not only self-reported from 
questionnaires)? 
( ) ( ) ( ) 
16. Were the study participant adequately described (baseline characteristics)? 
(Age, (BMD if measured) and risk factors for fracture included in the tool/tools used in the 
study (no more than 2 risk factors not reported in baseline characteristic)?) 
( ) ( ) ( ) 
17. Were all data available on all subjects to calculate the score of the tool/tools?  
(No missing data on the risk factors included in the tool/tools?) 
( ) ( ) ( ) 
18. Size of the study (subjects)? 
(Where the study sample of included subject over 1000?) 
( ) ( ) ( ) 
19. Size of the study (fractures)? 
(Where the number of major osteoporotic fracture during follow-up over 100?) 
( ) ( ) ( ) 
20. Was the follow-up period the “recommended” from the tools included in the study? 
(5 or 10 years for all subjects included in the study, depending on the outcome period of 
the tools) 
( ) ( ) ( ) 
 
